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Summary 
In mammals, the presence of excitable cells in muscles, heart and nervous system is crucial and 
allows fast conduction of numerous biological information over long distances through the 
generation of action potentials (AP). Voltage-gated sodium channels (Navs) are key players in the 
generation and propagation of AP as they are responsible for the rising phase of the AP. Navs are 
heteromeric proteins composed of a large pore-forming α-subunit (Nav) and smaller β-auxiliary 
subunits. There are ten genes encoding for Nav1.1 to Nav1.9 and NaX channels, each possessing its 
own specific biophysical properties. The excitable cells express differential combinations of Navs 
isoforms, generating a distinct electrophysiological signature.  
Noteworthy, only when anchored at the membrane are Navs functional and are participating in 
sodium conductance. In addition to the intrinsic properties of Navs, numerous regulatory proteins 
influence the sodium current. Some proteins will enhance stabilization of membrane Navs while 
others will favour internalization. Maintaining equilibrium between the two is of crucial importance 
for controlling cellular excitability. The E3 ubiquitin ligase Nedd4-2 is a well-characterized enzyme 
that negatively regulates the turnover of many membrane proteins including Navs. On the other 
hand, β-subunits are known since long to stabilize Navs membrane anchoring.  
Peripheral neuropathic pain is a disabling condition resulting from nerve injury. It is characterized 
by the dysregulation of Navs expressed in dorsal root ganglion (DRG) sensory neurons as 
highlighted in different animal models of neuropathic pain. Among Navs, Nav1.7 and Nav1.8 are 
abundantly and specifically expressed in DRG sensory neurons and have been recurrently 
incriminated in nociception and neuropathic pain development. 
Using the spared nerve injury (SNI) experimental model of neuropathic pain in mice, I observed a 
specific reduction of Nedd4-2 in DRG sensory neurons. This decrease subsequently led to an 
upregulation of Nav1.7 and Nav1.8 protein and current, in the axon and the DRG neurons, 
respectively, and was sufficient to generate neuropathic pain-associated hyperexcitability. Knocking 
out Nedd4-2 specifically in nociceptive neurons led to the same increase of Nav1.7 and Nav1.8 
concomitantly with an increased thermal sensitivity in mice. Conversely, rescuing Nedd4-2 
downregulation using viral vector transfer attenuated neuropathic pain mechanical hypersensitivity. 
This study demonstrates the significant role of Nedd4-2 in regulating cellular excitability in vivo 
and its involvement in neuropathic pain development.  
The role of β-subunits in neuropathic pain was already demonstrated in our research group. Because 
of their stabilization role, the increase of β1, β2 and β3 subunits in DRGs after SNI led to increased 
Navs anchored at the membrane. Here, I report a novel mechanism of regulation of α-subunits by β-
subunits in vitro; β1 and β3-subunits modulate the glycosylation pattern of Nav1.7, which might 
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account for stabilization of its membrane expression. This opens new perspectives for investigation 
Navs state of glycosylation in β-subunits dependent diseases, such as in neuropathic pain. 
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Résumé 
Chez les mammifères, la présence de cellules excitables dans les muscles, le cœur et le système 
nerveux est cruciale; elle permet la conduction rapide de nombreuses informations sur de longues 
distances grâce à la génération de potentiels d'action (PA). Les canaux sodiques voltage-dépendants 
(Navs) sont des participants importants dans la génération et la propagation des PA car ils sont 
responsables de la phase initiale de dépolarisation du PA. Les Navs sont des  
protéines hétéromériques composées d'une grande sous-unité α (formant le pore du canal) et de 
petites sous-unités β accompagnatrices. Il existe dix gènes qui codent pour les canaux sodiques, 
du Nav1.1 au Nav1.9 ainsi que NaX, chacun possédant des propriétés biophysiques spécifiques. Les 
cellules excitables expriment différentes combinaisons des différents isoformes de Navs, qui 
engendrent une signature électrophysiologique distincte. 
Les Navs ne sont fonctionnels et ne participent à la conductibilité du Na+, que s'ils sont ancrés à la 
membrane plasmique. En plus des propriétés intrinsèques des Navs, de nombreuses protéines 
régulatrices influencent également le courant sodique. Certaines protéines vont favoriser l’ancrage 
et la stabilisation des Navs exprimés à la membrane, alors que d'autres vont plutôt favoriser leur 
internalisation. Maintenir l'équilibre des deux processus est crucial pour contrôler l'excitabilité 
cellulaire. Dans ce contexte, Nedd4-2, de la famille des E3 ubiquitin ligase, est une enzyme bien 
caractérisée qui régule l’internalisation de nombreuses protéines, notamment celle des Navs. 
Inversement, les sous-unités β sont connues depuis longtemps pour stabiliser l'ancrage des Navs à la 
membrane. 
La douleur neuropathique périphérique est une condition débilitante résultant d'une atteinte à un 
nerf. Elle est caractérisée par la dérégulation des Navs exprimés dans les neurones sensoriels du 
ganglion spinal (DRG). Ceci a été démontré à de multiples occasions dans divers modèles animaux 
de douleur neuropathique. Parmi les Navs, Nav1.7 et Nav1.8 sont abondamment et spécifiquement 
exprimés dans les neurones sensoriels des DRG et ont été impliqués de façon récurrente dans le 
développement de la douleur neuropathique. 
En utilisant le modèle animal de douleur neuropathique d’épargne du nerf sural (spared nerve 
injury, SNI) chez la souris, j'ai observé une réduction spécifique des Nedd4-2 dans les neurones 
sensoriels du DRG. Cette diminution avait pour conséquence l’augmentation de l’expression des 
protéines et des courants de Nav1.7 et Nav1.8, respectivement dans l'axone et les neurones du DRG, 
et était donc suffisante pour créer l’hyperexcitabilité associée à la douleur 
neuropathique. L’invalidation pour le gène codant pour Nedd4-2 dans une lignée de souris 
génétiquement modifiées a conduit à de similaires augmentations de Nav1.7 et Nav1.8, 
parallèlement à une augmentation à la sensibilité thermique. A l'opposé, rétablir une expression 
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normale de Nedd4-2 en utilisant un vecteur viral a eu pour effet de contrecarrer le développement 
de l'hypersensibilité mécanique lié à ce modèle de douleur neuropathique. Cette étude démontre le 
rôle important de Nedd4-2 dans la régulation de l'excitabilité cellulaire in vivo et son implication 
dans le développement des douleurs neuropathiques. 
Le rôle des sous-unités β dans les douleurs neuropathiques a déjà été démontré dans notre groupe de 
recherche. A cause de leur rôle stabilisateur, l'augmentation des sous-unités β1, β2 et β3 dans les 
DRG après SNI, conduit à une augmentation des Navs ancrés à la membrane. Dans mon travail de 
thèse, j’ai observé un nouveau mécanisme de régulation des sous-unités α par les sous-unités β in 
vitro. Les sous-unités β1 et β3 régulent l’état de glycosylation du canal Nav1.7, et  stabilisent son 
expression membranaire. Ceci ouvre de nouvelles perspectives dans l’investigation de l’état de 
glycosylation des Navs dans des maladies impliquant les sous-unités β, notamment les douleurs 
neuropathiques. 
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Résumé destiné à un large publique 
Les canaux sodiques (Navs) sont impliqués dans la transmission de l’influx nerveux dans les 
neurones ; ils sont à la base de la génération des potentiels d’action, vecteurs de l’information 
électrique. Les Navs ne sont fonctionnels qu’une fois exprimés à la membrane ; plus leur nombre 
est grand, plus l’information se transmet efficacement. 
Les Navs forment une famille composée de dix différents isoformes, chacun ayant des propriétés 
spécifiques. Nav1.7 et Nav1.8, hautement exprimés dans le système sensoriel périphérique, sont 
considérés comme les plus importants dans le contexte de la douleur. La régulation de l’expression 
membranaire de Nav1.7 et Nav1.8 va modifier la conductance sodique et par conséquent 
l’excitabilité cellulaire des neurones sensoriels, ce qui va directement influencer l’intensité de la 
douleur. Il a déjà été démontré que dans les douleurs chroniques, ces canaux s’accumulent dans le 
système sensoriel périphérique, résultant dans l’hyperexcitabilité du système. Les mécanismes 
pouvant mener à cette accumulation des Navs n’ont été que peu investigués dans le cadre des 
douleurs chroniques. Cependant, plusieurs mécanismes de régulation membranaire des Navs ont 
déjà été identifiés. Nedd4-2, membre de la famille des ubiquitin ligases, participe à l’internalisation 
des canaux sodiques et diminue donc leur expression à la membrane. A l’opposé, les sous-unités β 
vont plutôt participer à la stabilisation des Navs à la membrane.  
Dans notre groupe de recherche, nous utilisons un modèle animal de douleur neuropathique, le 
modèle d’épargne du nerf sural (spared nerve injury, SNI) qui nous permet d’étudier les 
mécanismes à la base de la douleur neuropathique chez la souris. Il implique le sectionnement d’une 
partie du nerf sciatique, ce qui génère une hyperexcitabilité du système sensoriel périphérique. Dans 
ce modèle, j’ai pu montrer que la diminution de l’expression de Nedd4-2 dans les neurones 
sensoriels est à l’origine de l’augmentation de l’expression de Nav1.7 et Nav1.8. Pour démontrer le 
lien de causalité entre la diminution de Nedd4-2 et l’augmentation de Nav1.7 et Nav1.8, j’ai généré 
une lignée de souris génétiquement modifiée et invalidée pour le gène codant pour Nedd4-2. J’ai 
observé les mêmes augmentations de Nav1.7 et Nav1.8, confirmant que la diminution de Nedd4-2 
est suffisante pour générer de l’hyperexcitabilité cellulaire. De plus, ces souris ont aussi un 
phénotype d’hypersensibilité à la chaleur, démontrant le lien entre hyperexcitabilité cellulaire et 
augmentation de l’intensité de la douleur. Finalement, en utilisant une approche de thérapie 
génique, j’ai pu montrer que restaurer l’expression de Nedd4-2 dans les neurones sensoriels après le 
SNI est suffisant pour diminuer le développement de l’hypersensibilité mécanique. Ceci indique 
que Nedd4-2 a un rôle important de régulation de Nav1.7 et Nav1.8 et est donc impliqué dans les 
processus de modulation de la douleur. 
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Notre groupe de recherche a montré que l’expression des sous-unités β était augmentée dans les 
neurones sensoriels suite au SNI. De par leur rôle stabilisateur des Navs, cette augmentation des 
sous-unités β induit l’accumulation des Navs exprimés à la membrane. J’ai pu montrer que les sous-
unités β régulent l’état de glycosylation de Nav1.7 de façon différentielle, ce qui peut contribuer à 
sa stabilisation à la membrane. Cette découverte d’un nouveau mécanisme de régulation ouvre de 
nouvelles perspectives quant à la glycosylation des Navs dans des pathologies impliquant les sous-
unités β, notamment les douleurs neuropathiques. 
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1. Introduction 
Pain is a continuum of disagreeable sensory and emotional experience. On one extreme, pain carries 
a beneficial defensive function, whose system of detecting and coding noxious and dangerous 
stimuli is referred to as nociception. On the other extreme is the pathological aspect of pain, and 
particularly neuropathic pain, which serves no apparent advantageous function. Between the two, 
mechanisms of gain-of-sensitivity amplify the pain signal, aiming at avoiding further damage, but 
in pathological cases this amplification may outlive resolution of injury, and as a result chronic pain 
sets in. 
In this thesis, I will start by discussing general aspects of pain such as its anatomy and function. I 
will then go on to the other extreme of the spectrum and discuss current knowledge about 
neuropathic pain. This disorder is often associated with nervous system hyperexcitability. In this 
regard, I will discuss the role of voltage-gated sodium channel (Navs) in normal and pathological 
pain. Finally, I will discuss mechanisms of regulations of Navs, putting in perspective their 
involvement in neuropathic pain-associated hyperexcitability. This will introduce the two main 
research articles that came out of this thesis and that are presented in chapter 2. 
In Appendix, I added a third article where I am co-first author, which should be soon submitted to 
Molecular Pain, and two articles to which I also contributed, one in Anesthesiology and one in 
Neuroscience. 
1.1. Pain: 
1.1.1. Definition: 
Humans and other animals experience countless episodes of pain during a lifetime. Pain allows 
living organisms to escape from damaging situation, to protect a damaged body the time required 
for its healing and to avoid similar situations in the future. Doubtlessly, the acquirement of a system 
able to remember danger is one of the major evolutionary drives necessary for surviving in a hostile 
environment. When this body alarm does not work properly, for instance by not switching off when 
necessary or by being perpetually activated, individuals experience a chronic pain state, having no 
apparent useful function. As a result, patients endure debilitating conditions of living, potentially 
leading to several psychiatric comorbidities such as depression and anxiety (Bair Mj 2003). 
Conversely, in some genetic pathologies such as congenital insensitivity to pain, the signal is 
permanently shut off, which results in an inappropriate behavioural response and reduced life 
expectancy (Nagasako, Oaklander et al. 2003). Pain is the main complaint when visiting emergency 
departments and represents more than 50% of clinical cases (Cordell, Keene et al. 2002). 
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Because of its multidimensional aspects, no single definition can easily integrate the diverse 
features of pain. Hence, definitions already underwent several refinements by The International 
Association for the Study of Pain (IASP). The last one was proposed in 2008 and described pain as 
follow: "An unpleasant sensory and emotional experience associated with actual or potential 
tissue damage or described in terms of such damage ". Thus, pain intensity (sensory) and 
unpleasantness (emotional) can influence one another and do not only depend on the strength of the 
damaging stimulus but are also shaped by higher cognitive processes.  
1.1.2. History: 
Pain is one of the most important individual sensations and was very differently perceived across 
epochs and as a consequence, many divergent theories to explain it emerged. In the Ancient Greek 
Civilization, Aristotle believed that pain was a curse originating outside the body and was the result 
of a divine punishment. The injury was thought to be the entry point of the evil spirit through the 
body. Hippocrates believed that pain was due to an imbalance in the vital fluids of a human. At that 
time, it was widely believed that the heart was the central organ for this process.  
It was not until 1664 and René Descartes 
that the idea of pain travelling along 
nerves to eventually reach the brain was 
accepted. Descartes theorized that the 
body may be compared to a machine with 
complex wiring, and that alleviating pain 
was not necessarily dependent upon the 
willpower of a god. He rather suggested 
that pain could be treated by locating and then cutting pain fibers within the body to prevent painful 
signals to reach the brain. The idea of pain switched from a mystical to a physical experience. In the 
nineteenth century, a new theory emerged, the specific theory, which stated that pain is an 
independent sensory pathway, different from touch or other senses. To drive these different 
modalities, researchers postulated that there exist different kinds of sensory receptors, of nerves and 
of spinal cord pathways, which are recruited depending on the nature of the stimulus. Another 
theory was competing with this concept, the intensive theory, which defenders argued that a given 
nerve fiber could carry distinct sensations such as tick, touch and pain. This theory relied on 
additive mechanisms; non-noxious stimuli could accumulate, reach a certain threshold and 
eventually elicit pain signals. Finally, in 1965, the gate control theory by Ronald Melzack and 
Patrick Wall emerged, that somehow integrated both the specific and the intensive theories. The 
novelty of this concept was the postulate that the spinal cord contains a neurological gate that either 
Figure 1 Descartes pain 
pathway. The scheme 
representing a man’s foot 
getting burnt by fire. A 
hollow tube beginning at 
the end of the foot and 
finally reaching the brain 
was represented as the 
connection between the 
noxious stimuli and the 
place where the alarm 
rings.
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blocks pain signals or allows them to continue on to the brain. Non-painful transmission could 
deplete pain signals by activating an inhibitory interneuron in the spinal cord (Melzack and Wall 
1965) (see chapter 1.1.5.1.). Soon after came the discovery of the endogenous opioid system. 
Reynolds demonstrated that electrical stimulation of the periaqueductal gray matter (PAG) 
(Reynolds 1969) or the dorsal raphe nucleus (Akil, Mayer et al. 1972) elicits analgesia, an effect 
that is reversed by administration of the opioid antagonist naloxone (Akil, Mayer et al. 1976). 
Placebo analgesia is also based on the endogenous opioid system (Levine, Gordon et al. 1978). The 
next important step was the discovery of pain memory by Clifford Woolf (Woolf 1983) referred to 
as central sensitization. In his work, Clifford Woolf showed that a peripheral injury led to a 
maladaptive plasticity in the dorsal horn neurons (decreased threshold, increase of receptive fields, 
increase of response and spontaneous activity of the central neuron); a mechanism that could 
explain the transition from acute to chronic pain condition (see chapter 1.3.5). Last but not least, 
because of the explosion of neurobiological tools, the identification of transducers became 
widespread. It started with the identification of Transient receptor potential vanilloid-type 1 
(TRPV1) by David Julius (Caterina, Schumacher et al. 1997), a membrane protein responsible for 
heat sensing. Since then, the discovery of increasing receptors and ion channels has greatly 
developed.  
1.1.3. Role of the peripheral nervous system: 
Since Melzack and Wall’s theory, many detailed mechanisms have been added to the model, but the 
general framework remains intact. Pain is initiated by a specific subpopulation of peripheral sensory 
neurons, called nociceptive neurons, which constitute the primary afferent. Nociceptive neurons get 
activated when stimulus intensities reach the noxious range. These nerve fibers project on the dorsal 
horn of the spinal cord, allowing the pain signal to reach the central nervous system. They further 
follow different spinal cord pathways to reach the brain where they will be processed in the purely 
sensitive cortex and also in the emotional nuclei of the limbic system. Eventually, the brain can 
modulate the entrance of pain signals into the central nervous system via descending inhibitory of 
facilitatory pathways. I will now discuss in more detail the nociceptive pathway. For an extensive 
review see Almeida et al. (Almeida, Roizenblatt et al. 2004). 
1.1.3.1 Anatomy and function of nociceptive neurons: 
By their capacity to sense potential damaging stimuli, nociceptive neurons represent the first line of 
defence of the body. They can be found in any area of the body capable of sensing pain, either 
externally or internally, such as the skin, muscles, internal organs, arterial vessels and so on.  
17
The cell bodies of these neurons are located in the dorsal root ganglia (DRG, Figure 2) or the 
trigeminal ganglion for the innervations of the face, and have both a peripheral and central axonal 
branch that project to their target organ and to the spinal cord, respectively. Nociceptive neurons 
possess four functionally distinct features: (1) the free ending, that transduces the external stimuli 
into an electrical component, (2) the axon, that conducts this electrical information, (3) the cell 
body, which is necessary for the machinery to function properly and (4) the presynpatic termination 
that transmits the pain information into the central nervous system. 
 
 
 
 
 
 
Figure 2. Anatomy of nociceptive neurons. Somatosensory neurons cell bodies are located in dorsal root ganglia 
(DRGs) located next to the spinal cord. Most nociceptive neurons are unmyelinated and have small diameter axons (C-
fibers, yellow) and project to superficial lamina I and II of the dorsal horn. A-fiber nociceptors (Aδ, green) are 
myelinated with faster conduction velocities and in addition to projecting to superficial lamina I, they also project into 
deeper lamina V. Modified from (Milligan and Watkins 2009)
1.1.3.2. Fibers: 
Nociceptive neurons can be classified into two major classes. The first includes Aδ medium 
diameter myelinated fibers and convey what is called “fast” pain (the initial component of acute 
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pain). The other includes small diameter unmyelinated C-fibers, that mediate “slow” pain (Julius 
and Basbaum 2001). As represented in Figure 2, they project to different layers of the spinal cord. 
 
 
 
Figure 3. Function of nociceptive neurons. Several high threshold transducers depolarize the cell in response to 
stimuli until Navs generate AP. The axon conducts the AP from the peripheral terminal to the central terminal. The 
depolarization activates Cavs that will lead to calcium influx and ultimately to synaptic transmission. The central 
terminal also releases multiple regulating molecules. Nociceptive release glutamate as well as multiple synaptic 
modulators. Modified from (Woolf and Ma 2007).
glutamate 
SP 
CGRP 
ATP 
NO 
PGs 
Growth 
factors 
1.1.3.3. Transducers: 
Most of nociceptive neurons are capable of detecting a wide range of stimulus modalities such as 
heat and mechanical stimulus, and are thus defined as polymodal (Dubin and Patapoutian 2010). To 
integrate such variable stimuli, nociceptive neurons express a large variety of transducer proteins 
such as receptors and ion channels, each possessing their own specific properties (Figure 3). 
Nociceptive neurons can thus be classified according to their differential expression of membrane 
proteins. Transient receptor potential (TRP) vanilloid-type 1 (TRPV1) is responsible for conferring 
neurons with heat sensitivity. This channel only activates when temperatures are higher than 43 
degrees or upon capsaicin (pungent ingredient in chilli peppers) binding whereas TRP melastatin-
type 8 (TRPM8) senses cold temperature or menthol (Wang and Woolf 2005). Acid sensing ion 
channels (ASICs) sense an acidic environment whereas chemical irritants are activating TRP cation 
channel 1 (TRPA1) receptors (Julius and Basbaum 2001; Fukuoka, Yamanaka et al. 2012). 
Transducers implicated in mechanical sensation are still under debate and remain to be identified 
(Wood and Eijkelkamp 2012). For instance, DEG/ENaC channels are important in mechano-
transmission in C. elegans, and because they are largely expressed in high- and low-threshold 
mechanosensitive neurons, the mammalian orthologs acid sensing ion channels (ASICs) were 
proposed to carry the same function. Knockout animals for these genes have aberrant responses to 
mechanical stimuli (Price, Lewin et al. 2000; Price, McIlwrath et al. 2001). However, mechanically 
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evoked currents of cultured DRG neurons in these animals did not show a difference with wild-type 
mice (Drew, Rohrer et al. 2004).  
Nociceptive neuron classification can also be divided into two classes depending on the expression 
of peptidergic genes (Nagy and Hunt 1982). Peptidergic neurons are releasing calcitoning gene 
related peptide (CGRP), substance P (SP) and express tyrosine kinase receptor A (TrkA) while non-
peptidergic neurons express isolecting-binding protein 4 (IB4) (Marmigere and Ernfors 2007). The 
fact that these two populations project to distinct layers in the dorsal horn, respond to different 
neurotrophic factors and have different electrophysiological properties suggest different 
physiological functions (Snider and McMahon 1998; Stucky and Lewin 1999; Braz, Nassar et al. 
2005) that remain to be determined. 
1.3.3.4. Voltage-gated ion channels: 
After being activated at their free endings upon transducers opening, nociceptive neurons further 
transmit the pain signal by voltage-gated ion channels, which allow the transmission of action 
potentials (AP) along the axon. Voltage-gated sodium and potassium channels (Navs and KCNQ or 
Kvs) are key players in the generation of AP in neurons, and voltage-gated calcium channels (Cavs) 
play a significant role in synaptic transmission to the spinal cord.  
1.3.3.5. Voltage-gated sodium channels: 
Voltage-gated sodium channels (Navs) are responsible for the rising phase of the AP and also 
regulate neurons resting membrane potential. Sodium currents were first recorded by Hodgkin and 
Huxley who demonstrated the three principal features of Navs: (1) voltage-dependent activation, (2) 
rapid inactivation and (3) selective ion conductance (Hodgkin and Huxley 1952) which are the 
indispensable characteristics needed to generate and propagate APs. Upon minor depolarization 
Navs will activate following the “all or nothing” paradigm, generating a fast inward Na+ current. 
They remain open only for a short time, in the range of a millisecond, and then close thanks to the 
fast inactivation process. The membrane potential needs to be repolarised for a sufficiently long 
period for the recovery from inactivation process to occur, which is required to allow generation of 
a second AP. The previous highlight the three main conformations that Navs can undergo: closed, 
open and inactivated.  
Not before 1980 and the emergence of new biochemical methods, were the researchers able to 
characterize in more details Nav protein (Beneski and Catterall 1980) and the crystallography 
structure was only revealed in 2011 (Payandeh, Scheuer et al. 2011). The α-subunit is encoded by a 
single gene, which is structurally divided into four homologous domains (I-IV) connected by an 
intra and/or extracellular loop (Figure 4). Each domain is composed of six α-helical transmembrane 
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segments: S5 and S6 are composing the pore of the channel where as S1 to S4 are identified as 
being the voltage-sensors. 
 
Figure 4. Scheme of the primary structure of Nav. The α-subunit consists of four homologous domains each 
containing six trans-membrane domains. β-subunits, and binding site of several other regulatory proteins (see chapter 
1.3.4.3 to 1.3.4.8) are also represented. Modified from (Shao, Okuse et al. 2009). 
 
There are nine discrete genes (SCNxA) encoding for the α-subunits Nav1.1 to Nav1.9 isoforms (plus 
another atypical tenth isoform, NaX (Akopian, Souslova et al. 1997)), which are differentially 
expressed in the sensory system (Figure 5) and present different biophysical properties.  
 
 
Figure 5. Summary of DRG sodium channels. From (Rush, Cummins et al. 2007) 
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 The different isoforms tightly collaborate to generate electrogenesis in cells. Thus, in addition to 
myelination, the variable combinations of isoforms, with their own electrical properties, give rise to 
different conduction velocity in DRG neurons (Rush, Cummins et al. 2007). All isoforms, except 
Nav1.2, Nav1.4 and Nav1.5, are expressed in DRG nociceptive neurons (Fukuoka and Noguchi 
2011; Ho and O'Leary 2011). The slow sodium-dependent activity that can be recorded from 
nociceptive neurons is due to the presence of slow TTX resistant isoforms Nav1.8 and Nav1.9 
(Gaumann, Brunet et al. 1992; Akopian, Sivilotti et al. 1996; Cummins, Dib-Hajj et al. 1999). 
These neurons also expressed TTX sensitive isoforms Nav1.1, Nav1.6, and Nav1.7, the latter being 
the most importantly expressed in DRGs (Ho and O'Leary 2011). 
Human mutations for the genes coding for Nav1.7 and Nav1.8 are often linked with pathological 
pain states (Dib-Hajj, Binshtok et al. 2009; Liu and Wood 2011) highlighting their important role in 
pain transmission. For instance, a loss of function for Nav1.7 leads to congenital insensitivity to 
pain (Cox, Reimann et al. 2006) and conversely, gain of function for this gene lead to inherited 
painful channelopathies (Yang, Wang et al. 2004; Fertleman, Baker et al. 2006) such as 
erythromelalgia and paroxysmal extreme pain disorder. 
Nav1.7 produces a fast-activating and -inactivating current as well as a slow-repriming current 
(Klugbauer, Lacinova et al. 1995) making it not best designed for generating repetitive firing. 
Furthermore, thanks to its slow closed-state inactivation, it is able to generate ramp current in 
response to small depolarization (Cummins, Howe et al. 1998). This ability of Nav1.7 to amplify 
subthreshold stimuli increases the likelihood of a neuron to reach its threshold for firing AP. For 
this reason, Nav1.7 is considered as a threshold channel. Another characteristic of Nav1.7 is its 
ability to produce resurgent currents (Jarecki, Piekarz et al. 2010). This current is triggered by 
repolarization after a strong depolarization and can contribute to the formation of conglomerate APs 
(burst firing) (Raman and Bean 1997).  
Nav1.8, thought to be mostly a sensory specific isoform (Akopian, Sivilotti et al. 1996), presents 
distinct biophysical properties as compared to Nav1.7. It has slower-inactivating kinetics but a 
faster repriming rate, which allows it to generate repetitive firing (Renganathan, Cummins et al. 
2001). Voltage-dependence of both activation and inactivation is set at depolarized membrane 
potentials, making Nav1.8 available even at low voltage. Consequently, Nav1.8 is thought to be an 
important contributor to AP upstroke.  
The other TTX resistant isoform, Nav1.9, is preferentially expressed in small diameter DRG 
neurons (Dib-Hajj, Tyrrell et al. 1998; Tate, Benn et al. 1998) and is presumably associated with 
nociception (Fang, Djouhri et al. 2006). Because it activates at around -70 mV, it produces a 
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persistent current that has been proposed to participate in setting resting membrane potential 
(Herzog, Cummins et al. 2001). 
The TTX sensitive isoform Nav1.3 is able to generate relatively large ramp currents in response to 
slow ramp current depolarisations (Cummins, Aglieco et al. 2001). Because it is not significantly 
expressed in adult DRG neurons it is unlikely to participate in excitability.  However, Nav1.3 was 
demonstrated to be upregulated in diverse pain states (Waxman, Kocsis et al. 1994; Black, 
Cummins et al. 1999) and, hence could contribute to reduce the threshold for AP generation. 
Noteworthy, recovery from inactivation can be up to three times faster than Nav1.7, supporting a 
role in repetitive firing. 
Nav1.1 and Nav1.6 are the two other TTX sensitive isoforms expressed in DRGs, but their role in 
pain are yet unclear. The regulatory mechanisms of Navs will be discussed in chapter 1.3.4.3. to 
1.3.4.8., so that they can be put in perspective of neuropathic pain development. 
1.3.3.6. Voltage-gated potassium channels: 
Voltage-gated potassium channels (Kvs) are responsible for the falling phase of AP leading to cell 
membrane repolarization and hyperpolarization, which results in decrease of cell excitability. 
Because they do not inactivate at membrane potential, they generate a steady voltage-dependent 
outward current that is responsible for the stabilization of the membrane potential in the presence of 
small depolarizing currents. Recent studies in various pain models identified the Kv7 channels 
(KCNQ) as important players in pain pathways (Lawson 2006). Kv7 genes encode for 
homotetrameric proteins and are composed of five different members, Kv7.1 to Kv7.5; and out of 
these five only one is excluded from the nervous system (Kv7.1) (Jentsch 2000). It has been found 
that the anticonvulsant drug retigabin increases potassium current and reduces the transmission of 
Aδ and C-fibres into the spinal cord (Passmore, Selyanko et al. 2003), concomitantly with the 
hyperpolarization of the primary afferent (Rivera-Arconada and Lopez-Garcia 2006). More 
recently, retigabin has been found to attenuate C-fiber activity triggered by heat stimulation in 
humans (Lang, Fleckenstein et al. 2008) suggesting that enhancement of Kvs activity might be of 
therapeutic potential. However, the role of Kvs has only been sparsely investigated in pain so far. 
1.3.3.7. Voltage-gated calcium channels: 
Voltage-gated calcium channels (Cavs) (Catterall, Perez-Reyes et al. 2005) play several crucial 
physiological roles by modulating synaptic plasticity, neurotransmitter release and gene 
transcription to cite a few. When arriving at the central terminals of the primary afferent, AP cause 
a membrane depolarization that will activate Cavs allowing calcium influx, which in turns triggers 
synaptic vesicle exocytose. Glutamate and other multiple neurotransmitters will thus be secreted 
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and participate in transmission and modulation of spinal sensory signals (Figure 3). Cavs can be 
divided into two classes based on their voltage activation characteristic: low voltage-activated, 
known as T-type and high voltage-activated, represented by L, N, P/Q and R-type channels. Ten 
different Cavα subunits have been identified in mammals and are further associated with 
modulatory α2δ, β and γ subunits accounting for remarkably large possible combinations.  
Because these different classes exhibit different biophysical properties, they are specialized in 
distinct aspects in the processing of pain. For instance N-type channels such as Cav2.2 are largely 
found in superficial lamina of the spinal cord and blocking this channel gives rise to analgesic 
effects (Cao 2006). T-type channels are also found in DRGs, where Cav3.2 is the most 
predominantly expressed and presumably enhance sensory neurons excitability, possibly 
contributing to amplify pain transmission (Messinger, Naik et al. 2009). Drugs targeting these 
channels are of increasing interest even though finding specific blockers might represent an 
immense challenge for the drug developers. For a review on Cavs see (Park and Luo 2010) (see also 
chapter 1.3.7.). 
1.1.4. Role of ion channels and Channelopathies: 
In the previous chapter I discussed properties and function of several ion channels that are 
selectively expressed in nociceptive neurons, and some of them are also expressed in higher 
structures of the pain pathways. These players (Figure 6) have been demonstrated to have a role in 
pain generation or maintenance by using both genetically-modified animals and screening for 
human mutations. In some cases, theses mutations can lead to different pathological pain symptoms. 
Mutations can occur in transduction, transmission (axonal or synaptic) or modulatory mechanisms. 
An extensive review of these mutations and their consequences can be found in (Cregg, Momin et 
al. 2010). 
 
Figure 6. Ion channels 
associated with pain 
syndromes. The ion 
channels were identified 
using genetically-
modified mice and 
monogenic human 
diseases. Ion channels 
are classified by the 
principal deficits they 
produce in pain 
pathways. These deficits 
can occur at different 
stages. Ion channels 
responsible for migraines 
and visceral pain are also 
shown. From (Cregg, 
Momin et al. 2010) 
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1.1.5. Role of the central nervous system: 
1.1.5.1 Central terminal of nociceptive neurons and the spinal cord:  
Central afferents of primary sensory neurons project in the dorsal horn of the spinal cord. The grey 
matter of the spinal cord can be divided into 10 laminas defined by distinct electrophysiological and 
cytoarchitectural properties. Nociceptive neurons from Aδ fibres project mainly to lamina I, and to 
a lesser extent on lamina V, whereas C-fibers project specifically to lamina I and II, accounting for 
a notable specific somatotopic projections (Figure 2 and (Almeida, Roizenblatt et al. 2004)). The 
specificity of this stratification is further highlighted by projections of peptidergic and non-
peptidergic afferents; the first category exclusively projects to layer I and dorsal part of layer II 
where as the second project exclusively to the mid-region of layer II (Snider and McMahon 1998). 
Nociceptive neurons synthesize a diversity of substances that are involved in the central 
transmission of pain signal (Figure 3). Glutamate and other excitatory amino acids (EAAs) are of 
critical importance at the synapse, but other regulatory substances such as substance P, calcitonin 
gene-related peptide (CGRP), adenosine triphosphate (ATP), nitric oxide (NO), phospholipid 
metabolites such as prostaglandins (PGs) and several neurotrophins (growth factors) are involved in 
the fine tuning of synaptic transmission. Inhibitory (glycinergic and GABAergic) and excitatory 
interneurons further participate in the modulatory input of primary afferents into the central nervous 
system. Last but not least, two players found in the dorsal horn are the glial (astrocytes) and 
microglial cells (immune cells) that can also modulate synaptic transmission, mostly via the release 
of small molecules and by scavenging synaptic cleft neurotransmitters (Basbaum, Bautista et al. 
2009).  
1.1.5.2. Ascending pathways: 
Neurons within laminae I and V constitute the major output projecting to the brain (Basbaum and 
Jessell, 2000). These second-order neurons are at the origin of multiple ascending pathways, with 
two important tracts: the spinothalamic tract, which carries pain messages to the thalamus and 
brainstem and accounts for the sensory-discriminative aspects of pain, and the 
spinoreticulothalamic tract implicated in both the emotional and the sensory component of pain by 
its projection to the parabrachial nuclei, which further connect to nuclei of the limbic system  
(Figure 7). Many other spinal pathways exist such as spinomesencephalic, spinohypothalamic or 
spinocervical (Almeida, Roizenblatt et al. 2004).  
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Figure 7. Spinothalamic and 
spinoreticulothalamic tract. 
Two main pathways convey the 
information from the second-
order neuron to the brain. A 
first subset of these projection 
neurons transmits information 
to the somatosensory cortex via 
the thalamus (in green), 
providing information about the 
location and intensity of the 
painful stimulus. The other 
subset of neurons project to the 
cingulate and insular cortices 
via connections in the brainstem 
(parabrachial nucleus) and 
amygdala, contributing to the 
affective component of the pain 
experience. This ascending 
information also accesses 
neurons of the rostral ventral 
medulla and midbrain 
periaqueductal gray, which can 
further engage descending 
feedback pathways that regulate 
the input into the second order 
neuron. From (Basbaum, 
Bautista et al. 2009) 
 
1.1.5.3. Brain: 
First and second-order neurons will ultimately project to subcortical and cortical structures. There is 
no single brain area implicated in pain (Apkarian, Bushnell et al. 2005) but rather an activation of 
largely distributed structures and nuclei in the brain, the so-called pain matrix. Some of these 
structures are typically specialized in sensory-discriminative modality such as the somatosensory 
cortex, and others are implicated in the emotional aspect of pain such as the amygdala, the 
hippocampus or the cingulate cortex. Even structures implicated in more cognitive functions such as 
the prefrontal cortex, are activated upon pain stimulation and might also be implicated in regulating 
pain signal processing in the brain (Tracey and Bushnell 2009).  
The brain is also involved in descending pain modulation (Figure 7). The structures responsible for 
this modulation are multiple, including the hypothalamus, the amygdala or the rostral anterior 
cingulate cortex (rAAC). They project on the periaqueductal gray region and then to the rostra 
ventromedial medulla (RVM), making these two areas the main relays before these projections 
reach dorsal horn neurons. These descending circuits are mostly noradrenergic and serotoninergic 
and are opioid-sensitive (Ossipov, Dussor et al. 2010). These “Top-down” modulatory pathways 
have been shown to underlie the clinically important phenomenon of placebo effect. 
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1.1.6. Nociception pharmacology: 
Many drugs have been developed to treat pain across ages. Opium as probably been used for more 
than 5000 years to alleviate pain. Acetylsalicylic acid - aspirin - was patented in 1897 by Bayer, but 
the use of plant extracts, including willow bark and spiraea, containing salicylic acid was probably 
used since way longer to treat pain and fever. More recently, paracetamol was developed and is 
nowadays the most widely used medication to alleviate pain. However, its mechanism of action is 
still largely unknown and probably targets several different pronociceptive molecules. Prostanoids, 
metabolites of arachidonic acid through the cyclooxygenase (COX) pathway, are the best known 
lipid mediators that contribute to pain. The COX enzymes are described to be present in at least 
three versions, the best studied ones being COX1 and COX2. COX1 is constitutively expressed and 
has several physiological functions such as regulating blood fluidity (palettes aggregations) and 
blood pressure (vasodilatation, vasoconstriction). COX2 is induced in inflamed tissue and leads to 
prostalglandin E2 (PGE2) production. PGE2 is significantly involved in pain pathways, but also in 
inflammation and fever. Thus, many analgesics, including paracetamol, target the arachidonic acid 
pathway, often via COX inhibition. The non-steroidal anti-inflammatory analgesics (NSAIDS) are 
widely used medications. They are divided into two subclasses, the non-selective NSAIDS, which 
inhibit both COX2, leading to analgesic effect but also COX1, making it also responsible for 
multiple side effects. A more recent class specifically inhibits COX2, the selective NSAIDS and as 
a consequence mediates fewer side effects. Aspirin and ibuprofen are typical members of the 
NSAIDS. 
Opioids bind to specific opioid receptors, disseminated throughout the nervous system and other 
tissues. There are three principal classes of opioid receptors, μ, κ, δ (Massotte and Kieffer 1999). 
They are all inhibitory G-protein coupled receptors (GPCRs) and thus elicit inhibitory responses 
upon ligand binding. Noteworthy, each receptor elicits specific intracellular pathway and different 
neuronal responses. As a consequence, and because of their ubiquitous expression in the nervous 
system, opioids influence on numerous physiological functions such as reward, stress, mood, 
respiration and gastrointestinal motility. For these reasons, opioids are known to have many side 
effects. There exist a multitude of endogenous ligands synthesized by the body. All these agonists 
also elicit different signalling and trafficking pathways leading to alternative internalization and 
desensitization mechanisms, highlighting the complexity of the opioidergic system. Extensive 
review on the current knowledge of opioids agonists and their receptors can be found in (Pradhan, 
Smith et al. 2012).  
Local anaesthetics drugs act by blocking Navs, preventing the pain signal to reach to central 
nervous system.  Local anaesthetics bind more readily to Navs that are in the inactivated state and 
are thus more effectively blocking neurons that fire, a process referred to as state dependent 
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blockade. The site of binding is thought to be located in an intracellular portion of the sodium 
channel (Ragsdale, McPhee et al. 1994). 
The WHO (World Health Organization) classifies the use of analgesics by levels; the pain ladder. 
The first level is composed of non-opioid analgesics. The second step is the use of weak opioids 
(codein and tramadol) and finally strong opioids (morphine and derivatives) are recommended for 
the third step. Other molecules acting as Navs blockers (e.g. tricyclic antidepressants and 
anticonvulsants) or Cavs modulators (e.g. gabapentinoids) are also available but are rather used to 
treat chronic pain. These so called adjuvant pharmacological agents will thus be discussed in 
chapter 1.3.7. 
1.2. Types of Pain: 
Nociceptive pain is an essential physiological warning against damages which is mediated by high 
threshold primary sensory neurons. If the damage occurred anyway, the injury and the subsequent 
inflammation will lead to the sensitization of the nociceptive system (Woolf and Salter 2000), 
resulting in inflammatory pain. The expression of inflammatory pain is therefore linked to the 
persistence of inflammation, but should fade away when tissue is healed. Neuropathic pain results 
from damage to the nervous system and becomes persistent after the apparent resolution of initial 
insult. A fourth type of pain, dysfunctional pain, that includes fibromyalgia and tension type 
headache, is present even when no injury is detected and is thought to be due to a central abnormal 
process of pain inputs, but the exact mechanisms remain unknown. In the upcoming chapters, I will 
discuss neuropathic pain in more details. 
1.3. Neuropathic pain: 
1.3.1. Definition: 
Neuropathic pain (NP) as defined by the IASP is a “Pain caused by a lesion or disease of the 
somatosensory nervous system” (Loeser and Treede 2008). It may appear in the context of many 
different diseases such as multiple sclerosis, diabetic neuropathy, stroke, cancer or nerve injury. 
This highlights the several distinct etiologies that neuropathic pain presents (Ducreux, Attal et al. 
2006) and suggests that more than one mechanism may be responsible for generating multifaceted 
neuropathic pain symptoms (Woolf 2004; Scholz, Mannion et al. 2009). Conversely, among 
different neuropathic pain etiologies, some mechanisms might be common (Woolf and Decosterd 
1999). Among neuropathic pain conditions, mononeuropathy has the highest incidence rate 
(Dieleman, Kerklaan et al. 2008), highlighting the clinical importance of nerve injury. Compression 
of roots by disk hernia is a common feature of neuropathic pain, and diabetic peripheral neuropathy 
28
and post-herpetic neuropathy are also important contributors to the development of neuropathic 
pain. Nevertheless, a rule of this pathology is that it must directly involves the nociceptive pathways 
(Boivie, Leijon et al. 1989) and is the manifestation of maladaptive plasticity in the nervous system.  
1.3.2. Epidemiology: 
Neuropathic pain is estimated to affect 
more than 75 million people worldwide 
with poor success in alleviating pain 
(Brower 2000). Epidemiological studies 
from different countries and on different 
numbers of patients report varying 
prevalence rates for neuropathic pain. A 
large study performed in more than 
30’000 individuals of the French 
population reported that around 20% of patients suffered from moderate to severe chronic pain and 
that one third of these patients, i.e. 7% of the population presented neuropathic characteristics 
(Bouhassira, Lanteri-Minet et al. 2008). The prevalence of chronic pain increased with age, and was 
significantly higher for females (Perquin, Hazebroek-Kampschreur et al. 2000) and depends on 
genetic background (LaCroix-Fralish and Mogil 2009). Comorbidities such as depression, anxiety 
and poor sleep are often observed in patients suffering from neuropathic pain (Turk, Audette et al. 
2010) as well as work incapacity. 
Figure 8. « La 
Columna 
Rota » (the 
Broken Spine). 
A self-portrait 
of Frida Kahlo 
(a Mexican 
painter) who 
suffered from 
chronic pain all 
her life after 
being injured in 
a serious  car 
accident when 
she was 18 
years old. 
1.3.3. Mechanisms: 
Neuropathic pain is associated with a hyperexcitability of the central and the peripheral nervous 
systems, resulting in ongoing pain, allodynia (innocuous stimuli that become painful), 
hyperalgesia (exaggerated and prolonged pain response in response to noxious stimuli) and 
negative symptoms such as hypoalgesia. Increased neuronal activity can explain both spontaneous 
and exaggerated stimulus-evoked pain. First, a process of peripheral sensitization generates an 
hyperexcitability of peripheral sensory neurons evoking a primary neuropathic pain. The second 
step is the central sensitization mediated by increased synaptic strength between first and second 
order neurons, presumably triggered by increased electrical input among other molecular 
mechanisms. Central sensitization also involves glial reaction and loss of interneuron inhibition (see 
chapter 1.3.5.).  
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1.3.4. Peripheral sensitization: 
Peripheral sensitization occurs during and after peripheral inflammation and is due to the 
modification of the chemical environment and the accumulation of factors secreted by nociceptive 
neurons or by recruited cells such as mast cells, inflammatory cells and keratinocytes. These factors 
are of diverse origins but include protons (H+), nerve growth factors (NGF), cytokines (such as IL-
1β, IL-6), tumor necrosis factor alpha (TNFα), prostaglandins (PGE2), several neurotransmitters 
(serotonin, ATP), peptides (SP, CGRP). This mixture is commonly referred to as “the 
inflammatory soup” (Basbaum, Bautista et al. 2009). When binding their targets, these molecules 
will activate multiple intracellular pathways including Protein Kinase C (PKC) (Hucho, Dina et al. 
2005), Protein Kinase A (PKA) (Varga, Bolcskei et al. 2006), phosphoinositide 3-kinase (Pl3K) 
(Malik-Hall, Dina et al. 2005), and the Mitogen-activated protein (MAP) kinase ERK (Jin and 
Gereau 2006), among others. Two of the concrete effect of these cascades are the phosphorylation 
of TRPs (Mantyh, Koltzenburg et al. 2011) and Navs (Dib-Hajj, Cummins et al. 2010). This leads to 
increased neuronal excitability (Woolf and Ma 2007) by reducing its threshold and increasing its 
responsiveness. As a result, low-intensity stimuli may activate the nociceptive pathway. Once the 
inflammation fades away, these mechanisms should also disappear. However, in some cases, 
pronociceptive molecules are found long-lastingly in the site of injury, such as NGF and cytokines 
(Leung and Cahill 2010; Dogrul, Gul et al. 2011; Gaudet, Popovich et al. 2011) that can produce 
long-term changes. The case of TRPV1, illustrates these mechanisms. After nerve injury and 
diabetic neuropathy, TRPV1 is long-lastingly upregulated in sensory fibers (Hudson, Bevan et al. 
2001; Pabbidi, Yu et al. 2008) and was demonstrated to be associated with pain hypersensitivity. In 
addition, this receptor begins to be expressed in large myelinated A-fibers (Hong, Agresta et al. 
2008) a process referred to as phenotypic switch (Ueda 2006). By inducing profound changes in 
gene expression (Costigan, Befort et al. 2002), peripheral sensitization can confer to neurons a new 
molecular identity. For instance, substance P (SP) or brain-derived neurotrophic factor (BDNF), 
normally only expressed in nociceptive neurons, start to also be synthesized by Aβ-fibers 
(Malcangio, Ramer et al. 2000; Fukuoka, Tokunaga et al. 2002).  
1.3.4.1. Spontaneous discharge: 
A common aspect of neuropathic pain is the presence of pain in the absence of any identified 
stimulus. Spontaneous pain arises as a result of ectopic activity in the peripheral nervous system, 
driven by C-fibres (Djouhri, Koutsikou et al. 2006) and A-fibers (Liu, Wall et al. 2000). This 
spontaneous electric activity can originate from the site of injury (England, Gamboni et al. 1993; 
England, Happel et al. 1996), from both injured and non-injured DRG neurons (Wall and Devor 
1983; Liu, Wall et al. 2000; Wu, Ringkamp et al. 2001; Ma, Shu et al. 2003; Zhang, Zhou et al. 
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2004; Amir, Kocsis et al. 2005; Djouhri, Koutsikou et al. 2006) or from along the axons (Devor, 
Govrin-Lippmann et al. 1993). Because local anesthetics suppress ectopic discharges and attenuate 
allodynia and hyperalgesia (Mao and Chen 2000; Suter, Papaloïzos et al. 2003; Scholz, Broom et al. 
2005), sodium channels are thought to play an important role in the generation of ectopic activity. 
Other channels such as potassium channels KCNQ18 and KCNK10 (Tulleuda, Cokic et al. 2011) or 
Kvs (Kim, Choi et al. 2002), cation-nonselective, cyclic nucleotide-modulated channels (HCNs) 
(Lee, Chang et al. 2005) and Ca-activated chloride channels (CaCCs) (Hilaire, Campo et al. 2005) 
were demonstrated to be modulated after neuropathic pain and proposed to play a role in 
spontaneous discharges. 
1.3.4.2. Implication of Navs in neuropathic pain: 
It has long been known that Navs, by modifying the intrinsic electrical properties of neuronal 
membranes, are largely accountable for the neuropathic pain-associated hyperexcitability (Matzner 
and Devor 1994; Zhang, Donnelly et al. 1997). It is thought that a modification of the kinetics or the 
biophysical properties of the Navs after nerve injury is probably due to a change of expression of 
the different isoforms (Dib-Hajj, Cummins et al. 2010). This modification of expression can also 
account for the spontaneous membrane potential oscillation leading to a reduction in the firing 
threshold, which in turns is involved in the spontaneous activity of sensory neurons (Amir, 
Michaelis et al. 1999).  
Altogether, these observations point out the importance of Navs in the development of neuropathic 
pain, yet which isoforms take part and how they are implicated, remains largely unknown.  
Nav1.7: 
Despite its evident role in human pathological pain, Nav1.7’s role in neuropathic pain is still 
equivocal. For instance, Nav1.7 mRNA was reported to be reduced after SNI in rats (Berta, Poirot et 
al. 2008). However, transcriptional levels do not necessarily reflect the expression of functional 
proteins. Reduced levels of Nav1.7 were also reported in human studies after nerve injury (Coward, 
Aitken et al. 2001). Contrasting with these observations, protein level of Nav1.7 is increased in a 
model of diabetic neuropathy (Hong, Morrow et al. 2004) as well as in human painful dental pulp 
(Luo, Perry et al. 2008). The nociceptor-specific knockout of Nav1.7 does not prevent mice from 
developing neuropathic pain-mediated mechanical allodynia (Nassar, Stirling et al. 2004) but rather 
appears to be important for inflammatory and acute pain. Gain-of-function mutations of Nav1.7 
were recently reported to be associated with painful peripheral neuropathy syndromes (Faber, 
Hoeijmakers et al. 2012). Further evidence of its role in inflammatory pain, rather than neuropathic 
pain, was demonstrated by knocking-down Nav1.7 with a viral vector in primary afferents leading 
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to an attenuated development of hyperalgesia (Yeomans, Levinson et al. 2005). Other studies have 
reported an increase of Nav1.7 expression after injection of pro-inflammatory mediators (Gould, 
Gould et al. 2000; Black, Liu et al. 2004). Rather than being implicated in neuropathic pain by 
virtue of expression in the sensory system, Nav1.7 was recently reported to play an important role in 
neuropathic pain in lumbar sympathetic ganglion neurons (Minett, Nassar et al. 2012). 
Nav1.8: 
Nav1.8 was reported to be downregulated in terms of mRNA (Berta, Poirot et al. 2008), protein 
(Decosterd, Ji et al. 2002) and currents (Cummins and Waxman 1997; Berta, Poirot et al. 2008) in 
rat neuropathic pain models. Several explanations have been proposed to explain how a decrease of 
Nav1.8 could contribute to hyperexcitability. It was proposed that a high induction of translation in 
order increase de novo protein synthesis or the translocation of the Navs mRNA in the sciatic nerve 
could account for the reduction of Nav1.8 mRNA. In terms of protein, the decrease of Nav1.8 could 
be due to redistribution of the Navs proteins into uninjured neurons or along the sciatic nerve (Gold, 
Weinreich et al. 2003). In apparent contradiction with the above mentioned studies, another group 
reported an increase of Nav1.8 mediated current (Abdulla and Smith 2002). The nociceptor-specific 
knockout of Nav1.8 (Akopian, Souslova et al. 1999) demonstrated the importance of this isoform 
for sensing thermal, mechanical and inflammatory pain, but again authors reported no evidence for 
an implication in neuropathic pain (Kerr, Souslova et al. 2001). This was also confirmed by using 
diphtheria toxin to kill sensory neurons expressing Nav1.8 where animals exhibited normal 
development of neuropathic like symptoms (Abrahamsen, Zhao et al. 2008). However another study 
also using knockout mice line showed little implication of Nav1.8 in neuropathic pain (Leo, 
D'Hooge et al. 2010). In line with this, knocking down Nav1.8 using small interfering RNA (Dong, 
Goregoaker et al. 2007) or specific antisense oligodesoxynucleotides (Lai, Gold et al. 2002) 
reversed mechanical allodynia in neuropathic rats. It is likely that Nav1.8 involvement depends on 
the type of lesion and the model of chronic pain (Joshi, Mikusa et al. 2006).  
Nav1.3: 
Many studies reported an increase of mRNA for Nav1.3 in DRG using different experimental pain 
model (Waxman, Kocsis et al. 1994; Berta, Poirot et al. 2008), concomitant with an increase of the 
repriming rate of TTX sensitive currents, typical of Nav1.3 biophysical properties (Cummins and 
Waxman 1997). The implication of Nav1.3 was confirmed in a study using antisense nucleotides to 
silence this isoform, which attenuated neuropathic like symptoms as well as ectopic discharges. 
However, the Nav1.3 knockout mice developed normal neuropathic pain-like sysmptoms (Nassar, 
Baker et al. 2006). 
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Nav1.9: 
Nav1.9 role is also subject to discussion, but it is thought to play a role in inflammatory pain rather 
than neuropathic pain as observed with the knockout mice line (Amaya, Wang et al. 2006). 
Nav1.1 and Nav1.6 : 
The function of Nav1.1 or Nav1.6 is poorly understood and their implication in pathological pain 
conditions has never been investigated in detail. A study of Black et al. (Black, Liu et al. 2004)  
showed that neither Nav1.6 nor Nav1.1 were altered after carrageenan injection.  
1.3.4.3. Regulation and trafficking of Navs: 
Controlling Nav channel expression will impact on cellular excitability and involves the 
participation of multiple players (Figure 4). Mechanisms of transcriptional and translational 
regulation to control Nav channel expression have already been described (Diss, Fraser et al. 2004). 
Navs are designated to sense membrane potential oscillations, which lead to their opening and 
depolarizing Na+ influx. Consequently, only when anchored at the membrane are Navs functional. 
However, not solely membrane anchored channels are present in a cell, there is also large pool of 
intracellular Navs in a cell that can be rapidly recruited to the membrane when necessary (Schmidt, 
Rossie et al. 1985; Ritchie, Black et al. 1990). This pool may serve as a reserve and permits a 
neuron to respond rapidly to any kind of stimuli, allowing the increasing of channel surface 
expression faster than de novo synthesis would otherwise allow.  
Thus, tight balance between membrane anchored and intracellular pool, a process referred to as 
trafficking, is crucial for controlling cellular excitability. Maintaining this equilibrium is mediated 
by multiple enzymes, auxiliary subunit and partner proteins (Cusdin, Clare et al. 2008) that will be 
specialized in internalization or in stabilization of Navs at the membrane. I will discuss some of 
these regulatory mechanisms in the upcoming chapters.  
1.3.4.4. Regulation by partner proteins: 
Contactin (Ranscht 1988), which is a glycosyl-phosphatidylinositol (GPI)-anchored glycoprotein 
acting as an adhesion protein, is known to interact with sodium channels in vitro (Kazarinova-
Noyes, Malhotra et al. 2001) and ex vivo (Rush, Craner et al. 2005), leading to a modification of 
Na+ current densities. Many other proteins such as ankyrin (Malhotra, Kazen-Gillespie et al. 2000), 
spectrin (Bennett and Baines 2001), dystrophin and syntrophin (Gee, Madhavan et al. 1998; Abriel 
and Kass 2005) also modulate cell surface expression of Nav isoforms. Ankyrin was already 
investigated following peripheral nerve injury (Kretschmer, Nguyen et al. 2002). The authors 
33
proposed that this altered expression of ankyrin lead to the recruitment and clustering of Nav1.7 and 
Nav1.8 in neuromas, and might be responsible for neuropathic pain-associated hyperexcitability. 
Obviously, these interactions are often more complex and involve multiple players. Highlighting 
this, contactin interaction with ankyrin and β-subunits was shown to be necessary for Nav1.2 to be 
expressed at high density at the plasma membrane (McEwen, Meadows et al. 2004). It is also 
known that syntrophin and dystrophin are acting as a complex to regulate Nav1.5 membrane 
expression (Gavillet, Rougier et al. 2006). However, these proteins, and others (Shao, Okuse et al. 
2009), have only been sparsely investigated in terms of neuropathic pain. 
 
 
Figure 9. Two mechanisms 
involved in Nav turnover are 
shown in this scheme; the 
Nedd4-2 internalizing pathway 
and the β-subunit stabilizating 
pathway. The specific 
interaction takes place between 
one of Nedd4-2 WW domain 
and Navs PY-motif, which 
leads to the channel 
internalization. Once 
internalized, the channels may 
be directed toward a 
degradation pathway or 
recycled back to the plasma 
nce with the 
voltage-sensors.  
membrane.  
β-subunits stabilize the channel 
at the membrane and modify 
Nav gating properties via direct 
physical interfere  
1.3.4.5. Navs β-subunits: 
The β-subunits are multifunctional as they participate in cell-cell adhesion and cell migration, they 
interact with extracellular matrix and cytoskeleton molecules (Isom 2001). There are currently four 
different identified genes coding for the different β-subunits; SCN1B that codes for β1 (Isom, De 
Jongh et al. 1992) and its associated splice variant β1A (Kazen-Gillespie, Ragsdale et al. 2000) 
which is known to be secreted, SCN2B that codes for the β2 (Isom, Ragsdale et al. 1995), SCN3B 
for β3 (Morgan, Stevens et al. 2000) and SCN4B for β4 subunit (Yu, Westenbroek et al. 2003). 
These subunits are composed of an extracellular immunoglobulin-like in the N-terminal region, a 
single transmembrane segment and an intracellular carboxyl terminus tail (Isom, De Jongh et al. 
1992). β1 and β3-subunit interaction with the α-subunit occurs via a non-covalent link (Hartshorne, 
Messner et al. 1982). This interaction occurs via the extracellular loop of the β-subunit and involves 
multiple interaction sites (Qu, Rogers et al. 1999), identified as charged residues (McCormick, Isom 
et al. 1998) but also involves the C-terminal cytoplasmic tail of β1 for the interaction to occur 
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(Meadows, Malhotra et al. 2001; Yu, Ko et al. 2005). β2 and β4-subunits are associated with the α-
subunits via disulfide bonds (Hartshorne, Messner et al. 1982; Messner and Catterall 1985; Yu, 
Westenbroek et al. 2003) through their extracellular immunoglobulin-like structure, and the 
residues responsible for these interactions were recently identified (Chen, Calhoun et al. 2012). The 
assumed stoichiometry for α-β association is 1:1 (Catterall 1992). 
The pore-forming α-subunit is by itself functional and thus sufficient to allow Na+ conductance, but  
β–subunits can modulate the biophysical properties and the cell membrane stabilization of Navs 
(Figure 9) (Isom, Scheuer et al. 1995). The mechanism by which β-subunits regulates α-subunit 
gating properties is driven by direct interaction that interferes with the voltage-sensor (Zimmer and 
Benndorf 2002). The effects of the different β-subunits on biophysical properties put in light 
conflicting results depending on the cell type used (i.e. Xenopus oocytes and mammalian cell lines, 
(Nuss, Chiamvimonvat et al. 1995; Sangameswaran, Fish et al. 1997; Smith and Goldin 1998; 
Morgan, Stevens et al. 2000; Fahmi, Patel et al. 2001; Vijayaragavan, O'Leary et al. 2001; Zimmer 
and Benndorf 2002; Vijayaragavan, Powell et al. 2004)) and are presumably due to differential 
endogenous β-subunits expression as well as other partners (Meadows and Isom 2005) 
endogenously present.  
β-subunits can also affect current in ex vivo cell culture as highlighted by INa current recorded from 
SCNB knockout animals (Lopez-Santiago, Pertin et al. 2006; Lopez-Santiago, Brackenbury et al. 
2011). Our laboratory previously reported an increase of β2 subunit following nerve injury-induced 
neuropathic pain (Pertin, Ji et al. 2005). Moreover, β1 and β3-subunits were also reported to be 
increased in pathological pain (Shah, Stevens et al. 2000; Coward, Jowett et al. 2001) and could 
thus be implicated in modulating cellular excitability. Confirming this hypothesis, sensory neuron 
knockout of β2 subunit led to an attenuation of mechanical allodynia development after neuropathic 
pain (Pertin, Ji et al. 2005). 
1.3.4.6. Post-translational regulation: 
Several post-translational mechanisms were reported to regulate Nav surface expression (Figure 4). 
The protein kinase (PK) pathways is a well documented regulatory mechanisms of membrane Navs 
regulation (Shao, Okuse et al. 2009) principally mediated by PKAs (Zhou, Shin et al. 2002; Carr, 
Day et al. 2003; Vijayaragavan, Boutjdir et al. 2004; Chen, Yu et al. 2006), PKCs (Cantrell, Tibbs 
et al. 2002; Tateyama, Kurokawa et al. 2003; Vijayaragavan, Boutjdir et al. 2004), Ca2+, 
calmodulin (CaM) and Ca2+-dependent CaM kinase II (CaMKII)(Biswas, Deschênes et al. 2008). 
The effects on peak current or on biophysical properties of PKAs and PKCs, the sites of 
phosphorylations and the sodium channels isoforms have been extensively studied (Chahine, Ziane 
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et al. 2005). The role of these PKs was already demonstrated to be implicated in the development of 
chronic pain as discussed in chapter 1.3.4. 
1.3.4.7. Glycosylation: 
Another important post-translational modification affecting sodium channel function is 
glycosylation. In the ER and the Golgi, Nav α-subunits undergo extensive sequential glycosylation 
(Waechter, Schmidt et al. 1983; Schmidt and Catterall 1987), a process involving the addition of N-
acetylglucosamine which are capped by sialic acid residues and sequential addition of 
oligosaccharide chains. Glycosylation can represent up to 30% of the α-subunit molecular weight 
(Messner and Catterall 1985) with an estimated stoichiometry of up to 100 sialic acid molecules per 
channel (James and Agnew 1987). Glycosylation serves various functions such as protein folding, 
cell signalling, cell-cell adhesion and regulation, as well as being implicated in development and 
immunity (Moremen, Tiemeyer et al. 2012). Glycosylation is known since long to influence on the 
Nav α-subunit by modifying the voltage dependence of gating properties (Recio-Pinto, Thornhill et 
al. 1990; Bennett, Urcan et al. 1997; Zhang, Hartmann et al. 1999; Tyrrell, Renganathan et al. 
2001), probably by interfering with the electric field near gating sensors (Bennett, Urcan et al. 1997; 
Cronin, O'Reilly et al. 2004). It was proposed that the extracellular sialic acid residues, which are 
negatively charged at physiological pH, influence on how much the voltage sensor domains sense 
the transmembrane electrical potential difference (Ednie and Bennett 2011). Similar to α-subunits, 
β-subunits are also known to undergo extensive glycosylation, up to 36% of the total mass of the 
subunits, probably in its extracellular domain containing potential N-glycosylation sites (Isom, De 
Jongh et al. 1992; Johnson, Montpetit et al. 2004).  
1.3.4.8. Ubiquitylation:  
Mechanisms: 
Ubiquitylation is another well recognized post-translational process that negatively regulates the 
cell surface expression of many different plasma membrane proteins (Staub and Rotin 2006). 
Ubiquitylated proteins undergo internalization followed by degradation or recycling mechanisms 
(Abriel and Staub 2005). Ubiquitin is a small and highly conserved polypeptide of 76 amino acids 
that serves as a tag that becomes covalently attached to the lysine residues of the targeted protein. 
For a protein to be ubiquitylated, it needs three enzymatic successive steps (Pickart 2001): 
Ubiquitin is first activated by an ubiquitin-activating enzyme (E1) in an ATP-dependent manner. 
Ubiquitin is then transferred to an ubiquitin-conjugating enzyme (E2) via a thioester bond. This 
complex further interacts with an ubiquitin-protein ligase (E3) that will eventually ubiquitylate the 
substrate protein. E3 enzyme provides the specificity of the cascade as they promote the 
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conjugation of ubiquitin on the target protein by binding to a recognition motif in the target protein, 
usually on a lysine residue (Ciechanover 2005). There are at least 1000 different E3 enzymes in the 
human genome (Hicke, Schubert et al. 2005) further highlighting the specificity role of E3. As to 
compare, only ~10 different genes encode for E1 and ~100 for E2. The ubiquitin molecule 
possesses seven lysine residues that can serve for the formation of ubiquitin chains molecules called 
polyubiquitin chains. The fate of ubiquitylated proteins depends on the pattern of ubiquitylation; 
polyubiquitylated proteins (generally lysine K48) are generally degraded by the proteasome while 
monoubiquitylated (or diubiquitylated, generally on lysine K63) occurs to membrane proteins 
pending for internalization, which can further lead to lysosomal degradation or to recycling (Shih, 
Sloper-Mould et al. 2000; Ciechanover 2005). 
There are two major classes of E3 ubiquitin ligases: the RING finger (really interesting new gene) 
E3s, dependent on Zn2+ binding, and the Hect (homologous to E6-AP COOH terminal) E3s. The 
latter contain a HECT domain, which is the catalytic site responsible for the ubiquitylating the 
substrate protein (Huibregtse, Scheffner et al. 1995). The Nedd4/Nedd4-like (neuronal precursor 
cell-expressed developmentally downregulated gene 4) ubiquitin ligase family, composed of at least 
9 members (Ingham, Gish et al. 2004), is an important member of the Hect E3 ligases and is the 
best described family involved in the ubiquitylation of membrane proteins. In addition to the 
catalytic HECT domain, these members are composed of a NH2-terminal C2 (calcium-dependent 
lipid binding domain)(Rizo and Sudhof 1998) responsible for substrate localisation and variable 
number, from two to four, of WW domains (Staub and Rotin 1996) responsible for substrate 
recognition. The WW motifs binds to a short, proline-rich and conserved motif (Sudol and Hunter 
2000) called PY motif, consisting of PPxY sequence (Lu, Zhou et al. 1999; Kanelis, Rotin et al. 
2001). The Nedd4 family contains nine members in human; NEDD4, NEDD4-2, SMURF1, 
SMURF2, WWP1, WWP2, NEDL1, NEDL2 and ITCH (Harvey and Kumar 1999; Ingham, Gish et 
al. 2004) (Figure 10). Nedd4 is presumably the ancestral member of the family, whereas Nedd4-2 
emerged later in the evolution process (Yang and Kumar 2009). Nedd4 was first identified as part 
of a set of genes strongly downregulated in developing mouse brain (Sazuka, Tomooka et al. 1992). 
Nedd4 and Nedd4-2 are most closely related to each other and are widely expressed in different 
tissues in the body such as heart, kidney or the nervous system.  
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 Figure 10. The 
Nedd4 Family of 
E3 ubiquitin ligase 
in mice and 
humans. The 
accension number of 
each isoform is 
shown. In green is 
the C2 lipid binding 
domain, in 
red/purple are WW 
protein-protein 
interaction domain 
and in blue in the 
HECT catalytic site. 
Modified from 
(Ingham, Gish et al. 
2004)  
The case of epithelial sodium channel ENaC: 
The amiloride-sensitive epithelial sodium channel (ENaC), a channel important for controlling the 
electrolyte homeostasis was the first, and is probably the best described ion channel that undergoes 
the ubiquitin-mediated trafficking pathways. Mutations leading to a truncated ENaC were identified 
in Liddle’s syndrome, an hereditary hypertensive disease (Shimkets et al., 1994). ENaC subunits all 
possess a PY motif, and mutating this motif was sufficient to generate a hypertensive phenotype 
(Schild, Lu et al. 1996), which is  traduced by an increased ENaC function (Firsov, Schild et al. 
1996). Other groups highlighted the importance of the PY motif (Harvey, Dinudom et al. 1999; 
Fotia, Dinudom et al. 2003; Henry, Kanelis et al. 2003), which suggested a role for the Nedd4 
family in this regulation. This was confirmed in vitro where Nedd4-2 (Abriel, Loffing et al. 1999; 
Kamynina, Debonneville et al. 2001), and to a lesser extent Nedd4-1 (Henry, Kanelis et al. 2003), 
were shown to downregulate ENaC cell surface expression. Knocking out Nedd4-2 made the 
demonstration of a functional effect of Nedd4-2 in vivo. These knockout mice showed salt-sensitive 
hypertension, presumably mediated by an increased ENaC activity (Shi et al., 2008) and the 
subsequent increase Na+ reabsorption. 
Nedd4-2 regulates Na s: v
Interestingly, except for Nav1.4 and Nav1.9, every Navs isoform also possesses a conserved PY 
motif at their α-subunit C-terminal, making them potential targets of the Nedd4 ubiquitin ligase 
family (Figure 9). Nedd4-2 regulation of Nav1.5 was extensively investigated in HEK cells by our 
group, and we reported (1) a decrease in current density, (2) which was dependent on the PY motif, 
(3) concomitant with the ubiquitylation of the sodium channel, (4) relied on an intact catalytic site 
of Nedd4-2 and (5) interaction between the two protein (van Bemmelen, Rougier et al. 2004). These 
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results were further transposed to other neuronal isoform Nav1.2 and Nav1.3 in the same cell 
expression system (Rougier, van Bemmelen et al. 2005). Notably, the first proline of PPxY motif 
can be substituted for a leucin without notable loss of affinity (Kasanov, Pirozzi et al. 2001), a motif 
found in Nav1.6 (Rougier, van Bemmelen et al. 2005). This is in line with the fact that Nedd4-2 was 
also reported to decrease Nav1.6 in vitro (Gasser, Cheng et al. 2010). 
1.3.5. Central Sensitization: 
We discussed the importance of peripheral hyperexcitability and its involvement in neuropathic 
pain. Upon repetitive stimulation, such as the one driven by peripheral hyperexcitability, the 
synaptic strength between primary and secondary order neuron increases. This leads to 
hyperexcitability of the dorsal horn neurons and is referred to as central sensitization, a mechanisms 
first described by Clifford Woolf (Woolf 1983). In his initial work, Clifford Woolf showed that 
after injury, dorsal horn neurons have a decrease in the cutaneous mechanical threshold, expansion 
in the size of receptive fields, increase of neuronal response as well as spontaneous discharges, 
which were not abolished when blocking sensory input directly at the site of injury. Central 
sensitization is considered as an activity-dependent form of plasticity that shares similarities with 
LTP (Ji, Kohno et al. 2003; Scholz, Broom et al. 2005). Post-synaptic EPSPs in the spinal cord are 
mediated by NMDA glutamate receptors leading to the subsequent activation of calcium-induced 
intracellular kinases. This leads to the phosphorylation of AMPA and NMDA receptors and 
subsequently to their recruitment at the synapse, thus enhancing glutamatergic responses. All the 
intracellular pathways and receptors involved in the early phase of central sensitization mechanism 
are extensively described in the review from Latremoliere (Latremoliere and Woolf 2009). A 
second late phase of central sensitization involves the mitogen-activated protein kinase (MAPK) 
cascade, leading to activation of CREB phosophorylation and triggers transcription of 
pronociceptive genes. 
Another important mechanism significantly contributes the persistent enhancement of synaptic 
transmission; disinhibition. This occurs in two different ways, the loss of GABAergic inhibitory 
interneurons (Moore, Kohno et al. 2002) and the subsequent reduction of inhibitory currents, and 
the downregulation of potassium chloride co-transporter KCC2 in dorsal horn neurons (Coull, 
Boudreau et al. 2003). This exchanger is responsible for maintaining a low level of chloride 
intracellularly and its disruption leads to accumulation of this anion in the cell. As a result 
GABAergic and glycinergic inhibitory interneurons have depolarizing effect on dorsal horn 
neurons, increasing cellular excitability.   
The last established important mechanism responsible for central sensitization is the microglial 
activation (Watkins, Milligan et al. 2001; Beggs and Salter 2007). In short, activation of MAPKs 
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pathways will leads to the subsequent release of pronociceptive cytokins and neurtrophines that will 
impact on microglial neurotransmitter-scavenging capacity (Gosselin, Suter et al. 2010).  
 
 
Figure 11. Central 
Sensitization. The 
three major 
mechanisms leading 
to sensitization are 
highlighted on this 
scheme: NMDA-
mediated increase of 
synaptic strength, 
the loss of inhibition 
and the microglial 
activation.  Modified 
from (Basbaum, 
Bautista et al. 2009) 
1.3.6. Alteration in descending pathways: 
The role of the rostra ventromedial medulla (RVM) has been shown to be critical in the 
maintenance of hyperalgesic states following peripheral nerve injury. The mechanisms are largely 
unknown, but neurons within the RVM undergo changes in excitability, which contribute to the 
maintenance of overrated spinal nociceptive inputs (Gebhart 2004). 
1.3.7. Neuropathic pain Pharmacology: 
Treatments to alleviate acute and inflammatory pain are largely ineffective in neuropathic pain 
patients. Pharmacological treatment for neuropathic pain is limited, with only about 50% of patients 
obtaining partial pain relief, the other half being pharmaco-resistant. The fact that treatments are 
often inadequate could be due to the multiple mechanisms beyond the disease. Conventional 
analgesics were showed to be ineffective in relieving neuropathic pain symptoms while opioids are 
effective in alleviating pain in some patients.  
Gabapentin, an anticonvulsant initially developed to interact with GABA receptors, is effective for 
alleviating neuropathic pain symptoms, but is thought to act through α2-δ of Cavs (Taylor, Gee et al. 
1998). Calcium channels are becoming an increasingly attractive target for development of novel 
analgesic drugs (Perret and Luo 2009). Opioids are also effective in specific form of neuropathic 
pain treatment (Foley 2003), but are sometimes discouraged because of development of tolerance, 
risk of addiction and side effects.  
One of the first drug used in clinical trials was the tricyclic antidepressants (TCA) amitriptyline 
(Watson 1983) but produced many side effects. Nowadays, new classes of antidepressant, such as 
specific serotonin and norepinephrine reuptake inhibitors (SSNRIs) are better tolerated. 
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Noteworthy, there are some evidences that the analgesic effect of noradrenaline reuptake inhibition 
is necessary, while serotonine reuptake inhibition alone with the selective serotonin reuptake 
inhibitors (SSRI) is not sufficient for alleviating neuropathic pain (Lee and Chen 2010). The clinical 
rationale for using antidepressant is that in addition to controlling supraspinal availability of 
serotonine and norepinephrine in the descending inhibitory control pathway, they also activate μ 
and δ-opioid receptors and inhibit NMDA receptors (Micó, Ardid et al. 2006). Interestingly, they 
have also been reported to block Navs (Dick, Brochu et al. 2007). Anticonvulsant, such as 
carbamazepin and lamatrogin and which are also commonly used to treat neuropathic pain, have 
also been reported to negatively modulate Navs function (Dickenson, Matthews et al. 2002) but 
have sever side effect such as agranulocytosis (de Leon, Santoro et al. 2012). Other sodium channel 
blockers, such as lidocaine topical application (McQuay et al., 1995), lidocaine systemic injection 
(Kalso, Tramer et al. 1998) and transdermal formulation of lidocaine (Gammaitoni, Alvarez et al. 
2003) have already proven effective in treating some forms of neuropathic discomfort. Finally, 
mexiletine - an antiarrhythmic - is also a sodium channel blockers used to treat neuropathic pain 
(Priest and Kaczorowski 2007). The previous demonstrates the importance of Navs in neuropathic 
pain. 
Because none of the previously mentioned medications operate efficiently and satisfactorily 
individually, they are used in combination. First-line medications include TCAs, SSNRIs and α2-δ 
Cavs antagonist (Dworkin, O’Connor et al. 2007). Opioids are usually used in second-line 
medication, but remain inefficient in many cases. 
New promising perspectives for developing treatment to treat neuropathic pain are also carried by 
new therapeutical approaches such as cell based and gene therapy. For instance expressing 
preproenkephalin genes using viral vectors is currently on clinical trial phase I.  
1.3.8. Animal Models of Neuropathic pain: 
In vitro cellular biochemistry had helped identifying the important molecules potentially implicated 
in neuropathic pain, but a better understanding of the pathology requires for an entire organism to 
integrate every components of the pain experience.  
As already discussed, multiple diseases of the nervous system are associated with neuropathic pain 
and the clinical manifestations vary depending on the type. For instance, diabetic peripheral 
neuropathy and post-herpetic neuropathy are important contributors to the development of 
neuropathic pain (Dieleman, Kerklaan et al. 2008). However, streptozotocin and other chemically-
induced models of neuropathic pain have slow onsets and result in variable development of 
hypersensitivity and many other adverse effects (Courteix, Eschalier et al. 1993; Fox, Eastwood et 
al. 1999) making them not so reproducible when experimenting pain hypersensivity. Among 
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neuropathic pain conditions, mononeuropathy has the highest incidence rate (Dieleman, Kerklaan et 
al. 2008). The development of animal models for nerve injury–induced neuropathic pain has 
significantly contributed to the discovery of mechanisms that contribute to neuropathic pain 
syndromes. The animals in these models have been shown to develop abnormal pain sensations 
similar to those reported in neuropathic pain patients.  
The first behavioral model used complete transection of nerve and aimed at studying anesthesia 
dolorosa (Wall, Devor et al. 1979), which is pain in the absence of any sensory input in the rat and 
where  autotomy (self mutilation of the paw as an indirect sign of spontaneous pain) was observed 
after a total denervation of the limb by the transection of femoral and sciatic nerves. However this 
model does not allow the measurement of allodynia and hyperalgesia and does not best reflects the 
partial nerve injury observed in most neuropathic pain patients. To overcome this problem, partial 
transection (ligation or constriction) of nerves were developed and among them, spinal nerve 
ligation (SNL, (Kim and Chung 1992)), chronic constriction injury (CCI, (Bennett and Xie 1988)) 
and the spared nerve injury model (SNI, (Decosterd and Woolf 2000)). The latter involves a lesion 
of two of the three terminal branches of the sciatic nerve, the common peroneal and tibial nerves, 
whereas the sural nerve is spared. The SNI results in increased mechanical and thermal sensitivity 
in the territory of the sural nerve, thus mimicking some of the clinical features of neuropathic pain 
(Woolf and Mannion 1999). This model enables the neurons being severed and the ones that are 
intact to be intermingled in the same dorsal root ganglion (DRG) allowing chemical cross-talk 
between cells, but the proper role of injured versus non-injured neurons in the development of pain 
hypersensibility remains equivocal. Hyperalgesia and allodynia are relatively easy to investigate in 
animal models, but the measurement of ongoing pain is more problematic. It is thought that 
autotomy or spontaneous foot lifting behavior reflects ongoing pain, but this is still debated. Much 
hope is coming from the development of the Mouse Grimace Scale (MGS) (Langford, Bailey et al. 
2010), a facial-expression-based pain coding system which is thought to reliably reflect 
sponteanous pain in animals.   
1.4. Aim of my thesis: 
In this introduction, I extensively discussed the peripheral component of neuropathic pain-
associated hyperexcitability. I highlighted the significant role of Navs in normal and pathological 
pain. Notably, Nav1.7 and Nav1.8 have been shown to be crucial in the transmission of pain signals 
as illustrated by the increasing identified mutations of these isoforms, leading to increased sodium 
conductance. However, mechanisms that regulate the membrane pool of Navs, also important for 
modulating sodium conductance, are poorly understood. During my thesis research work, I 
investigated two antagonist mechanisms of Navs regulation; the “internalizing Nedd4-2 pathway” 
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Introduction 
and the “stabilizing β-subunit pathway”. I will first address the question of the in vivo implication 
of Nedd4-2 in the generation of neuropathic pain by dysregulating Nav1.7 and Nav1.8 expression. 
This part of my work has been accepted for publication in the Journal of Clinical Investigation. The 
second part of highlights a novel role for β-subunit in glycosylating Nav α-subunit in vitro which 
opens perspectives for investigating the potential physiological role of Nav glycosylation in pain 
pathways. This research is summarized in a manuscript that is published in Frontiers in Cellular 
Neuroscience. 
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2. Results 
2.1. Dysregulation of voltage-gated sodium channels by 
ubiquitin-ligase NEDD4-2 in neuropathic pain 
This article is published  in the Journal of Clinical Investigation (Laedermann, Cachemaille et al. 
2013). 
The core findings in this study are that the Nedd4-2 protein is an essential regulator of Navs in vivo, 
and that it is responsible for the genesis of neuropathic pain. 
In this manuscript, we explored the role of Nedd4-2 expressed in dorsal root ganglion (DRG) cells 
in the regulation of Nav1.7 and Nav1.8, and its potential involvement in the pathogenesis of 
neuropathic pain. We used a multi-facetted approach involving (1) the use of a mouse neuropathic 
pain model (spared nerve injury, SNI), (2) the generation of a mouse model with DRG-specific 
genetic ablation of Nedd4-2, (3) Nedd4-2 gene transfer experiments in DRG cells using viral 
vectors and (4) the utilization of a specific Nav1.7 selective blocker (ProTxII) to isolate Nav1.7-
mediated current for the first time. 
The main findings in this study are that in DRG cells of the SNI mouse model, there is a specific 
reduction of Nedd4-2 expression with concomitant increased expression and function of Nav1.7 and 
Nav1.8-mediated current. Similar alterations were observed in mice with knocked out expression of 
Nedd4-2 in DRG cells, demonstrating a causal link between Nedd4-2 downregulation and Nav1.7 
and Nav1.8 upregulation. These mice also showed an altered pain phenotype. Finally, we 
demonstrated that upon Nedd4-2 gene transfer in DRG cells of SNI animals, the SNI-mediated 
hypersensitivity phenotype could be partially rescued. 
Since Nedd4-2 can also regulate other sodium channel isoforms and membrane proteins (i.e. 
glutamate receptors), a better understanding of Nedd4-2 in sodium channel dysfunction may have 
far-reaching implications not only to pain, but also to epilepsy, migraines or cognitive impairment.  
In this article, I performed electrophysiological recordings in both cell expression system and 
dissociated DRG neurons. I performed all the biochemical experiments inherent to Figure 2 and 
generated the constructs (GST-fusion proteins, Nav1.7 and Nedd4-2 mutants). I also performed 
biochemistry on native DRG tissues. I performed qRT-PCR. I started the breeding of SNS-Nedd4-
2fl/fl mouse line and genotyped them. I participated in the design, production and quantification of 
the rAAV2/6 viral vectors. I wrote the first draft and corrected versions of the manuscript. 
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Dysregulation of voltage-gated sodium 
channels by ubiquitin ligase NEDD4-2  
in neuropathic pain
Cédric J. Laedermann,1,2 Matthieu Cachemaille,1 Guylène Kirschmann,1 Marie Pertin,1  
Romain-Daniel Gosselin,1 Isabelle Chang,1 Maxime Albesa,2 Chris Towne,3  
Bernard L. Schneider,3 Stephan Kellenberger,4 Hugues Abriel,2 and Isabelle Decosterd1,5
1Pain Center, Department of Anesthesiology, University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.  
2Department of Clinical Research, University of Bern, Bern, Switzerland. 3Brain Mind Institute, Ecole Polytechnique Fédérale de Lausanne (EPFL),  
Lausanne, Switzerland. 4Department of Pharmacology and Toxicology and 5Department of Fundamental Neurosciences,  
University of Lausanne, Lausanne, Switzerland.
Peripheral neuropathic pain is a disabling condition resulting from nerve injury. It is characterized by the 
dysregulation of voltage-gated sodium channels (Navs) expressed in dorsal root ganglion (DRG) sensory neu-
rons. The mechanisms underlying the altered expression of Navs remain unknown. This study investigated the 
role of the E3 ubiquitin ligase NEDD4-2, which is known to ubiquitylate Navs, in the pathogenesis of neuro-
pathic pain in mice. The spared nerve injury (SNI) model of traumatic nerve injury–induced neuropathic pain 
was used, and an Nav1.7-specific inhibitor, ProTxII, allowed the isolation of Nav1.7-mediated currents. SNI 
decreased NEDD4-2 expression in DRG cells and increased the amplitude of Nav1.7 and Nav1.8 currents. The 
redistribution of Nav1.7 channels toward peripheral axons was also observed. Similar changes were observed 
in the nociceptive DRG neurons of Nedd4L knockout mice (SNS-Nedd4L–/–). SNS-Nedd4L–/– mice exhibited ther-
mal hypersensitivity and an enhanced second pain phase after formalin injection. Restoration of NEDD4-2 
expression in DRG neurons using recombinant adenoassociated virus (rAAV2/6) not only reduced Nav1.7 and 
Nav1.8 current amplitudes, but also alleviated SNI-induced mechanical allodynia. These findings demonstrate 
that NEDD4-2 is a potent posttranslational regulator of Navs and that downregulation of NEDD4-2 leads to 
the hyperexcitability of DRG neurons and contributes to the genesis of pathological pain.
Introduction
Neuropathic pain is a direct consequence of alterations in the 
somatosensory system. It affects approximately 7% of the general 
population and is insufficiently treated with currently available 
drugs (1). Following nerve injury, there is ectopic spontaneous 
activity of afferent neurons due to the increased expression of 
voltage-gated sodium channels (Navs) (2, 3). This hyperexcitabil-
ity mediates enduring changes in the nervous system, contrib-
uting to both peripheral and central sensitization (4). Navs are 
heteromeric glycosylated protein complexes composed of a large 
pore-forming α subunit and auxiliary β subunits (5, 6). Nine 
genes encode for distinct channel isoforms (Nav1.1 to Nav1.9), 
each displaying specific properties. They are classified according 
to their sensitivity to tetrodotoxin (TTX). All isoforms, except 
Nav1.4 and Nav1.5, are expressed in the dorsal root ganglia 
(DRG) and trigeminal ganglia (TG) nociceptive neurons, with 
Nav1.8 and Nav1.9 being expressed almost exclusively in DRG/
TG neurons and Nav1.7 in DRG/TG and sympathetic ganglion 
neurons (7). Nav1.7 is expressed at higher levels in DRG/TG than 
are other TTX-sensitive isoforms (7, 8) and plays an essential 
role in the modulation of human pain perception. Naturally 
occurring mutations in SCN9A, the gene encoding Nav1.7, lead 
to either congenital insensitivity or severe episodic hypersen-
sitivity to pain (9–11). In addition, Nav1.7 and Nav1.8 gain-of-
function mutations in painful peripheral neuropathy syndromes 
were recently described (12, 13). Not only are Nav1.7 and Nav1.8 
important in inherited pain disorders, but also in acquired pain 
disorders, where their increased expression has already been 
linked to diverse chronic pain symptoms (14–16). Studies using 
knockout mice have implicated Nav1.7 and Nav1.8 in acute and 
inflammatory pain (17–20), but their involvement in hyperexcit-
ability and neuropathic pain remains to be determined.
The control of Nav density at the cell membrane is crucial to ensur-
ing normal neuronal excitability. Despite extensive research on the 
subject, the regulation of Navs in neuropathic pain remains poorly 
understood. Navs are subject to posttranslational modifications 
that may influence their cell membrane availability. Ubiquitylation 
is a key process that orchestrates the internalization and subsequent 
degradation or recycling of Navs (21). The final and limiting step 
is the covalent attachment of ubiquitin moieties to lysine residues 
of the target protein. This is accomplished by ubiquitin protein 
ligases, such as NEDD4-2 (neuronal precursor cell expressed devel-
opmentally downregulated-4 type 2). NEDD4-2 is a member of the 
NEDD4/NEDD4-like E3 subfamily of ubiquitin ligases, whose type 
I WW domains interact with the PY motifs (PPxY) of target proteins. 
All Nav isoforms, except Nav1.4 and Nav1.9, possess a PY motif and 
are potential targets of NEDD4-2. In vitro experiments have indi-
cated that NEDD4-2 can negatively regulate the epithelial sodium 
channel ENaC (22) and Navs (23, 24). The functional relevance of 
NEDD4-2 in sensory neurons, as well as its possible involvement in 
pain sensitivity, have yet to be investigated.
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NEDD4-2 was recently shown to be decreased in rat DRG in 
the spared nerve injury (SNI) model of traumatic nerve injury–
induced neuropathic pain (25). The present study postulated that 
reduced levels of NEDD4-2 jeopardize the correct addressing or 
anchoring of Navs in DRG nociceptive neurons. NEDD4-2 expres-
sion was controlled in cellular expression systems and in mice with 
DRG-specific gene deletions or rAAV-mediated gene transfers. 
This enabled the selective investigation of the effect of NEDD4-2 
on Nav1.7 and Nav1.8 currents, as well its impacts on pain sensi-
tivity. The results provide what we believe to be the first in vivo 
mechanistic evidence that NEDD4-2 enables the fine-tuning of 
neuronal excitability in DRG cells. Furthermore, these results may 
demonstrate that the pathological reduction of NEDD4-2 under-
lies traumatic nerve injury–induced neuropathic pain.
Results
Peripheral nerve injury reduces NEDD4-2 expression in DRG. The pro-
tein and mRNA levels of Nedd4L were measured to explore whether 
Nedd4L is regulated after nerve injury in mice and whether it contrib-
utes to phenotypic changes in DRG neurons. A substantial decrease 
of NEDD4-2 expression was observed by immunofluorescence 
in lumbar L4/L5 DRG 7 days after SNI (Figure 1, A and B). This 
decrease was further quantified using Western blot analysis. SNI 
decreased NEDD4-2 protein levels by greater tha 60% in DRG, an 
effect that lasted for at least 6 weeks (Figure 1C). Both SNI and spinal 
nerve ligation (SNL) reduced Nedd4L transcript levels (Figure 1D). 
Nedd4L mRNA was abundantly expressed in lumbar L4/5 DRG and 
was the only member of the Nedd4/Nedd4-like E3 subfamily to be 
downregulated after SNI (Figure 1E).
NEDD4-2 interacts with, ubiquitylates, and downregulates Nav1.7 in 
HEK293 cells. Since Nav1.7 is essential for pain sensation, NEDD4-
2 downregulation of Nav1.7 in mammalian cells was investigated, 
as previously reported in Xenopus oocytes (24). Whole-cell Na+ 
currents (INa) were recorded in HEK293 cells cotransfected with 
Nav1.7 and NEDD4-2. NEDD4-2 decreased Nav1.7 current den-
sity by approximately 80% (Figure 2, A and B). The biophysical 
properties of Nav1.7 were unaffected by NEDD4-2 (Supplemen-
tal Table 1 and Supplemental Figure 1A; supplemental material 
Figure 1
Peripheral nerve injury reduces NEDD4-2 expression in DRG. (A 
and B) Immunofluorescence of NEDD4-2 in coronal sections of 
L4 DRG from sham-operated and SNI mice. Scale bars: 30 μm. 
(C) Representative Western blot analysis showing the decrease 
in NEDD4-2 at days 7, 21, and 42 after SNI in L4/5 DRG and its 
associated quantification. Data are expressed as the means ± SEM; 
n = 4 samples for each time point per group. ***P < 0.001 by 1-way 
ANOVA with Bonferroni’s post-hoc test. GAPDH was used as a 
loading control. Lanes were run on the same gel but were noncon-
tiguous. (D) Effect of SNI and SNL on Nedd4-1 and Nedd4L tran-
scripts in L4/5 DRG 7 days after SNI or SNL (injury of L5 spinal 
nerve). Bar graph showing transcriptional levels of Nedd4-1 and 
Nedd4L normalized to GAPDH in SNI and SNL groups over the 
control group (sham for SNI and L4 DRG for SNL). Data represent 
the mean ± SEM; n = 4 samples per group. Isolated L4/5, L5, or L4 
DRG from 2 mice were pooled for each sample and run in triplicate. 
*P = 0.011, **P = 0.004, Student’s t test. (E) Constitutive transcript 
levels of Nedd4/Nedd4-like E3 subfamily members in L4/5 DRG 7 
days after sham and SNI surgery. Transcript levels were normal-
ized using HPRT as a reference gene and further normalized to 
Nedd4L levels in sham-operated mice. Data are expressed as the 
means ± SEM; n = 3–4 samples per group, which were run in trip-
licate. **P = 0.005, Student’s t test. We detected no amplification of 
NedL1 in the DRG samples.
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available online with this article; doi:10.1172/JCI68996DS1), sug-
gesting that NEDD4-2 mainly reduces the number of channels 
at the cell surface. Cell-surface proteins were then biotinylated 
and precipitated. Upon NEDD4-2 cotransfection, expression of 
the fully glycosylated form of Nav1.7 (Supplemental Figure 1B) 
was decreased by approximately 50% in the plasma membrane 
fraction, but remained unchanged in the total lysate (Figure 2C, 
see also Supplemental Figure 1, C and D, for additional in vitro 
experiments). The interaction between Nav1.7 and NEDD4-2 was 
examined by pull-down experiments using GST fused to the fur-
thest 66 C-terminal amino acid residues of Nav1.7, which include 
the PY motif (GST-Cter-Nav1.7). Nav1.7 GST fusion proteins 
interacted with endogenous and transfected NEDD4-2, whereas 
GST alone did not (Figure 2D). Finally, whether Nav1.7 could 
be a substrate of NEDD4-2 ubiquitylating activity was tested 
by pulling down ubiquitylated proteins using GST fused to the 
ubiquitin-binding proteasomal subunit S5A (GST-S5A). Overex-
pression of NEDD4-2 substantially increased GST-S5A–bound 
Nav1.7 (Figure 2E). Taken together, these results support a model 
in which NEDD4-2 interacts with and ubiquitylates Nav1.7 and 
thus controls the level of the functional channel at the cellular 
membrane in mammalian cells. Additional in vitro experiments 
demonstrating the importance of the PY motif in the NEDD4-2 
downregulatory effect on Nav1.7 are presented in Supplemental 
Figure 2, A–F and in the Supplemental Results.
SNI changes the expression of Navs. In freshly dissociated L4/5 
mouse DRG neurons, the different Nav components were func-
tionally dissected out 1 week after SNI by performing whole-cell 
patch-clamp recordings. From total INa (Navtotal), the specific 
Nav1.7 channel blocker ProTxII (26) and TTX were used to isolate 
the following 3 currents: the Nav1.7-mediated current (ProTxII-
sensitive current, referred to as Nav1.7 for simplicity), the remain-
Figure 2
NEDD4-2 downregulates membrane Nav1.7. (A) Representative cur-
rent traces obtained with a V-I protocol (see Methods) on HEK293 
cells after Nav1.7 transfection or cotransfection with NEDD4-2. (B) 
Quantification of current densities from A. NEDD4-2 reduced Nav1.7 
current density (***P < 0.001). See Supplemental Figure 1A and 
Supplemental Table 1 for values and biophysical properties. (C) 
Surface biotinylation of HEK293 cells and their associated quantifi-
cation. In membrane fractions, NEDD4-2 reduced the fully glycosy-
lated form of Nav1.7 (***P < 0.001), whereas the core glycosylated 
form remained unchanged (P = 0.416). Nav1.7 total expression was 
unchanged (P = 0.337; Input). The β1 subunit of the NaK/ATPase 
and actin were used as loading controls in input and biotinylation 
fractions, respectively. Deglycosylation experiments are presented 
in Supplemental Figure 1B. NEDD4-2 antibody recognizes both 
endogenous (120 kDa) and transfected (100 kDa) proteins. (D) 
GST pull-down experiment showing Nav1.7 PY motif interaction with 
NEDD4-2. HEK293 cells were transfected with NEDD4-2, and sol-
uble fractions were mixed GST proteins or GST-Cter-Nav1.7 fusion 
proteins. Bound NEDD4-2 was analyzed by Western blot. The entire 
Western blot with PY motif mutants can be seen in Supplemental 
Figure 2E. (E) NEDD4-2–mediated ubiquitylation. HEK293 cells 
were transfected with Nav1.7 or cotransfected with NEDD4-2, and 
soluble fractions were mixed with GST-S5A proteins to pull down 
ubiquitylated proteins. Bound Nav1.7 was analyzed by Western blot-
ting. The entire Western blot with PY motif mutants can be seen in 
Supplemental Figure 2F.
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ing TTX-sensitive currents (Nav1.1, Nav1.2, Nav1.3, and Nav1.6 
currents collectively referred to as NavrTTXs), and the TTX-resis-
tant currents (referred to as Nav1.8, since Nav1.9 was inactivated 
by an ad-hoc electrophysiological protocol; see Methods) (Figure 
3A). Recorded cells were small neurons (<30 pF), considered to 
be nociceptive neurons (27). Despite the fact that the distinction 
between intact or severed neurons was not made, a significant 
increase in the Navtotal (P = 0.013) and NavrTTXs (P = 0.021) 
current densities after SNI were measured (ipsilateral compared 
with the contralateral side, Supplemental Figure 3A). Since the 
expression of Navs in DRG is heterogeneous, the analysis was 
refined by segregating cells into fast and slow neurons, as previ-
ously reported (27). A neuron was characterized as slow when the 
INa density ratio of the Nav1.8/Navtotal was greater than 0.5, with 
Nav1.8 displaying slower inactivation kinetics. Conversely, when 
this ratio was less than 0.5, the neuron was defined as fast (27). 
This selection revealed that SNI significantly increased Nav1.7 
and Nav1.8 current densities in the slow subpopulation only (Fig-
ure 3B). The fast subpopulation showed a small but significant 
increase in NavrTTXs alone (Figure 3C; P = 0.014).
SNI had only a minor impact on the biophysical properties 
(voltage dependence of steady-state activation and inactivation) 
of some of the Nav components (Supplemental Table 2). In line 
with previous studies (28, 29), nerve injury induced an acceleration 
of the recovery from inactivation (repriming) for every component 
of INa of the fast subpopulation (Supplemental Table 2).
Western blots of pooled L4/5 DRG revealed no detectable modi-
fication of the expression levels of Navtotal, nor that of Nav1.7 (P = 
0.039) or Nav1.8 (P = 0.024) 1 week after SNI (Figure 3D). However, 
Nav1.7 and Navtotal levels were significantly increased in the sciatic 
nerve. Nav1.8 was undetectable in the nerves of sham-operated ani-
mals. The signal intensity was not significantly modified after SNI, 
but a distinct band at the expected molecular weight (230–240 kDa) 
was visible in all 4 SNI samples (see Supplemental Figure 3B).
Figure 3
Increase in Nav1.7 and Nav1.8 currents in DRG neurons and increased expression of Nav1.7 along the sciatic nerve after SNI. (A) Typical 
recordings of INa in DRG neurons using the V-I protocol and pharmacological isolation of Navtotal, Nav1.7, Nav1.8, and NavrTTXs currents 
with ProTxII and TTX (see Methods). (B and C) Scatter dot plot representing Navtotal, Nav1.7, Nav1.8, and NavrTTXs current densities in 
contralateral and ipsilateral sides recorded in L4/5 DRG neurons 1 week after SNI. Slow (B, in cyan) and fast (C, in magenta) neurons are 
shown. Mann-Whitney U test. See Supplemental Figure 3A for the total population and see Supplemental Table 2 for values and biophysical 
properties. (D) Left panel: representative Western blot analysis and quantification of Nav α subunits: Navtotal, Nav1.7, and Nav1.8 in DRG 7 
days after SNI. No modifications in Navtotal (P = 0.496), Nav1.7 (P = 0.690), or Nav1.8 (P = 0.311) were observed in sham- and SNI-oper-
ated mice. Right panel: same as above, but for sciatic nerve preparation. Nav1.7 (*P = 0.045) and Navtotal (*P = 0.021) were significantly 
increased in SNI compared with the sham samples. The Nav1.8 signal in the SNI sample did not reach significance compared with the 
background signal in the sham-operated group (P = 0.105) (see Supplemental Figure 3B). The 2 open arrowheads correspond to a distinct 
band of Nav1.8, with lower molecular weight than the band observed at 250 kDa. Data are expressed as the means ± SEM; n = 4 samples 
for each group. Student’s t test. Tubulin was used as a loading control. Int., intensity.
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Figure 4
SNS-Nedd4L–/– mice show increased Nav1.7 and Nav1.8 currents in DRG neurons and 
increased expression of Nav1.7 along the sciatic nerve. (A and B) Immunofluorescence 
of NEDD4-2 in coronal sections of L4 DRG from Nedd4Lfl/fl and SNS-Nedd4L–/– mice. 
Scale bars: 30 μm. (C and D) Immunofluorescence and corresponding bright-field 
images of NEDD4-2 in DRG neurons from Nedd4Lfl/fl and SNS-Nedd4L–/– mice after 
whole-cell patch-clamp recordings (36 hours after dissociation). Scale bars: 30 μm. (E) 
Western blot and quantification showing NEDD4-2 decrease in the DRG (**P = 0.003) 
of SNS-Nedd4L–/– mice compared with control Nedd4Lfl/fl mice. (F and G) Scatter dot 
plots representing Navtotal, Nav1.7, Nav1.8, and NavrTTXs current densities in L4/5 DRG 
neurons from SNS-Nedd4L–/– and Nedd4Lfl/fl mice. Slow (F, in cyan) and fast (G, in 
magenta) neurons are shown. Mann-Whitney U test. See Supplemental Figure 4A for 
total population and Supplemental Table 3 for values and biophysical properties. (H) 
Left panel: Western blot analysis and quantification of Nav α subunits in the DRG of 
SNS-Nedd4L–/– and Nedd4Lfl/fl mice. No significant modifications in Navtotal (P = 0.054) 
or Nav1.7 (P = 0.646) were observed, whereas the Nav1.8 signal was increased in the 
SNS-Nedd4L–/– mice (*P = 0.020). Right panel: same as above, but for sciatic nerves. 
Nav1.7 was significantly increased (*P = 0.022), whereas the increase in Navtotal was 
not significant (P = 0.089). Data are expressed as the means ± SEM; n = 4 samples for 
each group. Student’s t test. Tubulin was used as a loading control in E and H.
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Nav expression in SNS-Nedd4L–/– knockout mice. To investigate 
the contribution of NEDD4-2 to the expression of Navs in DRG 
in vivo and its impact on pain, a DRG neuron–specific Nedd4L- 
deficient mouse line was generated (SNS-Nedd4L–/–; see Supple-
mental Methods). Mice carrying a homozygous Nedd4L flox allele 
(Nedd4Lfl/fl) (30) were crossed with mice heterozygously express-
ing Cre recombinase under the control of the Nav1.8 promoter 
(referred to as SNS-Cre), which is predominantly active in DRG 
nociceptive neurons (31). Cre expression in this mouse line has 
been extensively characterized (32) and differs from another Nav1.8-
Cre mouse line generated by the Wood laboratory (33). NEDD4-2 
expression was greatly reduced in the DRG neurons of SNS-
Nedd4L–/– mice (Figure 4, A–E). A slight signal was still detectable 
in the SNS-Nedd4L–/– mice, most likely due to a residual expression 
of NEDD4-2 in neurons not expressing Nav1.8 (Figure 4E). Whole-
cell patch-clamp recordings showed a 2-fold upregulation of Nav-
total, Nav1.7 (P = 0.027), and Nav1.8 (P < 0.001) current densities 
in neurons from SNS-Nedd4L–/– mice (Supplemental Figure 4A and 
Supplemental Table 3) compared with neurons from Nedd4Lfl/fl 
control littermates. The NavrTTXs component was not signifi-
cantly altered. Subsequent analyses of slow and fast neuronal 
subpopulations revealed that, similar to the SNI condition, the 
changes were predominant in slow neurons (a 2-fold increase for 
Navtotal [P = 0.001], Nav1.7 [P = 0.042], and Nav1.8 [P < 0.001] 
current densities) (Figure 4, F and G). The biophysical properties 
were largely unaltered in the knockout mice (Supplemental Table 
3), consistent with a major role of NEDD4-2 in the regulation of 
Nav1.7 and Nav1.8 membrane density.
We then evaluated whether the expression of Navs was modified 
in DRG and the sciatic nerves of SNS-Nedd4L–/– mice (Figure 4H). 
We observed a markedly increased Western blot signal for Nav1.8 
in the DRG of knockout mice, while the signal was undetectable 
in Nedd4Lfl/fl DRG neurons. These observations were confirmed by 
immunofluorescence measurements (Supplemental Figure 4B). 
Although the Nav1.7 signal from DRG was not changed between 
the groups, a stronger signal was observed in the sciatic nerves of 
the SNS-Nedd4L–/– mice, similar to that observed after SNI. Nav1.8 
immunoreactivity was not detected in the sciatic nerves of the 
knockout mice or in those of the control mice, suggesting that the 
mechanisms underlying Nav1.8 redistribution in nerves after SNI 
are independent of NEDD4-2 downregulation.
Pain-related responses in SNS-Nedd4L–/– knockout mice. We then 
investigated whether peripheral deficiency of NEDD4-2 could 
modify pain behavior. While response latencies to radiant heat 
(tail-flick test) (Figure 5B) and acute mechanical nociception (tail 
pressure test) (Figure 5C) were unchanged, acute thermal hyper-
sensitivity in SNS-Nedd4L–/– mice was observed with the hot-plate 
test at 52°C and 55°C (Figure 5A). We also performed the hot-
Figure 5
SNS-Nedd4L–/– mice show increased thermal sensitivity and an increased second pain phase after formalin injection. (A) Significantly higher 
thermal sensitivity was detected in the hot-plate test at 52°C and 54°C in SNS-Nedd4L–/– mice. P = 0.112 at 49°C, **P = 0.009 at 52°C, and 
**P = 0.008 at 55°C; Mann-Whitney U test. (B) No differences were observed in the tail-flick test. P = 0.414 at intensity 4 and P = 0.830 at intensity 
7 (AU); Mann-Whitney U test. (C) Responses to the tail pressure test were unchanged. P = 0.452, Student’s t test. (D) Basal responses to mechan-
ical stimulation and development of SNI-related mechanical allodynia-like behavior were not different. P > 0.05, 2-way ANOVA on log values with 
post-hoc Bonferroni’s tests. (E) Higher thermal sensitivity was detected at 52°C in SNS-Nedd4L–/– mice, but this effect was not further increased 
after SNI. *P < 0.05 between groups using 2-way ANOVA with repeated measures. *P < 0.05 on day 7 with post-hoc Bonferroni’s tests. (F) Plan-
tar test 35 days after SNI. Higher thermal sensitivity was detected in SNS-Nedd4L–/– mice as compared with the noninjured paws of Nedd4Lfl/fl 
mice (contralateral). SNI induced thermal hyperalgesia in the injured paws of Nedd4Lfl/fl mice compared with noninjured paws. *P = 0.013 and 
**P = 0.006 at intensity 3 (AU), Student’s t test. (G) Time course of the nocifensive response to formalin injection revealed an increased response 
in SNS-Nedd4L–/– mice during the second phase of the test. ***P < 0.001, 2-way ANOVA with repeated measures with post-hoc Bonferroni’s tests. 
Insert shows the bar graph of this effect through AUC quantification. **P = 0.009, Mann-Whitney U test. Data are expressed as the means ± SEM 
and n = 7– 28 animals per group for all panels.
Downloaded on September 23, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/68996
50
research article
3008 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 7   July 2013
plate test at 52°C after SNI (Figure 5E). Nedd4Lfl/fl mice did not 
develop SNI-induced hyperalgesia. The observed thermal hyper-
sensitivity in the SNS-Nedd4L–/– mice under basal conditions was 
not further enhanced after SNI. The response of the hot-plate test 
depends on the strength applied by the paw to the plate, which may 
be impeded after SNI surgery due to the transection of motor neu-
rons. To overcome this problem, we performed the plantar test, an 
alternative thermal sensitivity test independent of strength, at the 
end of the SNI time course (i.e., 35 days after SNI). As illustrated 
in Figure 5F, the noninjured paws of SNS-Nedd4L–/– mice demon-
strated more thermal hypersensitivity than the noninjured paws 
of Nedd4Lfl/fl mice. SNI induced thermal hypersensitivity in the 
injured paws of Nedd4Lfl/fl mice, but did not further enhance the 
hypersensitivity in the injured paws of SNS-Nedd4L–/– mice. Basal 
mechanical innocuous sensitivity was not altered in Nedd4Lfl/fl 
mice (see baseline [BL] in the von Frey filaments test in Figure 5D). 
After SNI, the decrease in the withdrawal threshold related to the 
development of mechanical allodynia–like behavior was indis-
tinguishable between groups. Intraplantar injection of formalin 
in SNS-Nedd4L–/– mice led to an increased and earlier maximal 
Figure 6
Delivery of rAAV2/6-NEDD4-2 viral vector decreases functional currents after SNI and alleviates mechanical allodynia. (A–D) Immunofluorescence 
of NEDD4-2 in coronal sections of L4 ipsilateral DRG injected with rAAV2/6-NEDD4-2 or saline solution in sham- and SNI-operated mice. Scale bars: 
30 μm. (E and F) Scatter dot plots representing Navtotal, Nav1.7, Nav1.8, and NavrTTXs current densities 1 week after SNI in noninfected DRG neurons 
(NINF), rAAV2/6-NEDD4-2–infected cells (INFNEDD4–2), and in the control group infected with the rAAV2/6-NEDD4-2CS vector (INFNEDD4-2CS). Slow (E, 
in cyan) and fast (F, in magenta) neurons are shown. Nonparametric 1-way ANOVA (Kruskal-Wallis test) with Dunn’s post-hoc test. See Supplemental 
Figure 5F for total population, Supplemental Table 5 for biophysical properties and values, and Supplemental Figure 5, A–E. (G) Basal thermal sensi-
tivity showed no difference at 49°C (P = 0.987), 52°C (P = 0.186), or 55°C (P = 0.673) in the hot-plate test between the 2 groups. Student’s t test. (H) 
An increase in tail-flick latency (P = 0.018 at intensity 7) for high-intensity stimulation in the rAAV2/6-NEDD4-2 group was observed. Mann-Whitney 
U test. (I) Tail pressure sensitivity was increased in mice infected with rAAV2/6-NEDD4-2. **P = 0.006, Student’s t test. (J) Basal responses to innoc-
uous mechanical stimulation were not different between the 2 strands, but the development of mechanical allodynia was significantly diminished in 
rAAV2/6-NEDD4-2–infected mice. ***P < 0.001 at day 7 and **P < 0.01 at day 14; 2-way ANOVA on log values with post-hoc Bonferroni’s tests. Data 
are expressed as the mean ± SEM; n = 12–15 for rAAV2/6-stuffer and rAAV2/6-NEDD4-2.
Downloaded on September 23, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/68996
51
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 7   July 2013 3009
response (peak at 30.4 ± 1.4 minutes in SNS-Nedd4L–/– mice com-
pared with 36.3 ± 1.3 minutes in Nedd4Lfl/fl mice; P = 0.039) during 
the early second phase as compared with the Nedd4Lfl/fl mice, sug-
gesting a central consequence of increased peripheral activity due 
to Nedd4L deletion (Figure 5G). Acute nociception during phase 1 
of the formalin test was similar between the groups.
Functional effects of in vivo exogenous NEDD4-2 overexpression. To test 
whether the rescue of NEDD4-2 reduction in DRG may function-
ally modify Nav expression and influence the course of SNI-induced 
hypersensitivity, we generated a recombinant serotype 6 adenoas-
sociated viral vector expressing NEDD4-2 (rAAV2/6-NEDD4-2, 
Supplemental Figure 5A). Two control vectors were designed: 
noncoding (stuffer) vectors and those expressing the catalytically 
inactive form of NEDD4-2 (NEDD4-2CS). The infection efficiency 
of the viral vector was recently demonstrated for small DRG neu-
rons (presumably nociceptors) after intrathecal delivery, and the 
transduction efficiency was shown to be entirely preserved after 
peripheral nerve injury (34). Immunofluorescence experiments 
showed that rAAV2/6-NEDD4-2 increased NEDD4-2 expression 
in L4/5 DRG under naive conditions and after SNI (Figure 6, A–D 
and Supplemental Figure 5B). INa measurements were taken of small 
DRG neurons after Nedd4L gene delivery, followed by single-cell PCR 
to identify infected (INF) and noninfected neurons (NINF). In naive 
animals, NEDD4-2 overexpression altered neither the INa density, 
nor the biophysical properties of rAAV2/6-NEDD4-2–infected DRG 
neurons when compared with cells infected with the control vector 
(INFNEDD4–2CS) or the NINF neurons (Supplemental Figure 5, C–E, 
and Supplemental Table 4). In the SNI condition, exogenous expres-
sion of NEDD4-2 substantially reduced the INa densities for Navtotal 
(by 49%), Nav1.7 (by 53%), and Nav1.8 (by 58%) of infected neurons 
(INFNEDD4–2). This was observed mainly in the fast subpopulation 
of DRG neurons as compared with the controls (INFNEDD4–2CS and 
NINF; Figure 6F and Supplemental Table 5), accounting for the ten-
dency observed in the total population (Supplemental Figure 5F). 
The virus can potentially transduce all types of DRG cells, which 
may explain why effects were observed only in the fast population 
and not in the slow population. Before determining whether restor-
ing NEDD4-2 expression with this viral vector would impact SNI-
mediated hypersensitivity, we first tested the basal sensitivity. The 
response to innocuous mechanical stimuli remained unchanged 
(see baseline in the von Frey filaments test; Figure 6J). Responses 
to the hot-plate test (Figure 6G) and the low intensity of the tail-
flick tests were not different between rAAV2/6-NEDD4-2 or control 
vector (rAAV2/6-stuffer) mice (Figure 6H). However, mice infected 
with rAAV2/6-NEDD4-2 showed mild, but significant, hyposen-
sitivities to the higher stimulus of the tail-flick test, whereas they 
showed mild, but significant, hypersensitivity to mechanical noci-
ception (tail pressure test; Figure 6I). The development of mechan-
ical allodynia following SNI was repressed in rAAV2/6-NEDD4-2–
infected mice as compared with mice infected with the noncoding 
vector (Figure 6J), highlighting the behavioral consequences of the 
decrease in INa current.
Discussion
The present study provides what we believe to be the first in vivo 
evidence that the ubiquitin ligase NEDD4-2 exerts a strong influ-
ence on the neuronal excitability of the sensory system, and that 
dysregulation of this regulatory mechanism contributes to pain 
hypersensitivity. This is mainly due to a pathological redistribu-
tion of Nav1.7 and Nav1.8 in DRG cells.
Peripheral neuropathic pain develops across different disease 
states as a result of different mechanisms and depends on mul-
tiple etiological factors. In this study, we used the SNI model, a 
common traumatic nerve injury–induced neuropathic pain ani-
mal model (35). Although this may not mimic the mechanisms of 
other neuropathic pain syndromes, its fast onset and prolonged 
maintenance of thermal and mechanical hypersensitivity renders 
it very valuable.
Using this model of neuropathic pain in mice, NEDD4-2 expres-
sion was found to be substantially decreased in DRG neurons, 
with a concomitant increase in Nav1.7 and Nav1.8 current densi-
ties. The results also demonstrated that knocking out NEDD4-2 
expression in nociceptive neurons increased Nav1.7 and Nav1.8 
levels and enhanced basal pain sensitivity. Conversely, the overex-
pression of NEDD4-2 using rAAV2/6 vectors led to a reduction in 
Nav1.7 and Nav1.8 current densities and a decrease in neuropathic 
pain–like allodynia in the SNI model.
The different components of INa were identified in mouse 
DRG neurons by the use of specific electrophysiological proto-
cols and toxins. Nav1.7-mediated currents were isolated with the 
perfusion of ProTxII (26). SNI increased Nav1.7 and Nav1.8 cur-
rents, particularly in the slow neuron subpopulation. Because 
the biophysical properties of the different INa components were 
not modified in the slow subpopulation, it is unlikely that the 
increased current density encountered after SNI was due to a 
modification of single-channel properties. The results suggest 
that an increased number of functional channels at the cell 
membrane may be responsible, a mechanism to which NEDD4-
2 downregulation may contribute. This hypothesis is supported 
by the results obtained with the SNS-Nedd4L–/– mice, in which 
an increase in Nav1.7/1.8 current densities was also observed 
in slow neurons and is unlikely due to the modification of sin-
gle-channel properties. The specific roles of fast/slow neuronal 
subpopulations are not yet understood, but the present obser-
vations suggest a role for the slow population in modulating 
thermal sensation.
The protein levels in DRG result from the large intracellular 
pool of Navs and the small Nav fraction at the plasma mem-
brane (36). As a consequence, modifications of Nav expression 
that would be restricted to the plasma membrane may be below 
the sensitivity limits of the assay, thus accounting for the lack 
of observed modification of Nav expression in DRG. Interest-
ingly, both SNI and SNS-Nedd4L–/– mice showed an accumu-
lation of Nav1.7 along the sciatic nerve, suggesting NEDD4-2 
involvement in channel axonal trafficking. The generation of 
SNS-Nedd4L–/– mice enabled us to investigate the functional 
contribution of NEDD4-2 in pain pathways. These mice 
exhibit an abnormal pain phenotype with increased noxious 
heat sensitivity, as revealed in both the hot-plate and plan-
tar tests under basal conditions. Interestingly, the increase in 
thermal hypersensitivity seen with the plantar test in the SNS-
Nedd4L–/– mice reached similar levels to those seen after SNI 
in the injured paws of control littermates. This finding sug-
gests that genetic disruption of NEDD4-2 leads to thermal 
pain hypersensitivity similar to that observed when NEDD4-2 
is pathologically decreased after SNI. Because SNS-Nedd4L–/– 
mice did not develop mechanical allodynia under basal condi-
tions, the decrease in NEDD4-2 is probably not sufficient to 
render these mice mechanically hypersensitive. Neither thermal 
nor mechanical hypersensitivity was enhanced in SNS-Nedd4L–/– 
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mice after SNI, suggesting that a maximum effect of SNI-in-
duced hypersensitivity was reached. This is consistent with the 
fact that NEDD4-2 cannot be further decreased, or only to a 
minor extent, in the DRG of SNS-Nedd4L–/– mice. Finally, the 
responses in the early second phase of the formalin test were 
increased, and the kinetics were accelerated in SNS-Nedd4L–/– 
mice when compared with their controls. This result suggests 
that the peripheral deletion of NEDD4-2 enhances noxious/
nocive inputs in the dorsal horn and that it may be sufficient 
to impact the global mechanisms of central sensitization (37).
The pain behavior of the SNS-Cre mouse line does not differ from 
that of wild-type littermates (38), suggesting that the observed 
hypersensitive phenotype is due to the deletion of NEDD4-2 and 
not to the expression of Cre recombinase in Nav1.8-positive noci-
ceptors. The possibility that these differences may also involve 
non-nociceptive neurons that are potentially subject to Cre recom-
bination cannot be ruled out, as Nav1.8 expression was recently 
shown to extend to larger DRG neurons (39).
Major modifications of Nav1.8 and Nav1.7 density and dis-
tribution were observed in this study. Despite their well-estab-
lished roles in nociception, the mechanisms by which Nav1.7 
and Nav1.8 isoforms specifically contribute to neuropathic 
pain are still under debate. On the one hand, knocking down 
Nav1.8 prevents neuropathic pain in mice (40), Nav1.7 accumu-
lates in human painful dental pulp (15), and gain-of-function 
mutations of Nav1.7 and Nav1.8 are linked to exaggerated pain 
in humans (12, 13). A recent simulation study suggested that 
Nav1.7 and Nav1.8 may act synergistically to increase the ampli-
tude of subthreshold oscillations and increase the frequency of 
repetitive firing in the periphery (41). Increasing their expres-
sion in slow neurons might promote hyperexcitability. How-
ever, in sensory neuron–specific knockouts of Nav1.7, Nav1.8 
or double-knockout mice, neuropathic pain–like behavior still 
develops after nerve injury (18–20). It must be noted that com-
pensatory effects in the expression of the different Nav isoforms 
in genetically modified animals during development cannot be 
excluded. The accumulation of Nav1.7 and Nav1.8 observed 
along the sciatic nerve after SNI has already been reported for 
Nav1.8 in an experimental neuropathic pain model and was 
reported to contribute to neuropathic pain (14).
In the present study, counteracting the SNI-mediated 
decrease in NEDD4-2 using gene transfer further supports the 
functional importance of this ubiquitin ligase in traumatic 
nerve injury–induced neuropathic pain. Gene transfer has 
already been successfully used in mice to alleviate pain (42), 
and clinical trials with vectors engineered to express the pre-
proenkephalin gene for treating cancer pain are underway (43, 
44). In this study, rAAV-mediated overexpression of NEDD4-2 
led to a decrease in Nav1.7 and Nav1.8 current densities in fast 
DRG neurons, which was concomitant with the prevention of 
the full development of mechanical allodynia. It may be that 
rAAV overexpression of NEDD4-2 after nerve injury prevents 
an excess of abnormal peripheral input and reduces activity- 
dependent central sensitization. It is unlikely that the effects 
on mechanical allodynia are due to peripheral changes in the 
activation threshold of low-threshold mechanical afferent 
fibers, since basal mechanical sensitivity was minimally or not 
at all affected by rAAV-NEDD4-2 (nor was it after NEDD4-2 
knockout). The unexpected mechanical hypoalgesic effect of 
rAAV2/6-NEDD4-2 might be due to the ability of ubiquitin 
ligase to regulate other ion channels, such as voltage-gated 
potassium or chloride channels (45), which could inversely 
affect cellular excitability depending on the targeted neuronal 
subpopulation. Despite its effect on the INa of fast DRG neu-
rons, other effects of the viral vector rAAV2/6 on cells or fibers 
in the peripheral nerve cannot be ruled out.
NEDD4-2 was identified as a central in vivo posttranslational 
regulator of Nav1.7 and Nav1.8, whose altered function may con-
tribute to the development of neuropathic pain. Given that the 
abnormal functioning of sodium channels is a key event in the 
etiology of neuropathic pain, these results support a new para-
digm in the treatment of this pathology. Ubiquitylation-depen-
dent mechanisms have already been implicated in neuropathic 
pain in a study reporting that the intrathecal delivery of protea-
some inhibitors attenuated hyperalgesia in rats (46). Another 
posttranslational modification of sodium channels induced by 
the accumulation of the glycolytic metabolite methylglyoxal was 
recently found to play an important role in diabetic neuropathy 
(47). Posttranslational modifications of Nav1.8 accounted for 
small, but significant, changes in the biophysical properties of 
the channel and were responsible for increased excitability of 
primary sensory neurons and sensitivity in diabetic mice. These 
results, together with the findings of this study, strongly sup-
port the need to look for agents that can modulate Nav function 
and that can act as alternatives to the Nav blockers currently 
used to treat neuropathic pain.
The factors that lie upstream of the observed NEDD4-2 decrease 
remain to be identified. Similar to many downregulated genes 
after SNI, axonal injury and the deprivation of trophic factors 
from the target tissue likely influence the transcriptional mecha-
nisms involved in the NEDD4-2 decrease (48).
These results point to NEDD4-2 as a central regulator of noci-
ception and demonstrate that NEDD4-2 dysfunction leads to 
pathological pain. The enhancement of NEDD4-2 activity may 
provide a novel mechanistic alternative to sodium channel block-
ers for the treatment of neuropathic pain. NEDD4-2 may even be 
involved in other neurological diseases linked to altered Nav chan-
nel activity, such as epilepsy and migraine headaches.
Methods
DNA constructs
Human Nedd4L (KIAA0439) cDNA lacking a C2 lipid–binding domain 
cloned into pcDNA3.1 was a gift from T. Nagase (Kazusa DNA Research 
Institute, Kisarazu, Japan). Nav1.7 cDNA cloned into pCIN5h was pro-
vided by S. Tate (Convergence Pharmaceuticals). The QuickChange 
mutagenesis kit (Stratagene) was used to generate Nav1.7 and NEDD4-2 
mutants. Nav1.7 C-terminal PY mutants were generated as follows: 
Pro1944 was mutated into Ala to generate the PA mutant, Tyr1947 into 
Ala to generate the YA mutant, and Val1950 into Ala to generate the VA 
mutant. The NEDD4-2CS mutant was generated by mutating Cys801 
into a Ser. shRNA against NEDD4-2 cloned into a pGIPZ lentiviral vec-
tor was obtained from Open Biosystems. For pull-down experiments, 
the cDNAs encoding the 66 last amino acids of Nav1.7, the 3 different 
PY mutants, and the ubiquitin-binding proteasomal subunit S5A (GST-
S5A) were cloned into pGEX-4T1 (Amersham Bioscience) to generate 
GST fusion proteins.
Western blots, immunofluorescence
See Supplemental Methods.
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Plantar test. The plantar test was conducted by exposing the lateral plan-
tar surface of the paw to a beam of radiant heat through a transparent 
surface. The heat stimulation was repeated 3 times for each paw, and the 
mean latency time was calculated.
Electrophysiology
HEK293 cell recordings. The external and internal solutions used were as 
previously described (ref. 23 and see Supplemental Methods). Data were 
recorded using a VE-2 amplifier (Alembic Instruments) or an Axon 700A 
amplifier and analyzed using pClamp software, version 8 (Molecular 
Devices), KaleidaGraph, version 4.03 (Synergy Software), and MATLAB 
(The MathWorks). The resistance of the borosilicate pipettes (World 
Precision Instruments) was 2–6 MΩ. The leakage current was subtracted 
using the P/4 procedure.
INa densities (pA/pF) were obtained by dividing the peak INa by the cell 
capacitance obtained from the pClamp function. Current densities were 
normalized to WT Nav1.7 or pcDNA3.1 (empty vector control) in the stable 
cell line for each day of the experiment. The Na+ current for the steady-state 
activation (SSA) curves was evoked from a holding potential of −100 mV to 
test pulses of 100 ms ranging from −120 mV to +30 mV in increments of 
5 mV. Steady-state inactivation (SSI) curves were measured from a holding 
potential of −120 mV using 500-ms prepulses to the indicated potentials 
followed by a test pulse to 0 mV. To quantify the voltage dependence of SSA 
and SSI, data from individual cells were fitted with the Boltzmann relation-
ship, y (Vm) = 1 / (1 + exp[(Vm – V1/2) / k]), where y is the normalized current 
or conductance, Vm is the membrane potential, V1/2 is the voltage at which 
half of the available channels are inactivated, and k is the slope factor.
The recovery from inactivation (RFI or “repriming”) curves were 
obtained with a standard 2-pulse protocol consisting of a depolarizing 
pulse from a holding potential of −120 mV to 0 mV for 50 ms to inactivate 
the channels, followed by a variable duration (from 0.5 ms to 3,000 ms) 
step back to −120 mV to promote recovery. The availability of the channels 
was assessed with the first standard test pulse at 0 mV, and the normal-
ized currents of the second pulse at 0 mV were plotted versus the recovery 
interval. We calculated the t1/2 (ms), which is the time necessary for half of 
the channels to recover from the first pulse, by interpolation from a linear 
relation between the 2 points juxtaposing half recovery (y1<0.5<y2), using 
the relation x = [0.5 – (y1x2 – y2x1) / (x2 – x1)] × (x2 – x1) / (y2 – y1).
DRG neuron recordings. Twelve hours after plating, we performed 
whole-cell recordings of small neurons (Cm <30 pF) from L4/5 DRG, 
thought to be nociceptors (27). We used an EPC-10 amplifier and Patch-
master software (both from HEKA Electronics) for data acquisition and 
analysis. The external and internal solutions used were as previously 
described (ref. 49 and see also Supplemental Methods). Pipettes had 
a resistance of less than 3 MΩ, capacity transients were cancelled, and 
series resistance was compensated by approximately 90%. We used data 
only from cells in which the access resistance remained stable through-
out the duration of the experiment. The leakage current was digitally 
subtracted using the P/4 procedure.
INa densities (pA/pF) were obtained by dividing the peak INa by the cell 
capacitance obtained from the HEKA function. Once in whole-cell config-
uration, cells were held at –60 mV for 5 minutes for the following reasons: 
(a) to dialyze the cell with CsF solution; (b) to reach equilibrium of Nav1.8 
(steady-state activation is shifted to hyperpolarized potentials during the 
first few minutes because of CsF); and (c) to lastingly inactivate the Nav1.9 
current (50) in order to prevent contamination of the Nav1.8 current. Cells 
were clamped at –80 mV for 2 more minutes before starting the recordings. 
Activation, SSI, and RFI curves were obtained as described in the in vitro 
experiments, except that each pulse was preceded by a prepulse of 3 sec-
onds at –120 mV to promote recovery of every Navs isoform.
Pull-down and ubiquitylation experiments
pGEX-4T1 containing GST fused to the 66 last amino acids of Nav1.7 WT 
and PY mutants, as well as GST fused to ubiquitin-binding proteasomal 
subunit S5A proteins, were produced (see Supplemental Methods). Pulled-
down proteins were analyzed by Western blot.
Cell-surface biotinylation
HEK293 cells were incubated for 30 minutes at 4°C with biotin solution (0.5 
mg/ml biotin in cold PBS; Pierce Biotechnology) and then rinsed 2 times 
with PBS containing 200 mM glycine followed by 2 rinsings with PBS. Cells 
were then solubilized for 1 hour at 4°C on a wheel, and 50 μl of streptavidin-
neutravidin-sepharose beads (Invitrogen) was incubated in this fraction for 
binding to biotinylated proteins. Samples were analyzed by Western blotting.
Real-time RT-PCR
See Supplemental Methods.
Cell culture and transfection
See Supplemental Methods.
Neuron primary culture
See Supplemental Methods.
Mouse lines
See Supplemental Methods.
Animal surgery
In the SNI experiments, the biceps femoris was incised, exposing the sci-
atic nerve. The tibial and common peroneal nerves were ligated with a silk 
suture (Ethicon) and transected (35).
Viral vector and intrathecal injection
See Supplemental Methods.
Behavioral pain tests
Hot-plate assay. The hot-plate assay was conducted by placing the animals on 
the hot-plate surface set at varying temperatures (49°C, 52°C, and 55°C). 
The latency of response (in seconds) was determined by a hind paw lick or 
jump. The cutoff was adjusted for each temperature to avoid tissue damage 
(60 seconds for 49°C, 30 seconds for 52°C, and 20 seconds for 55°C).
Tail-flick assay. The tail-flick assay was conducted using a tail-flick anal-
gesia meter, and the mice were gently restrained in a conical plastic cloth. 
The latency of response (in seconds) was recorded at 2 different light beam 
intensities (4 and 7 AU).
Pincher test. The pincher test consists of a pair of large blunt forceps 
(15 cm long; flat contact area: 7 mm × 1.5 mm with smooth edges) 
equipped with 2 strain gauges connected to a modified electronic dyna-
mometer (Bioseb). The tips of the forceps were placed around the tail of the 
tested mice, and the force applied was incremented by hand until a with-
drawal response occurred. The measurement was repeated 3 times, and the 
mean force (in grams) that induced withdrawal was calculated.
von Frey assay. The von Frey assay was conducted by applying a series of 
calibrated von Frey filaments on the lateral side of the hind paw’s plantar 
surface (sural nerve territory). Mice were thus placed on a platform with a 
wire netting floor. The mechanical stimulus producing a 50% likelihood of 
withdrawal was determined using the up-down method.
Formalin test. The formalin test was conducted by injecting 10 μl of 5% 
formalin subcutaneously into the left hind paw. The time the animal 
spent shaking or flinching and licking its paw was recorded at 5-minute 
intervals for 60 minutes.
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International Association for the Study of Pain (Zimmermann, 1983). 
Animals were housed under a 12-hour light/12-hour dark cycle and had 
free access to food and water.
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Pharmacological separation of Nav1.7, Nav1.8, and rTTXs sodium currents. 
Navtotal current-voltage (I-V), Navtotal SSI, and Navtotal RFI curves 
were obtained as mentioned above for the total Nav isoform component 
present in DRG neurons. ProTxII (5 nM; provided by B. Priest, Merck 
Serono), a selective blocker of Nav1.7, was then perfused, and a test 
pulse at 0 mM was performed until the diminution of peak amplitude 
reached its steady state (toxin maximal effect). A 5-nM concentration of 
the toxin would block over 90% of Nav1.7 and less than 10% of the other 
isoforms (26). NavtotalProTxII I-V, NavtotalProTxII SSI, and NavtotalProTxII 
RFI were then recorded. Subtracting the total curves for Navtotal I-V, 
Navtotal SSI, and Navtotal RFI from those of NavtotalProTxII I-V, Nav-
totalProTxII SSI, and NavtotalProTxII RFI allowed us to measure Nav1.7 
I-V, Nav1.7 SSI, and Nav1.7 RFI. Finally, TTX (300 mM) was added to 
isolate the Nav1.8 I-V, Nav1.8 SSI, and Nav1.8 RFI curves. Subtracting 
the Nav1.8 I-V, Nav1.8 SSI, and Nav1.8 RFI curves from those of Nav-
totalProTxII I-V, NavtotalProTxII SSI, and NavtotalProTxII RFI allowed us to 
record NavrTTXs I-V, NavrTTXs SSI, and NavrTTXs RFI, representing 
the remainder of the TTX-sensitive current. For examples of this proto-
col for I-V curves, see Figure 3A.
Statistics
For in vitro experiments (current densities, biophysical properties, and 
protein quantification), data were analyzed using an unpaired, 2-tailed 
Student’s t test when 2 groups were compared, or 1-way ANOVA for 
multiple group comparisons. For ex vivo recordings (current densities 
and biophysical properties) and behavioral pain tests, normality was 
tested with a D’Agostino-Pearson omnibus test to determine whether 
parametrical (Student’s t) or nonparametrical (Mann-Whitney U) tests 
would be used when 2 groups were compared. The same normality test 
was performed for multiple group comparisons to determine whether a 
regular 1-way ANOVA and post-hoc Bonferroni’s tests, or the nonpara-
metric equivalence test (Kruskal-Wallis and Dunn’s post tests) would 
be performed. For behavioral pain time courses (von Frey filaments, 
formalin), 2-way ANOVA with repeated measures were performed. The 
statistical tests used are described in each figure legend. A P value less 
than 0.05 was considered significant.
Study approval
All experimental procedures were approved by the Committee on Ani-
mal Experimentation of the Canton de Vaud, Switzerland, in accordance 
with the Swiss Federal Laws on Animal Welfare and the guidelines of the 
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Supplemental Methods 
Western blots: 
For in vitro experiments, protein extraction was performed 48 hours after transfection. 
HEK293 cells were lysed (50 mM Tris at pH 7.5, 150 mM NaCl, Complete Protease inhibitor 
cocktail tablets (Roche), 1 mM PMSF, 1% Triton) and soluble fractions were recovered in 
supernatants after 15 min of centrifugation at 13,000 x g at 4 °C. For ex vivo experiments, 
mice were sacrificed (sodium pentobarbital) and L4/L5 DRGs or sciatic nerve (from the distal 
trifurcation into sural, common peroneal and tibial to the proximal bifurcation into L4 and L5, 
neuromas were excluded) were quickly dissected. L4 and L5 DRGs or sciatic nerves from 2 
mice were pooled for each sample. Lysis (100 mM Tris HCl at pH 6.8, SDS 2%, Glycerol 
20% and Complete Protease inhibitor cocktail tablets) of tissues was done and soluble 
fractions were recovered in supernatants after 20 min centrifugation at 13,000 x g at 4°C. 
Protein concentration was measured using Bradford test-based CooAssay reagent (Uptima). 
Proteins were separated on acrylamide SDS-PAGE and then transferred to a nitrocellulose 
(HEK293) or PVDF (mouse tissue) membrane that were immunoblotted with the following 
antibodies: antibody to Nav1.7 (1:500, mouse monoclonal clone N68/6, UC Davis/National 
Institute of Health (NIH) NeuroMab Facility, University of California), antibody to Nav1.8 
(1:200, NeuroMab), pan antibody to Navs (SP19, 1:500, rabbit polyclonal antibody, Sigma), 
antibody to NEDD4-2 (1:100, rabbit polyclonal antibody, kindly provided by O. Staub, 
Lausanne University), antibody to GM130 (1:500, mouse monoclonal clone 35/GM130, BD 
Transduction Laboratories), antibody to calreticulin (1:2000, rabbit polyclonal antibody, 
kindly provided by A. Abderrahmani, Lille University), antibody to BiP (1:500, rabbit 
monoclonal clone C50B12, Cell Signalling Technology), antibody to EEA1 (1:1000, rabbit 
polyclonal antibody, Abcam), antibody to LAMP1 (1:500, rabbit polyclonal antibody, 
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Abcam), antibody to alpha 1 subunit of the NaK/ATPase (1:5000, mouse monoclonal clone 
464.6, Abcam), antibody to beta 1 subunit of the NaK/ATPase (1:1000, rabbit polyclonal 
antibody, kindly provided by K. Geering, Lausanne University), antibody to caveolin1 (1:200, 
rabbit polyclonal antibody, Santa Cruz Biotechnology) and antibody to α-tubulin (1:10,000, 
mouse monoclonal clone B-5-1-2) or antibody to GAPDH (1:5,000, rabbit polyclonal 
antibody, Abcam). For HEK293 cells we used infrared IRDyeTM (680 or 800 CW)-linked 
goat anti-rabbit or anti-mouse IgG (1:15,000, LI-COR Biosciences) and for mouse tissue we 
used secondary peroxidase-linked goat anti-rabbit or anti-mouse IgG (1:20,000, Pierce) and 
SuperSignal West Dura Chemiluminescent Substrate (Pierce). Protein quantification was 
performed using ImageJ software (US NIH).  
Immunofluorescence: 
Animals were transcardially perfused with saline, followed by 4% paraformaldehyde in PBS. 
DRGs were dissected and fixed at 4°C for 90 min and then transferred in 20% sucrose in PBS 
overnight. DRGs were mounted in cryoembedding fluid (Tissue-Tek, Sakura Finetek), 
cryosectioned at 12 µm thickness and mounted directly onto slides.  
NEDD4-2 primary antibody was used at 1:100 and Nav1.8 (rabbit polyclonal antibody 
provided by S. Tate, GSK) at 1:100. Sections of DRGs were blocked for 30 min at room 
temperature with normal goat serum (NGS) 10% and PBS 1X-Triton X-100 0.3%. Then 
primary antibodies were diluted in NGS 5% and PBS 1X-Triton X100 0.1% and placed onto 
the sections overnight at 4°C. Slides were washed in PBS and incubated at room temperature 
with secondary antibodies as follows: Fluorescein (FITC)-conjugated anti-rabbit (1: 200, 
Jackson Immunoresearch Laboratories) for Nav1.8 and Cy3 anti-rabbit (1:400, Jackson 
Immunoresearch Laboratories) for NEDD4-2, diluted in NGS 1% and PBS 1X-Triton X100 
0.1% for 90 min. Slides were washed again in PBS and mounted with Mowiol mounting 
medium (Calbiochem). 
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Pulldown and ubiquitylation experiments:  
Generation of fusion proteins: pGEX-4T1 containing GST-66 last amino acids of Nav1.7 WT 
and PY mutants (for pulldown experiment, Figure 3B) as well as GST-S5A (for ubiquitylation 
experiment, Figure 3D) were expressed in E.coli K12 cells after induction with 0.5 mM IPTG 
for 2 h at 30°C. Cells were resuspended in lysis buffer (20 mM Tris at pH 7.5, 250 mM NaCl, 
0.5% NP40, 1 mM EDTA, 1 mM PMSF, 0.2 mg/ml DNASE I (Roche) and 0.2 mg/ml 
Lysozyme (Roche)) and rotated for 1 hour in the presence of GSH-Sepharose beads 
(Amersham Bioscience). 
Pulldown: HEK293 cells were lysed for 45 minutes at 4°C with lysis buffer. Following a 15 
min centrifugation at 13,000 x g at 4°C, soluble fractions were incubated with GSH-sepharose 
beads containing either GST (as a negative control) or the different GST fusion proteins. 
Pulled-down proteins were analyzed by Western Blot. 
Subcellular fractionation:  
HEK293 cells, DRGs and sciatic nerves were homogenized in Tris HCl 10mM, pH7.4 and 
0.25M sucrose using a mortar and pestle. The lysate was charged on a sucrose gradient 
increasing from 15 to 50% concentration (8 fractions of 400 μl in Tris 10mM at pH 7.4) and 
centrifuged at 200,000 x g for 2 hours, 4°C. The whole gradient was further divided into 14 
fractions of 250 μl that were analyzed by western blot. 
Real time RT-PCR: 
DRGs were rapidly dissected and collected in RNA-later solution (Qiagen). mRNA was 
extracted and purified with RNAeasy Plus Minikit (Qiagen) and quantified using RNA 6000 
Nano Assay (Agilent Technologies). TaqMan mRNA Assays, specific to mRNA targets were 
obtained from Applied Biosystems. qRT-PCR was performed using TaqMan Fast Universal 
PCR Master Mix on a 7500 Fast Real-Time PCR System according to the manufacturer's 
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protocol. All samples were run in triplicate. Normalized signal levels for each mRNA were 
calculated using comparative cycle threshold method (ddCT method) relative to the mean of 
GAPDH or HPRT following the manufacturer's instructions.  
Single cell PCR: 
After whole-cell recording, single neurons were harvested and transferred to a PCR tube 
containing 5 µl of Proteinase K (400 ng/μl) and 17 μM of SDS. The mixture was then 
incubated at 50°C for 1h and at 99°C for 30 min to inactivate Proteinase K.  Real-time PCR 
amplification and a melting curve peaking at the right temperature using beta-globin primer 
revealed infected cells. 
Cell culture and transfection: 
HEK293 cells were cultured as previously described (1). 1 μg of Nav1.7 cDNA or PY mutants 
were transfected into HEK293 cells, concomitantly with 0.8 μg EBO-pCD-Leu2-CD8 cDNA 
encoding the CD8 antigen as a reporter gene and 0.8 μg of NEDD4-2 or NEDD4-2CS. For 
patch clamp experiments, calcium phosphate transfection was used and for biochemistry 
experiments we used lipofectamine (Invitrogene). Experiments were performed 48 hours after 
transfection unless otherwise stated. 
Neuron primary culture: 
Mice (C57BL/6 mice, Charles River Lab) were sacrificed at 4-8 weeks old. L/5 DRGs were 
harvested and digested in 5 ml of solution containing: Liberase blendzyme TM (Roche) at a 
concentration of 0.5U/DRG, 12 μM EDTA in oxygenated Complete Saline Solution (CSS 
composition: 137 mM NaCl, 5.3 mM KCl, MgCl2-6H2O, 25 mM Sorbitol, 10 mM HEPES, 3 
mM CaCl2 and pH ajusted to 7.2 with NaOH) for 20 min at 37°C. Neurons were further 
digested with Liberase blendzyme TL in 5 ml solution (0.5U/DRG, 12 μM EDTA in 5 ml 
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CSS) + Papaïn (30U/ml) for 10 min. Finally neurons were suspended in 1 ml of DRG medium 
Mix (89% DMEM/F-12, 10% BSA, 1% penicillin/streptomycin) supplemented with 1.5 mg of 
trypsin inhibitor and 1.5 mg of purified BSA. Mechanical dissociation was performed using a 
P1000 pipetman to gently triturate the DRG for 12 strokes. Finally, 80 μl of isolated neurons 
were plated on poly-D-lysine coated coverslips and incubated 12 hours before recordings to 
allow recovery and adhesion of neurons. Neurons were only recorded for 12 hours to prevent 
long-term culture phenotypic changes and neurite outgrowth that degrades space clamp. 
Mouse lines: 
The floxed Nedd4L (2) in C57BL6 background was kindly provided by O. Staub (Lausanne 
University). Briefly, the Nedd4L conditional gene targeting construct was assembled using 
three PCR fragments covering exons 6 through 10. One loxP site was inserted into intron 5 
and the second loxP site was inserted into intron 8; this linearized targeting vector was then 
electroporated into ES cells to generate the homozygote floxed Nedd4L mouse line. This 
mouse line was crossed with another C57BL6 background transgenic mouse line (Cre-SNS) 
selectively expressing Cre recombinase in sensory ganglia using promoter elements of the 
Nav1.8 gene (3) kindly provided by R. Kuner (Heidelberg University). A 230-kb-large 
bacterial artificial chromosome (BAC) containing the mouse SCN10A locus was identified by 
PCR. A cassette consisting of the Cre recombinase, β-actin, polyA and 500 bp homologous 
sequences to SCN10a was injected into mouse pronuclei. The two genetically modified mouse 
lines were backcrossed with C57BL6 mice (Charles River) for more than 8 generations. 
Homozygous floxed Nedd4L mice were crossed with Cre heterozygous mice in order to 
obtain 50% SNS-Nedd4L-/- and 50% Nedd4Lfl/fl mice, which were then used as test animals 
and control littermates, respectively. Mice progeny were identified by PCR. SNS-Cre mice did 
not display any overt phenotype and were indistinguishable from wildtype when tested for 
thermal or mechanical sensing (3).  
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Viral Vector: 
mNedd4L (NP_114087.2) coupled to a s-tag (provided by O. Staub, Lausanne University) was 
cloned into the multiple cloning site of pAAV-MCS (Stratagene) that lies downstream of the 
PGK promoter and β-globin intron in order to create rAAV2/6-NEDD4-2 (Figure S3A). 
Production and titration were performed as previously described (4). Briefly, rAAV2/6 was 
produced by cotransfection of the pAAV-PGK shuttle plasmid with the pDF6 packaging 
plasmid into the 293AAV cell line that stably expresses the E1 gene needed for activation of 
rep and cap promoters (5). We added proteasome inhibitor MG132 to increase viral vector 
production. Cell lysates were purified by high-pressure liquid chromatography on the HiTrap 
Heparin column (GE Healthcare Bio-Sciences AB) 48 hr later. The obtained viral suspension 
was concentrated with Centricon Plus-20 (Regenerated Cellulose 100,000 MWCO, Millipore) 
and the suspension medium replaced with PBS. The infectivity (transduction units per 
volume, tu) of the virus rAAV2/6 was determined by flow cytometry for direct eGFP 
fluorescence. The percentage of eGFP-positive cells was quantified 48h after infection of 
293T cells with respect to uninfected control cells. The number of transduction events was 
calculated using the Poisson equation. 
Intrathecal Injection: 
Intrathecal injection were performed using Omnican U-100 insulin syringes (30Gx1/2'', 
B.Braun). Animals backs were shaved, and mice were restrained in a towel. The needle was 
inserted between spinal cord L5 and L6 to deliver 3.3 X 10e7 tu (transduction units per 
volume) of rAAV2/6 viruses. A brief tail reflex confirmed that we attained the intrathecal 
space. 
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Electrophysiology: solutions 
HEK293 cells recordings: 
Whole cell patch-clamp recordings were carried-out using an internal solution containing 60 
mM CsCl, 70 mM Cs Aspartate, 11 mM EGTA, 1 mM MgCl2, 1 mM CaCl2, 10 mM HEPES, 
and 5 mM Na2-ATP, pH 7.2 with CsOH and external solution containing 130 mM NaCl, 2 
mM CaCl2, 1.2 mM MgCl2, 5 mM CsCl, 10mM HEPES, 5 mM glucose, pH 7.4 with CsOH. 
For the stable cell line expressing Nav1.7, the extracellular sodium was reduced to 50 mM and 
n-methyl-D-glutamine was used to substitute for sodium. 
DRG neuron recordings: 
The pipette solution for whole-cell measurements contained: 140 mM CsF, 10 mM NaCl, 
MgCl2, 0.1 mM CaCl2, 1.1 mM EGTA, 10 mM HEPES, pH was adjusted to 7.2 with CsOH. 
Extracellular solutions contained 30 mM NaCl, 110 mM TEA–Cl, 3 mM KCl, 1 mM CaCl2, 
1 mM MgCl2, 10 mM HEPES, 10 mM Glucose, 0.1 mM CdCl, pH was adjusted to 7.3 using 
Tris base.  
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Supplemental Results 
Endogenous NEDD4-2 and PY-dependence of NEDD4-2 downregulatory effect on 
Nav1.7 in HEK293 cells (related to Supplemental Figure 2). 
Whole-cell Na+ current (INa) were recorded in HEK293 cells co-transfected with wild-type 
(WT) Nav1.7 and NEDD4-2. NEDD4-2 decreased Nav1.7 current density by ~80% 
(Supplemental Figure 2A, left, same as in Figure 2B). Conversely, co-transfection of the 
catalytically inactive NEDD4-2 mutant (NEDD4-2CS) increased INa density by ~70%. This 
effect suggests competition against endogenous NEDD4-2. Accordingly, INa density was 
similarly increased by NEDD4-2 silencing using shRNA in HEK293 cells stably expressing 
Nav1.7 (Supplemental Figure 2B). Because NEDD4-2 is known to interact with the PY-motif 
located in the C-terminus domain of Nav1.7, an alanine scan of the conserved sequence 
xP1P2xYxxV was performed (1). When the Nav1.7 P2A (PA) and YA mutants were co-
transfected with NEDD4-2, negative regulation was abolished (Supplemental Figure 2C). 
Conversely, a mutation within the “extended PY motif” (VA mutant) only modestly interfered 
with the NEDD4-2 effect (bar graph for Nav1.7 WT and Nav1.7 co-expressed with NEDD4-2 
is the same as in Figure 2B and Supplemental Figure 2A). Because PA and YA mutants 
abolished the NEDD4-2 downregulatory effect, the current densities mediated by these 
mutants should not be subject to endogenous NEDD4-2. However PA and YA mutants 
current densities were not significantly increased as compared to Nav1.7 WT or VA mutant. 
This effect is observed when at later time points after transfection. Forty eight hours after 
transfection, Nav1.7 WT, PA, YA and VA mutants have similar current densities 
(Supplemental Figure 2D, white bars). When recorded 72 hours transfection, INa mediated by 
the PA and YA mutants were significantly increased as compared to Nav1.7 WT and VA 
mutants, suggesting defective internalization by endogenous NEDD4-2 and accumulation of 
Nav1.7 PY-motif mutants at the cell surface (Supplemental Figure 2D, black bars). The PY-
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dependent interaction between Nav1.7 and NEDD4-2 was further examined by pulldown 
experiments using GST fused to the furthest 66 C-terminal amino acid residues of Nav1.7 
(Supplemental Figure 2E is the extension of Figure 2D). WT Nav1.7 and VA mutant GST-
fusion proteins interacted with endogenous and transfected NEDD4-2 (Supplemental Figure 
2E), whereas no NEDD4-2 interaction was detected with the PA and YA mutant GST-fusion 
proteins. Finally, whether ubiquitylation was also dependent on the PY-motif was tested 
(Supplemental Figure 2F is the extension of Figure 2E). Over-expression of NEDD4-2 
substantially increased the GST-S5A-bound Nav1.7 signal for WT Nav1.7 and the VA mutant, 
but there was only a slight increase with the PA and YA mutants, consistent with the role of 
the PY-motif in this interaction (Supplemental Figure 2F). 
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Supplemental Figure 1. NEDD4-2 downregulates Nav1.7 (additional in vitro experiments).
(A) Biophysical properties of Na
v
1.7 and Na
v
1.7 with NEDD4-2 in HEK293 cells. Steady-state activation (circles) and 
inactivation (square) curves of Na
v
1.7 either transfected alone or co-transfected with NEDD4-2. See Supplemental 
Table 1 for values. (B) Deglycosylation of biotinylated proteins. Different migration patterns of Na
v
1.7 in membrane 
fraction samples were observed. Only the slower migrating band of Na
v
1.7 (~270 kDa) was down-regulated by 
NEDD4-2 (Figure 2C), suggesting that the upper band corresponds to the functional maturated channel at the 
membrane. Inputs signal of Na
v
1.7 presented a single migrating band at 250 kDa that was not modified when treated 
with N-Glycosidase F (PGNase F). Deglycosylation of the biotinylated fraction resulted in a merging of the two bands 
into one faster migrating band. (C) Characterization of subcellular fractionation in HEK293 cells. Fractions 7-13 were 
enriched in plasma membrane (NaK/ATPase β1 and α1-subunit) and an exclusive enrichment was observed in 
fractions 7-9, where all the other markers were expressed at low levels. Golgi (GM130) was strongly enriched in 
fraction 10. Lysosomes (LAMP1) were mainly present in fractions 5-6 and 10-14. Lighter fractions were enriched in 
cytoplasmic (tubulin) and early endosome (EEA1) components. Endoplasmic reticulum (calreticulin) was enriched in 
fractions 1 and 2 as well as fractions 10-14. Markers had the same distribution with Na
v
1.7 transfection alone (shown 
here) or when Na
v
1.7 was co-transfected with NEDD4-2 (data not shown). (D) Subcellular distribution of Na
v
1.7 and 
NEDD4-2. HEK293 cells were transfected with either Na
v
1.7 alone or Na
v
1.7 and NEDD4-2. Bar graph shows the 
distribution of Na
v
1.7 (% of signal in each fraction over the total Na
v
1.7 signal), with a decrease of 48% (*P = 0.022) 
in the plasma membrane fraction 7. Fractions exclusively enriched in plasma membrane are highlighted in grey 
based upon characterization (Supplemental Figure 1C). Data are expressed as means ± SEM Student’s t-test, n = 4 
independent experiments for each condition.
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Supplemental Figure 2. NEDD4-2 downregulates Nav1.7 in a PY dependent manner.
(A) Effect of NEDD4-2 on Nav1.7 current density in HEK293 cells. NEDD4-2 reduced WT Nav1.7 current density (***P 
< 0.001), whereas the NEDD4-2CS inactive mutant increased INa density (**P = 0.001). (B) Effect of NEDD4-2 
silencing on Nav1.7 current density in Nav1.7 HEK293 stable cell line. NEDD4-2 decreased Nav1.7 current density 
(***P < 0.001), whereas silencing of NEDD4-2 with shRNA increased INa density (*P = 0.025). (C) Effect of NEDD4-2 
co-transfection on WT and mutated Nav1.7 (PY-motif mutants) current densities in HEK293 cells. NEDD4-2-related 
INa density downregulation was abolished in PA (P = 0.820) and YA (P = 0.165) PY-motif mutants, but not in the VA 
(**P = 0.009) mutant. See Supplementary Table 1 for values and biophysical properties. Current densities were 
normalized to WT Nav1.7 (as in Figure 2B). (D) PY-motif - dependent accumulation of Nav1.7 at the membrane. 
HEK293 cells were transfected with Nav1.7 WT and PY mutants and current densities recorded 48h and 72h 
post-transfection. Current densities remained similar between Nav1.7 and PY mutants (VA, PA and YA mutants) 48 
h after transfection (P > 0.05 for each mutant). 72h after transfection, Nav1.7 and VA mutant current densities 
decreased compared to 48h post-transfection (by ~58% for Nav1.7 WT and 52% for VA mutant, not visible in the 
histogram due to data normalization). PA and YA mutant current densities persisted (3% increase for PA and 6% 
decrease for YA mutant) 72h after transfection and were significantly larger than WT Nav1.7 currents, suggesting a 
defective internalization by endogenous NEDD4-2 and an accumulation of PA (**P = 0.002) and YA (*P = 0.012) 
mutants at the cell surface.  For A to D, data are expressed as means ± SEM. Student’s t-test. Number of recorded 
cells is indicated in bars. (E) GST pulldown experiment showing Nav1.7 PY-motif - dependent interaction with 
NEDD4-2. HEK293 cells were transfected with NEDD4-2 and soluble fractions were mixed with the respective 
GST-fusion proteins (GST-Cter-Nav1.7 WT and GST-Cter-PY mutants). Bound NEDD4-2 was analyzed by western 
blot. (F) NEDD4-2-mediated ubiquitylation and PY-motif dependency. HEK293 cells were transfected with Nav1.7 
WT, VA, PA and YA mutants alone, or co-transfected with NEDD4-2 and soluble fractions were mixed with GST-S5A 
proteins. Bound Nav1.7 was analyzed by western blot. 
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Supplemental Figure 3. 
(A) Scatter dot plot representing Navtotal, Nav1.7, Nav1.8 and NavrTTXs current densities in 
contra- and ipsilateral sides recorded in L4/5 DRG neurons one week after SNI. Slow (in cyan, 
see Figure 3B also) and fast (in magenta, see Figure 3C also) neurons are distinguishable.  In 
black (uncat. for uncategorized) are recordings that did not undergo the entire protocol. Mann 
Whitney test. See Supplemental Table 2 for values and biophysical properties. (B) Western blot 
of sciatic nerve revealed that Nav1.8 immunoreactivity is undetectable in sham animals, but SNI 
induced variable signal intensity (related to Figure 3D). The open arrowheads corresponds to a 
distinct band of Nav1.8, observed with lower molecular weight than 250 kDa. 
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Supplemental Figure 4. Immunofluorescence of Nav1.8 from L4 DRG of SNS-Nedd4L-/- mice 
and control Nedd4Lfl/fl littermates.
(A) Scattered dot plot representing Navtotal, Nav1.7, Nav1.8 and NavrTTXs current densities in 
L4/5 DRG neurons from SNS-Nedd4L-/- and Nedd4Lfl/fl mice. Slow (in cyan, see Figure 4F also) 
and fast (in magenta, see Figure 4G also) neurons are distinguishable. In black (uncat. for 
uncategorized) are recordings that did not undergo the entire protocol. Mann Whitney test. See 
Supplemental Table 3 for values and biophysical properties. (B) Nav1.8 immunoreactivity was 
almost undetectable in control mice using anti-Nav1.8 antibody, while a distinct signal is observed 
in DRG of SNS-Nedd4L-/- mice. Scale bars: 30 μm. 
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Supplemental Figure 5. Administration of rAAV2/6 viral vector does not modify Navs 
current densities in naive animals.
(A) Schematic structure of the recombinant adeno-associated viral vector (rAAV2/6) encoding 
NEDD4-2 coupled to an s-tag peptide (see Methods). (B) Representative western blot of 
NEDD4-2 in ipsilateral L4 DRG after injection with either rAAV2/6-NEDD4-2 or saline solution. 
Note that endogenous NEDD4-2 has an apparent molecular weight of 120 kDa, while the virally 
expressed NEDD4-2 (lacking a C2 domain) migrates at 100 kDa. (C-E) Scatter dot plot 
representing Navtotal, Nav1.7, Nav1.8 and NavrTTXs current densities in non-infected cells 
(NINF), rAAV2/6-NEDD4-2 infected cells (INFNedd4-2) and in rAAV2/6-NEDD4-2CS (INFNedd4-2CS) in 
non-operated animals infected with either rAAV2/6-NEDD4-2 or rAAV2/6-NEDD4-2CS. Slow (in 
cyan, see panel D also) and fast (in magenta, see panel E also) neurons are distinguishable.  In 
black (uncat. for uncategorized) are recordings that did not undergo the entire protocol. 
Non-parametric one-way analysis of variance (Kruskal-Wallis test) with Dunn post hoc test. For 
values see Supplemental Table 4. (F) same as C, but after SNI surgery for total population. Slow 
and fast neurons are shown in Figure 6E and F).     
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Biophysical properties of Nav1.7, Nav1.7 + NEDD4-2 and PY mutants in HEK293 cells 
Supplemental Table 1. Values for Nav1.7, Nav1.7 co-transfected with NEDD4-2 and the PY 
mutants in HEK cells. The V1/2 of steady-state activation and inactivation and their associated 
slope factors as well as the t1/2 of recovery from inactivation (see Methods) under the different 
conditions were not different from WT Nav1.7, except for the slope factor of inactivation of the YA 
mutant. *P < 0.05, one-way ANOVA, post hoc Bonferroni tests between WT Nav1.7 and other 
conditions for every parameter. Data are expressed as mean ± SEM.
transfection WT Na v1.7 WT + NEDD4-2 VA mutant PA mutant YA mutant 
 
Activation      
Vm (mV)  -18.6 ± 0.6 -17.2 ± 0.6 -18.4 ± 0.9 -17.0 ± 0.8 -17.1 ± 0.7 
slope (mV)  6.9 ± 0.2 7.7 ± 0.3 6.5 ± 0.3 7.3 ± 0.3 7.2 ± 0.5 
n 26 9 14 14 9 
 
Steady-state inactivation      
Vm (mV)  -71.6 ± 0.5 -72.4 ± 1.1 -72.9 ± 0.9 -69.9 ± 0.8 -73.0 ± 0.9 
slope (mV)  8.0 ± 0.3 6.8 ± 0.5 7.7 ± 0.5 7.4 ± 0.4 9.9 ± 1.3 *  
n 30 11 15 16 8 
 
Recovery from inact.      
t1/2 (ms) 7.76 ± 0.38 6.48 ± 0.36 7.79 ± 0.27 7.07 ± 1.12 7.70 ± 0.63 
n 23 15 15 7 6 
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Biophysical properties of Na+ current from ipsi- and contralateral DRG neurons after SNI
Supplemental Table 2. Values for contralateral and ipsilateral DRG neurons after SNI. The 
capacitance (pF) was not different between the two groups (14.0 ± 0.5 pF, n = 38 for the 
contralateral side; 15.5 ± 0.6 pF, n = 38 for ipsilateral side, respectively. P = 0.053, Student’s t 
test). The proportions of fast (14/26, 54% in contralateral and 18/29, 62% in ipsilateral) and slow  
neurons between groups were not significantly different (χ2 = 0.12, with 1 degree of freedom P = 
0.73, chi-square test with Yates correction). SNI had a minor impact on the biophysical properties 
except for the 7-9 mV hyperpolarizing shift in the V1/2 of the steady-state inactivation of Navtotal in 
the total population and fast subpopulation, and little modification of some slope factors. 
Recovery from inactivation (RFI) was accelerated for every Navs component in the fast 
subpopulation after SNI. Data are expressed as mean ± SEM. Student’s t-test or Mann Whitney 
tests.
cell type density 
(pA/pF)
n Act. Vm (mV) slope Act (mV) n Inact. Vm (mV) n slope Inact 
(mV)
RFI t1/2 (ms) n
contralateral 444 ± 56 38 -28.1 ± 1.4 8.8 ± 0.5 35 -63.6 ± 1.7 33 10.2 ± 0.5 2.12 ± 0.17 38
ipsilateral 598 ± 52 * 38 -27.6 ± 1.1 8.8 ± 0.3 32 -71.1 ± 2.1 ** 33 8.6 ± 0.7 * 1.94 ± 0.18 35
contralateral 584 ± 111 14 -32.6 ± 1.4 7.3 ± 0.5 11 -70.5 ± 1.5 12 9.6 ± 0.8 2.69 ± 0.22 14
ipsilateral 612 ± 72 18 -31.1 ± 1.5 7.0 ± 0.3 14 -79.2 ± 1.9 ** 14 7.5 ± 0.6 * 2.07 ± 0.18 * 15
contralateral 265 ± 48 12 -22.4 ± 3.0 11.2 ± 0.5 10 -57.5 ± 2.3 10 11.6 ± 0.8 1.81 ± 0.36 12
ipsilateral 475 ± 82 * 11 -23.63 ± 1.3 9.3 ± 0.4 ** 11 -61.03 ± 3.2 11 10.1 ± 1.6 1.82 ± 0.45 11
contralateral 258 ± 40 36 -31.2 ± 1.2 6.8 ± 0.4 25 -76.1 ± 1.1 20 5.8 ± 0.4 2.84 ± 0.33 18
ipsilateral 296 ± 35 37 -28.8 ± 1.3 6.2 ± 0.2 26 -76.8 ± 1.3 21 5.0 ± 0.4 2.24 ± 0.25 20
contralateral 398 ± 62 14 -32.0 ± 1.6 6.8 ± 0.6 11 -74.8 ± 1.4 11 5.2 ± 0.6 2.76 ± 0.32 11
ipsilateral 349 ± 51 18 -30.2 ± 1.4 5.7 ± 0.3 13 -74.0 ± 1.3 13 4.8 ± 0.3 1.90 ± 0.21 * 12
contralateral 92 ± 31 12 -26.7 ± 3.3 8.9 ± 0.9 5 -77.0 ± 3.7 4 7.2 ± 0.8 3.64 ± 0.83 5
ipsilateral 179 ± 40 * 11 -26.4 ± 3.0 7.1 ± 0.6 7 -79.8 ± 2.8 5 5.3 ± 1.6 3.04 ± 0.63 6
contralateral 168 ± 19 26 -25.6 ± 1.4 9.6 ± 0.4 21 -53.2 ± 1.3 18 6.5 ± 0.2 1.13 ± 0.07 16
ipsilateral 227 ± 46 29 -24.5 ± 1.8 9.3 ± 0.4 19 -50.5 ± 1.1 18 5.7 ± 0.2 * 0.82 ± 0.07 ** 14
contralateral 131 ± 21 14 -25.9 ± 2.5 9.1 ± 0.5 8 -52.6 ± 1.9 6 6.4 ± 0.5 1.29 ± 0.10 7
ipsilateral 108 ± 26 18 -21.6 ± 2.8 10.0 ± 0.4 10 -51.1 ± 1.7 10 5.9 ± 0.3 0.76 ± 10 ** 8
contralateral 209 ± 33 12 -24.0 ± 1.6 10.1 ± 0.5 10 -53.1 ± 2.0 10 6.5 ± 0.2 1.06 ± 0.10 9
ipsilateral 421 ± 89 * 11 -27.7 ± 2.1 8.5 ± 0.6 * 9 -50.1 ± 1.7 7 5.5 ± 0.5 * 0.90 ± 0.08 6
contralateral 131 ± 34 26 -34.1 ± 2.1 8.2 ± 0.4 12 -83.1 ± 2.9 9 6.8 ± 1.0 4.81 ± 0.61 11
ipsilateral 206 ± 33 * 29 -33.9 ± 1.3 7.6 ± 0.3 18 -80.7 ± 1.2 18 7.0 ± 0.3 3.09 ± 0.38 * 14
contralateral 165 ± 61 14 -34.2 ± 2.9 7.7 ± 0.4 6 -79.5 ± 4.8 4 8.5 ± 0.5 4.51 ± 0.32 6
ipsilateral 249 ± 37 * 18 -34.7 ± 1.4 7.6 ± 0.3 14 -80.6 ± 1.6 13 6.8 ± 0.3 ** 3.08 ± 0.41 * 13
contralateral 91 ± 23 12 -33.1 ± 4.1 9.3 ± 0.5 5 -84.6 ± 3.6 5 6.5 ± 0.8 5.17 ± 1.37 5
ipsilateral 136 ± 61 11 -30.8 ± 3.4 7.7 ± 1.1 4 -82.6 ± 2.5 3 7.9 ± 2.0 3.3 1
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Biophysical properties of Na+ current from Nedd4Lfl/fl and SNS-Nedd4L-/- mice DRG 
neurons
Supplemental Table 3. Values for SNS-Nedd4L-/- and Nedd4Lfl/fl DRG neurons. The capacitance 
(pF) was not different between the two groups (13.8 ± 0.8 pF, n = 24 and 13.5 ± 0.8 pF, n = 24, P 
= 0.84, Student’s t test). Fast neurons correspond to 50% of Nedd4Lfl/fl (8/16) and 65% of 
SNS-Nedd4L-/- (11/17). The proportion of fast and slow neurons between genotypes was not 
different (χ2 = 0.25, with 1 degree of freedom P = 0.62, chi-square test with Yates correction). The 
two mice lines had the same biophysical properties except for the 10 mV hyperpolarizing shift in 
the V1/2 of activation of Navtotal in the total population and slow subpopulation, and little 
modification of some slope factors. Data are expressed as mean ± SEM. Student’s t-test or Mann 
Whitney tests.
cell type density (pA/pF) n Act. Vm (mV) slope Act (mV) n Inact. Vm (mV) slope Inact (mV) n
Nedd4L fl/fl 565 ± 78 24 -30.8 ± 1.6 7.9 ± 0.4 23 -63.0 ± 4.4 7.8 ± 0.5 14
SNS-Nedd4L -/- 1062 ± 121 ** 24 -38.1 ± 2.2 ** 6.9 ± 0.4 21 -69.9 ± 4.0 9.9 ± 0.9 * 14
Nedd4L fl/fl 790 ± 125 8 -35.5 ± 2.1 7.2 ± 0.4 8 -79.3 ± 2.8 7.3 ± 0.4 6
SNS-Nedd4L -/- 1166 ± 137 11 -38.9 ± 4.5 7.1 ± 0.8 10 -77.0 ± 3.6 9.0 ± 1.1 7
Nedd4L fl/fl 195 ± 43 8 -23.7 ± 1.5 9.9 ± 0.4 6 -51.0 ± 2.7 8.2 ± 0.9 6
SNS-Nedd4L -/- 617 ± 58 ** 6 -34.2 ± 2.5 ** 7.1 ± 0.6 ** 4 -54.0 ± 3.9 10.5 ± 1.4 4
Nedd4L fl/fl 241 ± 63 18 -31.9 ± 2.4 6.1 ± 0.4 15 -78.7 ± 1.5 7.4 ± 0.9 6
SNS-Nedd4L -/- 455 ± 77 * 20 -36.2 ± 2.7 5.8 ± 0.4 14 -80.2 ± 2.0 5.6 ± 0.6 7
Nedd4L fl/fl 415 ± 108 8 -36.7 ± 2.6 5.5 ± 0.5 7 -77.2 ± 2.9 8.75 ± 3.7 2
SNS-Nedd4L -/- 487 ± 116 11 -36.1 ± 3.9 5.9 ± 0.6 8 -77.7 3.5 1
Nedd4L fl/fl 70 ± 33 8 -25.4 ± 4.1 7.3 ± 0.6 6 -79.5 ± 2.1 6.8 ± 0.5 4
SNS-Nedd4L -/- 487 ± 116 * 6 -27.9 ± 2.0 6.9 ± 0.5 3 -79.2 ± 2.4 5.7 ± 0.6 5
Nedd4L fl/fl 132 ± 20 17 -28.4 ± 1.5 9.8 ± 0.7 17 -56.6 ± 1.7 6.7 ± 0.5 14
SNS-Nedd4L -/- 371 ± 50 *** 17 -32.9 ± 2.9 11.4 ± 1.3 12 -54.6 ± 1.9 5.4 ± 0.3 * 12
Nedd4L fl/fl 117 ± 29 8 -28.3 ± 1.8 11.2 ± 0.9 8 -54.7 ± 2.7 7.1 ± 0.9 7
SNS-Nedd4L -/- 286 ± 58 * 11 -34.7 ± 5.3 12.5 ± 1.5 7 -55.4 ± 3.2 5.8 ± 0.4 7
Nedd4L fl/fl 152 ± 34 8 -27.4 ± 3.3 8.9 ± 1.1 7 -58.6 ± 2.5 6.4 ± 0.7 6
SNS-Nedd4L -/- 527 ± 53 *** 6 -32.0 ± 3.4 8.3 ± 0.6 5 -53.5 ± 1.8 4.8 ± 0.3 5
Nedd4L fl/fl 220 ± 59 16 -39.7 ± 1.7 6.9 ± 0.5 10 -85.0 ± 2.0 8.2 ± 1.0 6
SNS-Nedd4L -/- 394 ± 90 17 -43.6 ± 2.8 7.1 ± 0.4 9 -88.1 ± 1.6 7.4 ± 0.7 7
Nedd4L fl/fl 399 ± 72 8 -40.9 ± 2.1 7.3 ± 0.6 6 -84.1 ± 2.2 7.4 ± 0.5 5
SNS-Nedd4L -/- 544 ± 112 11 -46.6 ± 2.5 7.2 ± 0.4 7 -88.4 ± 1.6 7.4 ± 0.8 5
Nedd4L fl/fl 42 ± 14 8 -33.4 ± 4.4 7.2 ± 0.3 2 -89.3 12.1 1
SNS-Nedd4L -/- 119 ± 71 6 -33.2 ± 1.2 6.6 ± 1.5 2 -87.5 ± 3.6 7.6 ± 2.7 2
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Biophysical properties of Na+ current of DRG neurons from naive mice infected with either 
rAAV2/6-NEDD4-2 or rAAV2/6-NEDD4-2CS
Supplemental Table 4. Values for cells transduced with rAAV2/6-NEDD4-2 (INFNEDD4-2) and 
control cells either transduced with rAAV2/6-NEDD4-2CS (INFNEDD4-2CS) or not transduced (NINF) 
in naive animals. The capacitance (pF) was significantly higher in cells infected with 
rAAV2/6-NEDD4-2 (15.4 ± 0.4 pF with n = 85 for NINF, 17.4 ± 0.7 with n = 37 for INFNEDD4-2 and 
15.5 ± 0.7 pF with n = 22 for INFNEDD4-2CS, P < 0.05 between NINF and INFNEDD4-2 cells, 
Kurskal-Wallis and post hoc Dunn tests). NINF cells recorded from each group of vector-injected 
animals exhibited no differences in the current densities of any of the components and were thus 
pooled into one group. Data are expressed as mean ± SEM. One-way ANOVA (post hoc 
Bonferroni tests) or Kruskal-Wallis test (Dunn post hoc test).
cell type density 
(pA/pF)
n Act. Vm (mV) slope Act. (mV) n Inact. Vm 
(mV)
slope Inact. (mV) n RFI t1/2 (ms) n
NINF 457 ± 41 85 -26.9 ± 0.9 8.3 ± 0.2 71 -62.9 ± 1.7 10.3 ± 0.4 51 2.35 ± 0.20 41
INFNEDD4-2 410 ± 50 37 -24.3 ± 1.3 9.0 ± 0.5 33 -57.3 ± 2.5 9.7 ± 0.6 24 1.86 ± 0.21 22
INFNEDD4-2CS 394 ± 80 22 -24.6 ± 1.9 8.6 ± 0.5 20 -55.2 ± 5.2 7.4 ± 0.7 *** 12 1.46 ± 0.26 13
NINF 600 ± 83 25 -30.4 ± 1.5 7.4 ± 0.3 20 -69.7 ± 1.9 10.9 ± 0.6 14 2.94 ± 0.43 12
INFNEDD4-2 413 ± 69 14 -27.1 ± 2.0 8.1 ± 0.6 12 -69.2 ± 2.5 9.4 ± 0.7 8 2.51 ± 0.46 7
INFNEDD4-2CS 573 ± 195 8 -31.7 ± 2.8 7.3 ± 0.7 7 -75.8 ± 2.6 6.5 ± 0.2 4 2.41 ± 0.34 4
NINF 356 ± 42 32 -22.7 ± 0.9 9.1 ± 0.4 29 -53.1 ± 2.1 11.0 ± 0.8 19 1.66 ± 0.25 13
INFNEDD4-2 399 ± 107 12 -24.2 ± 2.3 9.1 ± 0.8 12 50.5 ± 4.0 9.0 ± 1.6 7 1.56 ± 0.36 7
INFNEDD4-2CS 265 ± 61 9 -19.62 ± 2.0 9.6 ± 0.7 9 -44.9 ± 4.1 8.4 ± 1.7 4 1.0 ± 0.22 4
NINF 235 ± 22 75 -27.5 ± 1.0 7.5 ± 0.3 49 -75.0 ± 1.0 7.2 ± 0.9 23 3.08 ± 0.28 19
INFNEDD4-2 205 ± 31 32 -28.2 ± 1.8 7.5 ± 0.7 18 -74.4 ± 1.4 7.6 ± 0.7 9 2.46 ± 0.29 9
INFNEDD4-2CS 224 ± 67 19 -28.2 ± 2.3 7.7 ± 0.8 12 -72.6 ± 1.6 5.3 ± 0.8 7 2.27 ± 0.20 6
NINF 317 ± 40 25 -29.1 ± 1.5 6.9 ± 0.4 21 -73.2 ± 1.8 6.7 ± 0.9 10 3.12 ± 0.45 9
INFNEDD4-2 230 ± 28 14 -28.1 ± 2.5 7.1 ± 0.7 10 -74.3 ± 2.5 7.6 ± 0.8 5 2.37 ± 0.55 5
INFNEDD4-2CS 404 ± 131 8 -31.6 ± 3.1 6.5 ± 0.8 7 -72.7 ± 3.1 4.3 ± 0.9 4 2.21 ± 0.32 4
NINF 137 ± 21 32 -23.8 ± 1.5 8.4 ± 0.5 20 -75.2 ± 1.6 7.0 ± 1.9 8 3.02 ± 0.48 7
INFNEDD4-2 188 ± 61 12 -29.0 ± 3.9 7.0 ± 1.5 6 -73.8 ± 2.2 7.8 ± 2.4 3 2.72 ± 0.23 3
INFNEDD4-2CS 112 ± 46 9 -23.5 ± 2.6 9.3 ± 1.5 5 -72.6 ± 0.9 6.7 ± 0.9 3 2.3 1
NINF 239 ± 27 57 -25.6 ± 1.0 9.3 ± 0.3 44 -47.6 ± 0.7 5.9 ± 0.3 34 0.76 ± 0.04 28
INFNEDD4-2 218 ± 43 26 -25.6 ± 1.5 8.6 ± 0.6 20 -48.5 ± 1.0 6.0 ± 0.6 17 0.85 ± 0.07 16
INFNEDD4-2CS 171 ± 29 17 -20.4 ± 1.4 9.8 ± 0.5 10 -48.5 ± 0.8 6.2 ± 0.3 10 0.71 ± 0.03 10
NINF 177 ± 36 25 -27.5 ± 1.5 9.5 ± 0.6 16 -49.3 ± 1.1 6.3 ± 0.4 13 0.82 ± 0.06 12
INFNEDD4-2 124 ± 31 14 -22.9 ± 1.2 9.5 ± 0.7 10 -49.6 ± 1.6 6.4 ± 1.2 9 0.79 ± 0.08 8
INFNEDD4-2CS 101 ± 20 8 -19.2 ± 1.6 ** 10.6 ± 0.5 6 -50.1 ± 0.8 6.6 ± 0.2 6 0.75 ± 0.03 6
NINF 285 ± 38 32 -25.1 ± 1.4 9.0 ± 0.5 26 -46.6 ± 0.8 5.7 ± 0.3 21 0.82 ± 0.06 16
INFNEDD4-2 327 ± 76 12 -28.2 ± 2.6 7.8 ± 0.9 10 -47.3 ± 1.1 5.6 ± 0.4 8 0.79 ± 0.08 7
INFNEDD4-2CS 234 ± 41 9 -22.2 ± 3.0 8.58 ± 0.8 4 -46.0 ± 0.7 5.7 ± 0.6 4 0.75 ± 0.03 4
NINF 153 ± 26 57 -32.7 ± 1.5 8.3 ± 0.5 27 -80.1 ± 1.0 6.9 ± 0.6 16 3.37 ± 0.35 16
INFNEDD4-2 132 ± 38 26 -29.9 ± 2.3 8.4 ± 0.7 11 -78.6 ± 2.0 9.5 ± 1.3 8 3.41 ± 1.06 6
INFNEDD4-2CS 110 ± 35 17 -31.3 ± 3.0 9.8 ± 1.0 8 -83.6 ± 1.1 6.6 ± 0.7 5 3.66 ± 0.72 4
NINF 223 ± 48 25 -34.9 ± 2.0 7.9 ± 0.6 14 -80.5 ± 1.0 7.7 ± 0.6 9 3.64 ± 0.49 9
INFNEDD4-2 163 ± 59 14 -31.0 ± 1.0 8.1 ± 0.6 7 -80.1 ± 0.7 8.9 ± 1.8 5 3.93 ± 1.65 4
INFNEDD4-2CS 169 ± 70 8 -31.5 ± 3.4 9.7 ± 1.1 7 -82.9 ± 1.0 6.9 ± 0.7 4 3.07 ± 0.35 3
NINF 100 ± 24 32 -30.3 ± 2.2 8.7 ± 0.9 13 -79.6 ± 2.2 5.9 ± 0.9 7 3.02 ± 0.54 7
INFNEDD4-2 96 ± 48 12 -28.1 ± 7.3 8.9 ± 1.8 4 -76.0 ± 6.2 10.4 ± 2.6 3 2.37 ± 0.70 2
INFNEDD4-2CS 57 ± 16 9 -29.4 10.4 1 -86.4 5.1 1 5.44 1
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Biophysical properties of Na+ current of DRG neurons from mice infected with either 
rAAV2/6-NEDD4-2 or rAAV2/6-NEDD4-2CS after SNI
Supplemental Table 5. Values for cells transduced with rAAV2/6-Nedd4-2 (INFNEDD4-2) and 
control cells either transduced with rAAV2/6-Nedd4-2CS (INFNEDD4-2CS) or not transduced (NINF) 
after SNI. The capacitance (pF) was not significantly different between groups (15.9 ± 0.5 pF with 
n = 63 for NINF, 16.4 ± 0.8 with n = 28 for INFNEDD4-2 and 15.3 ± 1.0 pF with n = 11 for INFNEDD4-2CS, 
P = 0.832. NINF cells recorded from animals injected with rAAV2/6-NEDD4-2 or 
rAAV2/6-NEDD4-2CS exhibited no difference in the peak INa densities and were thus pooled in 
one group. Data are expressed as mean ± SEM. One-way ANOVA (post hoc Bonferroni tests) or 
Kruskal-Wallis test (Dunn post hoc test).
cell type density 
(pA/pF)
n Act. Vm (mV) slope Act. (mV) n Inact. Vm (mV) slope Inact. (mV) n RFI t1/2 (ms) n
NINF 455 ± 41 63 -26.4 ± 1.0 8.5 ± 0.3 55 -61.0 ± 2.0 8.8 ± 0.4 46 1.99 ± 0.13 45
INFNEDD4-2 313 ± 37 28 -26.0 ± 1.8 8.4 ± 0.4 25 -62.5 ± 3.0 7.9 ± 0.5 21 2.10 ± 0.18 19
INFNEDD4-2CS 585 ± 143 11 -31.6 ± 2.1 7.6 ± 0.7 8 -70.0 ± 3.0 8.8 ± 1.5 5 1.98 ± 0.26 5
NINF 650 ± 69 25 -30.2 ± 1.3 7.3 ± 0.3 24 -69.5 ± 1.3 9.58 ± 0.5 20 2.33 ± 0.12 20
INFNEDD4-2 334 ± 48 ** 13 -27.3 ± 1.2 8.1 ± 0.5 11 -70.1 ± 0.9 6.6 ± 0.5 ** 9 2.26 ± 0.17 9
INFNEDD4-2CS 798 ± 261 * 5 -33.6 ± 1.9 6.2 ± 0.5 4 -72.1 ± 3.7 6.8 ± 1.0 3 1.91 ± 0.41 3
NINF 287 ± 46 22 -19.5 ± 1.4 10.2 ± 0.5 18 -46.9 ± 2.3 8.4 ± 0.6 15 1.30 ± 0.18 14
INFNEDD4-2 222 ± 52 7 -19.7 ± 3.8 9.2 ± 1.3 7 -49.7 ± 5.4 7.9 ± 1.0 5 1.82 ± 0.39 4
INFNEDD4-2CS 309 ± 213 2 -25.5 ± 8.0 9.5 ± 1.4 2
NINF 266 ± 30 57 -26.8 ± 1.1 7.4 ± 0.3 40 -73.6 ± 1.0 6.8 ± 0.9 22 2.42 ± 0.16 25
INFNEDD4-2 160 ± 24 26 -25.2 ± 1.3 7.4 ± 0.4 15 -70.8 ± 2.7 7.0 ± 1.5 5 1.68 ± 0.18 * 9
INFNEDD4-2CS 351 ± 92 9 -30.2 ± 2.3 7.0 ± 0.7 6 -71.8 ± 2.3 4.1 ± 0.7 2 1.68 ± 0.45 3
NINF 412 ± 47 25 -29.8 ± 1.1 6.5 ± 0.3 23 -73.7 ± 1.0 6.1 ± 0.4 15 2.31 ± 0.16 15
INFNEDD4-2 193 ± 34 ** 13 -26.3 ± 1.3 7.4 ± 0.4 10 -69.6 ± 3.1 7.3 ± 1.9 4 1.53 ± 0.22 * 6
INFNEDD4-2CS 421 ± 145 5 -37.3 ± 2.6 6.1 ± 0.4 4 -71.8 ± 2.3 4.1 ± 0.7 2 1.68 ± 0.45 3
NINF 120 ± 25 22 -22.9 ± 1.7 8.2 ± 0.5 11 -74.9 ± 3.9 9.9 ± 4.1 5 3.14 ± 0.22 7
INFNEDD4-2 85 ± 28 7 -20.49 ± 3.5 7.3 ± 1.3 3
INFNEDD4-2CS 83 ± 63 2 -22.5 9.4 1
NINF 187 ± 25 46 -25.0 ± 1.1 9.5 ± 0.3 33 -48.4 ± 0.7 5.9 ± 0.2 31 0.86 ± 0.05 29
INFNEDD4-2 98 ± 18 * 20 -25.0 ± 1.8 9.6 ± 0.8 10 -50.7 ± 1.1 5.7 ± 0.3 10 0.85 ± 0.06 9
INFNEDD4-2CS 199 ± 92 7 -28.9 ± 1.9 9.5 ± 0.7 5 -51.1 ± 1.4 5.6 ± 0.4 4 0.71 ± 0.06 5
NINF 140 ± 18 25 -26.0 ± 1.5 9.9 ± 0.4 17 -49.8 ± 0.9 6.4 ± 0.5 15 0.90 ± 0.06 15
INFNEDD4-2 59 ± 16 * 13 -23.4 ± 2.5 11.2 ± 0.6 4 -52.9 ± 0.6 6.2 ± 0.4 5 0.86 ± 0.08 5
INFNEDD4-2CS 199 ± 137 5 -29.4 ± 1.8 9.7 ± 1.4 3 -52.3 ± 1.1 5.9 ± 0.2 2 0.71 ± 0.10 3
NINF 239 ± 46 22 -23.6 ± 1.7 9.0 ± 0.6 14 -47.1 ± 1.1 5.4 ± 0.2 16 0.82 ± 0.07 16
INFNEDD4-2 170 ± 22 7 -26.1 ± 2.8 8.5 ± 1.1 6 -48.5 ± 1.7 5.1 ± 0.2 5 0.83 ± 0.12 4
INFNEDD4-2CS 197 ± 53 2 -21.1 ± 6.6 9.3 ± 0.2 2 -49.9 ± 3.4 5.3 ± 0.8 2 0.72 ± 0.17 2
NINF 142 ± 27 46 -31.5 ± 1.5 8.7 ± 0.5 21 -80.0 ± 1.5 7.5 ± 0.5 21 3.80 ± 0.31 19
INFNEDD4-2 116 ± 22 20 -32.3 ± 1.3 8.5 ± 0.5 13 -79.9 ± 1.6 7.2 ± 0.7 6 3.56 ± 0.49 8
INFNEDD4-2CS 322 ± 108 * 7 -39.3 ± 1.4 * 6.7 ± 0.9 6 -81.6 ± 2.7 6.4 ± 0.3 3 2.38 ± 0.41 2
NINF 220 ± 44 25 -32.6 ± 1.8 8.6 ± 0.6 16 -79.2 ± 2.0 8.1 ± 0.6 15 3.80 ± 0.42 13
INFNEDD4-2 149 ± 25 13 -32.2 ± 1.6 8.9 ± 0.6 10 -79.1 ± 1.6 6.7 ± 0.6 5 3.56 ± 0.49 8
INFNEDD4-2CS 384 ± 143 5 -39.6 ± 1.4 6.2 ± 1.0 4 -81.6 ± 2.7 6.4 ± 0.3 3 2.38 ± 0.41 2
NINF 50 ± 12 22 -26.5 ± 2.6 9.1 ± 1.1 4 -81.9 ± 1.9 6.4 ± 0.8 6 3.81 ± 0.44 6
INFNEDD4-2 54 ± 33 7 -33.0 ± 2.6 7.3 ± 0.5 3 -84.0 9.8 1
INFNEDD4-2CS 166 ± 169 2 -38.9 ± 5.6 7.9 ± 2.3 2
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Results 
2.2. β1- and β3- voltage-gated sodium channel subunits 
modulate cell surface expression and glycosylation of 
Nav1.7 in HEK293 cells 
This article is published in Frontiers in Cellular Neuroscience (Laedermann, Syam et al. 2013).   
The core findings in this study is that voltage-gated sodium channels (Navs) β1- and β3-subunits 
enhance the membrane expression of two distinct and differentially glycosylated forms of Nav1.7 
when expressed in HEK293 cells. This effect is concomitant to an increase of Nav1.7-mediated 
current and modification of its biophysical properties. 
Navs β-subunits are well known protein carrying multiple functions. In particular, they are known to 
regulate the gating of Navs α-subunits, maturation, and stabilization at the cell membrane. 
Glycosylation, an important process for protein biosynthesis, also influences Navs α-subunit gating. 
This led us to hypothesize that β-subunits could directly influence Nav1.7 glycosylation. 
In this manuscript, we found that each β-subunit influences the kinetics of Nav1.7 when co-
expressed in HEK293 cells. We also observed that only Navs β1- and β3-subunits can modify 
biophysical properties as well as the current density of Nav1.7. Biotinylation of cell surface 
confirmed that the increase in current density is, at least partially, due to an increase of expression 
at the plasma membrane. This approach also revealed for the first time that β1- and β3-subunits are 
able to modulate the glycosylation pattern of membrane Nav1.7, highlighting a new function for 
these subunits.  
In this manuscript, I performed electrophysiological recordings in HEK293 cells. I also contributed 
to biochemistry and performed qRT-PCR.  I wrote the first draft and corrected versions of the 
manuscript. 
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Voltage-gated sodium channels (Navs) are glycoproteins composed of a pore-forming
α-subunit and associated β-subunits that regulate Nav α-subunit plasma membrane
density and biophysical properties. Glycosylation of the Nav α-subunit also directly affects
Navs gating. β-subunits and glycosylation thus comodulate Nav α-subunit gating. We
hypothesized that β-subunits could directly influence α-subunit glycosylation. Whole-cell
patch clamp of HEK293 cells revealed that both β1- and β3-subunits coexpression
shifted V of steady-state activation and inactivation and increased Nav1.7-mediated I½ Na
density. Biotinylation of cell surface proteins, combined with the use of deglycosydases,
confirmed that Nav1.7 α-subunits exist in multiple glycosylated states. The α-subunit
intracellular fraction was found in a core-glycosylated state, migrating at ∼250 kDa. At
the plasma membrane, in addition to the core-glycosylated form, a fully glycosylated
form of Nav1.7 (∼280 kDa) was observed. This higher band shifted to an intermediate
band (∼260 kDa) when β1-subunits were coexpressed, suggesting that the β1-subunit
promotes an alternative glycosylated form of Nav1.7. Furthermore, the β1-subunit increased
the expression of this alternative glycosylated form and the β3-subunit increased the
expression of the core-glycosylated form of Nav1.7. This study describes a novel role for
β1- and β3-subunits in the modulation of Nav1.7 α-subunit glycosylation and cell surface
expression.
Keywords: voltage-gated sodium channels (Navs), Navs β-subunits, glycosylation, biophysical properties,
trafficking
INTRODUCTION
Voltage-gated sodium channels (Navs) are large glycoprotein
complexes responsible for the initial rising phase of the action
potential in excitable cells. They are composed of a highly pro-
cessed α-subunit and are associated to one or more β-subunits
(Brackenbury and Isom, 2011). The α-subunit is the pore-
forming unit of the channel through which the Na+ ions pass
(Catterall, 2000). Nine genes encoding Nav α-subunits have been
found in the human genome. In addition, four genes coding for
the different Nav β-subunits have been identified: SCN1B (Isom
et al., 1992; Kazen-Gillespie et al., 2000), SCN2B (Isom et al.,
1995a), SCN3B (Morgan et al., 2000) and SCN4B (Yu et al., 2003)
coding for β1- to β4-subunits, respectively. The α-subunit is com-
posed of four homologous domains (Noda et al., 1984). Each
of these domains contains six α-helical transmembrane domains
(S1–S6). S1–S4 form the voltage-sensing domains and thus regu-
late α-subunit opening. S5 and S6 form the pore of the channel
(Guy and Seetharamulu, 1986; Payandeh et al., 2011). The pore-
forming α-subunit permits the flow of Na+, but its biophysical
properties are modulated by the β-subunits (Isom et al., 1995b),
most likely via direct interference with gating (Zimmer and
Benndorf, 2002). The influence of β-subunits on the biophysical
properties of the recorded sodium current (INa) vary with cell
type, possibly due to different endogenous β-subunit expression
and the presence of different partner proteins (Meadows and
Isom, 2005). The β-subunits also participate in cell–cell adhesion
and cell migration via the interaction with the extracellular matrix
and cytoskeletal molecules. They also serve as important signal-
ing molecules (Isom, 2001). Naturally occurring genetic variants
in humans and genetically modified animal models have shown
that β-subunits are implicated in numerous diseases, i.e., pain,
epilepsy, migraines and cardiac arrhythmias (Brackenbury and
Isom, 2011). This highlights their importance in the regulation
of cellular excitability. The β-subunits are composed of an extra-
cellular immunoglobulin-like domain in the N-terminal region,
a single transmembrane segment and an intracellular carboxy-
terminus tail (Isom et al., 1992). β1- and β3-subunits interact
with the α-subunit via a non-covalent bond (Hartshorne et al.,
1982), while β2- and β4-subunits are covalently linked to the α-
subunit via disulfide bonds (Hartshorne et al., 1982; Messner and
Catterall, 1985; Yu et al., 2003).
Out of the total pool of Navs, most of the α-subunits are
localized intracellularly: in the endoplasmic reticulum (ER) for
synthesis, in the Golgi where post-translational modifications
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occur and in the secretory pathway where they are trafficked to
the plasma membrane to exert their main functions (Schmidt
et al., 1985; Ritchie et al., 1990; Okuse et al., 2002). In the ER
and the Golgi, Nav α-subunits undergo extensive sequential gly-
cosylation (Waechter et al., 1983; Schmidt and Catterall, 1987), a
process involving the addition of N-acetylglucosamine capped by
sialic acid residues and the sequential addition of oligosaccharide
chains. Glycosylation can account for up to 30% of the α-subunit
molecular weight (Messner and Catterall, 1985). Protein glyco-
sylation serves various functions such as protein folding, cell
signaling, protection from proteases, cell-cell adhesion and regu-
lation. It has also been implicated in development and immunity
(Moremen et al., 2012). Glycosylationmodifies the gating proper-
ties of the Nav α-subunits (Recio-Pinto et al., 1990; Bennett et al.,
1997; Zhang et al., 1999; Tyrrell et al., 2001), most likely by inter-
fering with the electric field near the gating sensors (Bennett et al.,
1997; Cronin et al., 2005; Ednie and Bennett, 2012).
Because both β-subunits and glycosylation modify the intrin-
sic biophysical properties of the Nav α-subunit, we hypothesized
that β-subunits might directly influence α-subunit glycosyla-
tion. This study investigated the effect of the four β-subunits
on the Nav1.7-mediated current when co-expressed in HEK293
cells. Each of the four β-subunits influenced the biophysi-
cal properties and kinetics of the Nav1.7-mediated current to
varying degrees, but only the β1- and β3-subunits increased
Nav1.7 current density. Cell surface biotinylation and subse-
quent deglycosylation of the samples revealed the presence of
differentially glycosylated forms of Nav1.7 in the cell; a core-
glycosylated and a fully-glycosylated form of Nav1.7. β1- and
β3-subunits mediated the differentially glycosylated form of
Nav1.7 and enhanced its expression at the membrane. This sug-
gests that the increase in Nav1.7 INa may be explained by a
glycosylation-dependent stabilization of Nav1.7 at the cell mem-
brane. This work reveals a novel mechanism by which Nav
β-subunits modulate α-subunit glycosylation and cell surface
density.
MATERIALS AND METHODS
DNA CONSTRUCTS
Nav1.7, β1-, β2-, and β4-subunit cDNA cloned into pCINh and
β3-subunit cloned into pFBM were provided by Dr. S. Tate
(Convergence Pharmaceuticals, Cambridge, UK).
CELL CULTURE AND TRANSFECTION
Human embryonic kidney (HEK293) cells were cultured in
DMEM medium supplemented with 10% FBS, 4mM Glutamine
and 20μg/ml Gentamicin, at 37◦C in a 5% CO2 incubator (Life
Technologies Inc.). For patch clamp experiments, 1μg of Nav1.7
cDNA concomitantly with 0.4μg of a β-subunit and 0.8μg EBO-
pCD-Leu2-CD8 cDNA encoding CD8 antigen as a reporter gene
were transfected using the Ca2+-phosphate method in a T25
(∼2 × 106 cells). For biotinylation and deglycosylation assays,
HEK293 cells were transiently co-transfected with 6μg of Nav1.7
and 6μg of each β-subunit or empty vector mixed with 30μl
JetPEI (Polyplus-Transfection) and 250μl 150mM NaCl in a
P100 dish (∼9 × 106 cells, BD Falcon). For a negative control,
the cells were transfected with 12μg of empty vector. The cells
were used in patch clamp or biochemical experiments 48 h post
transfection.
CELL SURFACE BIOTINYLATION ASSAY
HEK293 cells transiently co-transfected were treated with
0.5mg/ml EZ-link™ Sulfo-NHS-SS-Biotin (Thermo Scientific) in
cold 1X PBS for 15min at 4◦C. The cells were then washed twice
with 200mM Glycine in cold 1X PBS to inactivate biotin, and
twice with cold 1X PBS to remove excess biotin. The cells were
then lysed with 1X lysis buffer [50mM HEPES pH 7.4; 150mM
NaCl; 1.5mM MgCl2; 1mM EGTA pH 8; 10% Glycerol; 1%
Triton X-100; 1X Complete Protease Inhibitor Cocktail (Roche)]
for 1 h at 4◦C. Whole cell lysates were centrifuged at 16,000
g at 4◦C for 15min. 2mg of the supernatant was incubated
with 50μl Streptavidin Sepharose High Performance beads (GE
Healthcare) for 2 h at 4◦C, and the remaining supernatant was
kept as input. The beads were subsequently washed five times with
1X lysis buffer before elution with 50μl of 2X NuPAGE sample
buffer (Invitrogen) and 100mM DTT at 37◦C for 30min. These
biotinylated fractions were analyzed as Nav1.7 expression at the
cell surface. The input fractions, representing total expression of
Nav1.7, were resuspended with 4X NuPAGE sample buffer plus
100mMDTT to give a concentration of 1mg/ml (60μg/well) and
were then incubated at 37◦C for 30min.
DEGLYCOSYLATION ASSAY
For the total fractions, 60μg of proteins of whole cell lysates were
denatured at 37◦C for 30min in the presence of 1X Glycoprotein
denaturing buffer. The denatured protein lysates were subse-
quently incubated at 37◦C for 1 h with 1500 units PNGaseF (New
England Biolabs) in the presence of 1X NP-40 and 1X G7 buffer
to cleavemost of the highmannose, hybrid and complex oligosac-
charides from N-linked glycoproteins. The reaction was stopped
by adding 4X NuPAGE sample buffer plus 100mM DTT and
incubating them at 37◦C for 30min. For the biotinylated frac-
tions, 35μl ddH2O were added into Streptavidin Sepharose High
Performance beads previously incubated with whole cell lysate
and denatured at 37◦C for 30min in the presence of 1X gly-
coprotein denaturing buffer. The denatured proteins bound to
Streptavidin beads were subsequently incubated at 37◦C for 1 h
with 2000 units of PNGaseF in the presence of 1X NP-40 and 1X
G7 buffer. Following this incubation step, the beads were washed
five times with the same lysis buffer used in the biotinylation assay
and eluted with 2X NuPAGE sample buffer and 100mM DTT at
37◦C for 30min.
WESTERN BLOTS
Protein samples were separated on a 5–15% polyacrylamide gra-
dient gel and blotted onto a nitrocellulose membrane using
TransBlot Turbo transfer system (Biorad, Hercules). Antibody
detections were performed in the SNAP i.d. system (Millipore)
using the following antibodies: mouse monoclonal anti-Nav1.7
clone N68/6 (UC Davis/National Institute of Health (NIH)
NeuroMab Facility, University of California), mouse monoclonal
clone 464.6 anti-Na+/K+ ATPase α-1 (Abcam), rabbit poly-
clonal anti-actin A2066 (Sigma) and rabbit polyclonal anti-β4
(EnoGene). Rabbit polyclonal homemade anti-β1, anti-β2 and
Frontiers in Cellular Neuroscience www.frontiersin.org August 2013 | Volume 7 | Article 137 | 2
80
Laedermann et al. Navs β1/β3-subunits modulate α-subunit glycosylation
anti-β3 antibodies were provided by Dr. S. Tate (Convergence
Pharmaceuticals, Cambridge, UK). Infrared IRDyeTM (680 or
800 CW)-linked goat anti-rabbit or anti-mouse IgG (LI-COR
Biosciences) was used as secondary antibody. The blots were
revealed and quantified with Odyssey Li-Cor (Lincoln).
ELECTROPHYSIOLOGY
Twenty-four hours after transfection, cells were split at low den-
sity and whole-cell recordings were performed 48 h after transfec-
tion. Anti-CD8 beads (Dynal, Oslo, Norway)were used to identify
transfected cells. Whole cell patch-clamp recordings were carried-
out using an internal solution containing 60mM CsCl, 70mM
Cs Aspartate, 11mM EGTA, 1mM MgCl2, 1mM CaCl2, 10mM
HEPES, and 5mM Na2-ATP, pH 7.2 with CsOH and an external
solution containing 130mM NaCl, 2mM CaCl2, 1.2mM MgCl2,
5mM CsCl, 10mM HEPES, 5mM glucose, pH 7.4 with CsOH.
Data were recorded with a VE-2 amplifier (Alembic Instruments,
Montreal, Canada) or an Axon amplifier 700A and analyzed using
pClamp software (version 8, Molecular Devices), Kaleidagraph
(version 4.03) and MatLab. The sampling interval was set to
5μs (200 kHz) and low-pass filtering to 5.0 kHz. Resistance of
the borosilicate pipettes (World Precision Instruments, Sarasota,
FL, USA) was 2–6M. Leakage current was subtracted using the
P/4 procedure. INa densities (pA/pF) were obtained by dividing
the peak INa by the cell capacitance obtained from the pClamp
function. Voltage dependence of activation (SSA) curves were
determined from I/V curves where the Na+ current was evoked
from a holding potential of −100mV to test pulses of 100ms
ranging from −120 to +30mV in increments of 5mV. The linear
ascending segment of the I/V relationship was used to estimate
the reversal potential for each trace. Time constant of inactivation
was determined by fitting the current decay with the Levenberg-
Marquardt single exponential function. The time constant was
plotted against the test voltage, with I = A ∗ exp(−t/τ) + C:
where I is the current, A is the percentage of channel inactiva-
tion with the time constant τ, t is time and C if the steady-state
asymptote. Steady-state inactivation curves (SSI) were measured
from a holding potential of −120mV using 500ms prepulses to
the indicated potentials, followed by a test pulse to 0mV. To quan-
tify the voltage-dependence of SSA and SSI, data from individual
cells were fitted with the Boltzmann relationship, y (Vm)= 1/(1+
exp[(Vm–V½)/k]), in which y is the normalized current or con-
ductance, Vm is the membrane potential, V½ is the voltage at
which half of the available channels are inactivated and k is the
slope factor.
Recovery from inactivation curves (RFI or “repriming”) were
obtained with a standard two-pulse protocol consisting of a depo-
larizing pulse from a holding potential of −120 to 0mV for
50ms to inactivate the channels, followed by a variable duration
(from 0.5 to 3000ms) step back to −120mV to promote recov-
ery. Channel availability was assessed with the first standard test
pulse at 0mV. The normalized currents of the second pulse at
0mV were plotted against the recovery interval. We calculated t½
(ms), the time necessary for half of the channels to recover from
the first pulse, by interpolation from a linear relation between
the 2 points juxtaposing half recovery (y1 < 0.5 < y2), using the
equation x = [0.5–(y1x2–y2x1)/(x2–x1)]∗(x2–x1)/(y2–y1).
QUANTITATIVE REAL-TIME REVERSE TRANSCRIPTION PCR (qRT-PCR)
HEK293 cells transfected with Nav1.7 (1μg) alone or with
each of β-subunits (0.4μg) were collected in RNA-later solution
(Qiagen, Basel, Switzerland). mRNA was extracted and purified
with RNeasy Plus Mini kit (Qiagen) and quantified using RNA
6000 Nano Assay (Agilent Technologies AG, Basel, Switzerland).
A total of 600 ng of RNA was reverse transcribed for each sample
using Omniscript reverse transcriptase (Qiagen). Nav1.7 primer’s
sequence is as follow; 5′-TCTGTCTGAGTGTGTTTGCACTAA-
3′ and 5′-AAGTCTTCTTCACTCTCTAGGGTATTC-3′. We used
GAPDH as reference gene to normalize Nav1.7 mRNA expres-
sion. Gene-specific mRNA analyses were performed using the iQ
SYBR-green Supermix (BioRad, Reinach, Switzerland) and the
iQ5 real-time PCR detection system (BioRad). Only reactions
with appropriate amplification and melting curves determining
the amplicon specificity were analyzed. For all conditions tested
we used n = 3 samples. All samples were run in triplicate.
STATISTICS
For electrophysiological experiments (current densities and bio-
physical properties) normality with D’Agostino-Pearson was
tested to determine whether a regular One-Way ANOVA and
post-hoc Bonferroni tests, or the non-parametric equivalent test
(Kruskal-Wallis test and Dunn post-hoc tests), should be per-
formed. For RFI, a Two-Way ANOVAwas used to compare Nav1.7
alone with Nav1.7 co-transfected with each β-subunit, and the
impact of the voltage on this comparison. Biochemical exper-
iments and transcriptional quantification data were analyzed
using bilateral Student’s t.
RESULTS
The functional impact of the co-expression of the four β-
subunits on Nav1.7-mediated INa was studied by performing
whole cell patch-clamp experiments in HEK293 cells. Each β-
subunit was independently co-transfected with Nav1.7 and then
compared to Nav1.7 expressed alone. Figure 1A shows typical
traces of Nav1.7 INa obtained with a current-voltage protocol.
A hastening of the Nav1.7 current decay kinetics was observed
with each of the β-subunits tested (Figure 1B). The shorten-
ing of the Nav1.7 time constant of current decay was observed
for a wide range of voltages and showed voltage-dependency
for every β-subunit (Figure 1B). The shortening was particu-
larly prominent for the β3-subunit. In addition, β1- and β3-
subunits also significantly increased (∼2-fold) Nav1.7-mediated
current density as compared to Nav1.7 alone or to Nav1.7 co-
expressed with β2- or β4-subunits (Figure 1C and Table 1). We
also observed that β2 and β4-subunits did not antagonize β1
and β3-subunits-dependent up-regulation, and that the two lat-
ter have additive positive effect on Nav1.7-mediated current
(data not shown).
Whether the INa density increase mediated by both β1- and
β3-subunits was also accompanied by alterations of other Nav1.7
biophysical properties was also assessed. The voltage dependence
of macroscopic INa activation and inactivation (see Materials
and Methods) of Nav1.7 in the absence and presence of each β-
subunit was recorded and analyzed. The co-transfection of the β1-
subunit significantly shifted the V½ of steady-state inactivation
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FIGURE 1 | β-subunits regulate Nav1.7 currents. (A) Typical whole-cell
Na+ currents of HEK293 cells transfected with Nav1.7 alone or Nav1.7
co-expressed with individual β-subunits elicited with a typical
current-voltage protocol. (B) Voltage-dependence of current decay of
Nav1.7 alone compared to Nav1.7 with each individual β-subunit. Inset:
Normalized representative current traces of Nav1.7 elicited by test pulses
at 0mV. Co-transfection of the β1- (p = 0.011, n = 39), β2- (p < 0.0001,
n = 25), β3- (p < 0.0001, n = 16), and β4-subunit (p = 0.006, n = 13)
decreased the time constant decay as compared to Nav1.7 alone
(n = 81). Two-Ways ANOVA and Bonferroni post-hoc tests. Data are
expressed as mean ± s.e.m. (C) INa densities from HEK293 cells
transfected with Nav1.7 alone or co-transfected with individual β-subunits.
β1- (n = 55) and β3-subunits (n = 34), but not β2- (n = 67) nor β4-subunits
(n = 27), increased the Nav1.7 current densities. p < 0.0001 for β1- and
β3-subunits with One-Way ANOVA followed by Bonferroni post-hoc tests.
Data are expressed as mean ± s.e.m. and were normalized to Nav1.7
alone for each experiments. Values can be found in Table 1. ∗p < 0.05,
∗∗p < 0.01 and ∗∗∗p < 0.001.
toward depolarized potentials by ∼5.8mV, but had no influence
on V½ of activation (Figure 2A and Table 1). The β3-subunit
shifted the V½ of inactivation toward depolarized potentials by∼3.5mV and the V½ of activation toward hyperpolarized poten-
tials by ∼3.7mV (Figure 2C and Table 1). Neither the β2- nor
β4-subunits affected Nav1.7 voltage dependence of activation or
inactivation (Figures 2B,D and Table 1).
The influence of the β-subunits on recovery from inactivation
(RFI) was also tested. Because the RFI relationships could not
always be fitted with the exponential functions to the same degree,
an interpolation from a linear relation between the 2 points
juxtaposing half recovery to obtain the half-time (t½) of RFI was
used. Only the β1-subunit significantly hastened t½ of RFI to 6.19
vs. 7.55ms for the control (Figures 3A–D and Table 1).
As only minor modifications of the INa biophysical proper-
ties were observed, it is unlikely that the 2-fold increase in the
Nav1.7 current density mediated by β1- and β3-subunits is only
due to alterations of the single channel properties. Whether the
increase of the Nav1.7 current may have been due to an increase in
channel synthesis was investigated. Nav1.7mRNA levels remained
unchanged with β-subunit co-transfection, as observed by q-RT-
PCR (Figure 4), discounting this hypothesis.
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Table 1 | Biophysical properties of Nav1.7 alone or upon β-subunit co-transfection in HEK293 cells.
Current density Activation Inactivation Recovery
normalized pA/pF n V½ (mV) slope kv n V½ (mV) slope kv n t½ (ms) n
Nav1.7 1.00 ± 0.04 140 −18.6± 0.4 6.8 ± 0.2 81 −70.9± 0.5 8.1 ± 0.3 92 7.55 ± 0.21 72
Nav1.7 + β1 2.08 ± 0.23*** 55 −17.4 ± 0.8 5.8 ± 0.2*** 39 −65.7± 0.5*** 7.0 ± 0.2* 51 6.19 ± 0.23** 27
Nav1.7 + β2 1.31 ± 0.12 67 −18.2± 0.9 6.2 ± 0.3 25 −70.9± 0.6 7.5 ± 0.2 43 7.03 ± 0.34 34
Nav1.7 + β3 2.10 ± 0.21*** 34 −22.3 ± 1.0* 5.4 ± 0.3*** 17 −67.4± 0.8*** 7.0 ± 0.3 18 6.69 ± 0.25 16
Nav1.7 + β4 1.02 ± 0.21 27 −16.1± 1.1 7.1 ± 0.3 13 −70.8± 0.5 7.2 ± 0.5 20 7.38 ± 0.33 19
Values for Nav 1.7 and Nav 1.7 co-transfected with β-subunits. The V½ of steady-state activation and inactivation and their associated slope factors, as well as the
t½ of recovery from inactivation, were obtained as described in the Materials and Methods. *p < 0.05, **p < 0.01, and *** p < 0.001, One-Way ANOVA, post-hoc
Bonferroni tests or Kruskal–Wallis with Dunn post-hoc test between Nav 1.7 and Nav 1.7 with each β-subunit. Data are expressed as mean ± s.e.m.
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FIGURE 2 | The influenceofβ1-andβ3-subunitsonNav1.7
voltage-dependenceofactivationand inactivation. (A–D)Normalized
currents for both activation and steady-state inactivation (seeMaterials and
Methods)areplottedagainstthetestpotential.EachpanelcomparesNav1.7alone
toNav1.7 co-expressedwith individualβ-subunits. Aminor butsignificanteffect
ontheV½ofactivationwasobservedforβ3-subunit (n = 17,hyperpolarizingshift,
p < 0.05) co-expression ascompared toNav1.7 alone (n = 81).β1- (n = 39),β2-
(n = 25)andβ4-subunits(n = 13)didnotmodifytheV½ofactivationofNav1.7.The
effecton theV½of inactivationwashighlysignificant forβ1- (n = 51,depolarizing
shiftwithp < 0.0001)andβ3-subunit (n = 18,depolarizingshiftwithp < 0.0001)
compared toNav1.7 alone (n = 92);whereasβ2- (n = 43) and β4-subunits
(n = 20) hadnoeffect. Individual points are themean±s.e.m. of thenormalized
current at each voltagepoint. ThesmoothcurvesareBoltzmannfitswhose
equationsgiveboth theV½ofactivation and inactivation (midpoints) and their
associated slope factors (seeMaterials andMethods). TheV½ofsteady-state
activation and inactivation comparingNav1.7 alone vs. the co-expressionwith
each subunitwere testedbyOne-WayANOVAfollowedbyBonferroni’smultiple
comparison tests. Valuesand statistics canbe found inTable1.
Whether the Nav1.7-mediated INa upregulation could be due
to an increase of Nav1.7 protein density at the cell mem-
brane was investigated by performing biotinylation of plasma
membrane proteins. After lysis, proteins were sampled under
reducing conditions known to dissociate the covalently bound
β2- and β4-subunits from α-subunits (Messner and Catterall,
1985). Co-transfection of β1-, β2-, and β4-subunits significantly
decreased Nav1.7 protein expression in the total cell lysate frac-
tion (input, Figure 5A). The quantification revealed a ∼2-fold
decrease for each of these three subunits. Co-transfection of
the β3-subunit had no effect on Nav1.7 expression in the total
cell lysate fraction. In the biotinylated membrane fraction two
bands at different apparent molecular weights were observed
when Nav1.7 was expressed alone (white and black arrow heads
in Figure 5A). These bands correspond to different glycosy-
lated states of Nav1.7 as demonstrated by using deglycosylating
enzymes (Figure 5B). Endoglycosidase H (EndoH) only cleaves
core N-glycans from proteins whereas Peptide-N-Glycosidase F
(PNGaseF) does not discriminate between full and core glyco-
sylated proteins. Of the two bands of biotinylated Nav1.7, only
Frontiers in Cellular Neuroscience www.frontiersin.org August 2013 | Volume 7 | Article 137 | 5
83
Laedermann et al. Navs β1/β3-subunits modulate α-subunit glycosylation
Nav1.7 + β1
Nav1.7 + β3
Nav1.7 + β2
Nav1.7 + β4
0
0.2
0.4
0.6
0.8
1
1 10 100 1000N
or
m
al
iz
ed
 c
ur
re
nt
Recovery interval (ms)
0
0.2
0.4
0.6
0.8
1
1 10 100 1000N
or
m
al
iz
ed
 c
ur
re
nt
Recovery interval (ms)
0
0.2
0.4
0.6
0.8
1
1 10 100 1000N
or
m
al
iz
ed
 c
ur
re
nt
Recovery interval (ms)
0
0.2
0.4
0.6
0.8
1
1 10 100 1000N
or
m
al
iz
ed
 c
ur
re
nt
Recovery interval (ms)
A B
C D
FIGURE 3 | Only β1-subunit significantly increases Nav1.7 recovery
from inactivation (RFI). (A–D) RFI from HEK293 cells transfected with
Nav1.7 alone or co-transfected with individual β-subunits. Smooth curves
were fitted incorporating a geometric weight to arrive at the final curve
(no equation) and the t½ was calculated by interpolation on the x-axis
from a linear relation between the 2 points juxtaposing half recovery
(y1 < 0.5 < y2, see Materials and Methods). Only when co-expressed
with β1-subunit (n = 27, p < 0.01) was Nav1.7 RFI significantly faster as
compared to Nav1.7 alone (n = 72). β2- (n = 34), β3- (n = 16), and
β4-subunits (n = 19) did not significantly alter RFI when co-expressed
with Nav1.7. Individual points are the mean ± s.e.m. of the normalized
current at each time point. Non-parametric One-Way analysis of variance
(Kruskal-Wallis test) with Dunn post-hoc tests to compare each subunit
co-expressed with Nav1.7 vs. Nav1.7 alone.
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FIGURE 4 | Nav1.7 transcripts upon β-subunit co-transfection. Bar graph
showing transcriptional levels of Nav1.7 in control conditions (co-transfected
with empty vector) over Nav1.7 levels when cells were co-transfected with
each individual β-subunit. Transcripts were normalized to GAPDH and run in
triplicate. Data represent the mean ± s.e.m., n = 3 independent
transfections for every condition.
the lower was sensitive to EndoH and was shifted to an appar-
ent lower molecular weight band (compare white arrowhead in
the first lane to gray arrowhead in the third lane), indicating
that this band corresponds to the core-glycosylated form of the
channel (Figure 5B). Because PNGaseF was able to digest both
bands, it can be proposed that the higher band corresponds to
the fully-glycosylated form of Nav1.7. The lower band of biotiny-
lated Nav1.7 migrates at the same apparent molecular weight as
the band observed in the input fraction (white arrow heads in
Figure 5A) suggesting that most of Nav1.7 in the intracellular
pool is core-glycosylated. This is consistent with the channel being
early and rapidly, but only partially, glycosylated after its syn-
thesis. The upper band in the total cell lysate fraction was faint
and blurry (Figure 5A), suggesting that the fully-glycosylated
channel only represents a small fraction of the total Nav1.7 cel-
lular pool. It was only by enriching the membrane proteins
through the precipitation of the biotinylated membrane frac-
tion (the ratio between the amount of lysate protein loaded and
the amount of streptavidin beads needed to precipitate biotiny-
lated proteins was ∼1:30) that the upper band was distinctly
observed. Co-expression of the β1-subunit reproducibly shifted
the upper band to an intermediatemigrating band of lower appar-
ent molecular weight. This suggests that the β1-subunit mediates
an alternative glycosylated form of Nav1.7. When comparing the
β1-subunit-modified intermediate band with the upper band of
the control condition (Nav1.7 alone), a significant increase in
signal intensity was observed (Figure 5A, quantification), which
is consistent with the increase in the Nav1.7 current density
(Figure 1C). Co-transfection of the β2-subunit neither modi-
fied the glycosylation pattern nor the expression of any of the
two bands, consistent with the fact that the current density
was not modified. β3-subunit expression also altered the Nav1.7
band pattern in the biotinylated fractions. The upper band over-
lapped with the lower band under the migrating conditions used.
The β3-subunit significantly increased (∼7-fold) the intensity
of the lower band as compared to the lower band of con-
trol, consistent with the increase of the Nav1.7 current density
elicited by the β3-subunit (Figure 1C). Finally, β4-subunit co-
transfection led to a small but significant decrease of the lower
band.
To confirm that the different bands observed when β-subunits
are coexpressed, particularly β1 and β3-subunits, represent alter-
native glycosylated form of Nav1.7, we again incubated the
input and biotinylated fractions with PNGaseF. A small but
consistent shift of the Nav1.7 band into a lower apparent
molecular weight band in the total cell lysate fraction was
observed (the white arrow heads shifted to the gray arrow
heads, Figure 6). Furthermore, when incubating the biotiny-
lated fraction of β-subunit and Nav1.7 co-expression experi-
ments with PNGaseF, all of the Nav1.7 bands shifted to a sin-
gle band (gray arrow heads) of the same molecular weight.
This confirms that the β1- and β3-subunits modulate differen-
tial glycosylation patterns on Nav1.7 (Figure 6, black and white
arrow heads). Noteworthy, when comparing the single band of
Nav1.7 when samples are treated with PNGaseF in the input
fraction with the one in the biotinylated fraction, it seems
that this band migrates slower in the input as compared to
biotinylated fraction when β-subunits are coexpressed (com-
pare bands highlighted by gray arrows for each blots). This may
be due to other post-translational modification such as sialy-
lation or palmitoylation of the channel. Further experiments
using desialylation or depalmitoylation treatment are needed to
confirm this possibility.
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FIGURE 5 | β1- and β3-subunit mediate differential forms of Nav1.7 whose
expression is increased at the membrane. (A) Representative western blot
of a biotinylation assay with total lysate (input, left) and cell surface
(biotinylation, right) fractions from HEK293 cells transiently transfected with
Nav1.7 alone, or co-expressed with each individual β-subunit and the
associated quantifications. Input: Nav1.7 is detected in two forms: a fast
migrating band (∼250kDa, that will be referred to as lower band) that consist
mostly of the Nav1.7 immunoreactive signal and a slow migrating band
(∼280kDa, that will be referred to as upper band). β1- (p = 0.006), β2-
(p = 0.003), and β4-subunits (p = 0.009) significantly decreased Nav1.7
expression, whereas the β3-subunit had no effect (p = 0.570). Because the
upper band was below the sensitivity threshold, both bands were quantified
together. Biotinylation: Nav1.7 membrane protein is detected in three forms.
When expressed alone, one lower band (white triangle, ∼250kDa) and one
upper band (black triangle, ∼280kDa) were present (for identification of these
bands, see PanelB). When the β1-subunit is co-expressed, the upper bandwas
clearly shifted into an intermediate migrating band (∼260kDa) with increased
expression (p = 0.047). β2- and β4-subunits revealed the same pattern as
when Nav1.7 was transfected alone and did not change its expression, except
for the small decrease of the lower band when the β4-subunit is co-transfected
(p = 0.020). The β3-subunit clearly increased Nav1.7 immunoreactivity of the
lower band (p < 0.0001). For input and biotinylation fractions, actin and the
α1-subunit of NaK-ATPase were used as biotin leakiness and loading controls,
respectively. Data represent mean ± s.e.m, n = 4 independent experiments.
Student’s unpaired t-test, each condition being compared with Nav1.7. ∗p <
0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001. (B) Representative western blot and
identification of glycosylation state of Nav1.7 in biotinylated fraction from
HEK293 cells transiently transfected with Nav1.7. EndoH only cleaves the
lower band of biotinylated Nav1.7, demonstrating that this band represents the
core-glycosylated form of the channel. The upper band is digested by
PNGaseF, demonstrating that it corresponds to fully-glycosylated form of the
channel. PNGaseF can also digest the core-glycosylated form of Nav1.7.
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FIGURE 6 | The different forms of Nav1.7 observed with β-subunits are
due to differential glycosylation patterns. Western blot of a biotinylation
assay followed by deglycosylation with total lysate and cell surface fractions
from HEK293 cells transiently transfected with Nav1.7 alone, or co-expressed
with each individual β-subunit. Samples were non-treated or treated with
Peptide: N-Glycosidase F (PNGaseF) to remove glycosylated residues of the
protein. The total lysate Nav1.7 band (black/white triangle) was slightly shifted
to an apparent lower molecular weight (gray triangle) when treated with
PNGaseF. In the biotinylation fraction, the pattern of Nav1.7 glycosylation by
the β-subunits was the same as in Figure 4.(black and white triangles). When
treated with PNGaseF, all the different bands shifted to the lower band of the
same apparent molecular weight, irrespective of the β-subunit co-expressed.
DISCUSSION
This study demonstrates that Nav β1- and β3-subunits modulate
the cell surface expression and glycosylation patterns of Nav1.7
when co-expressed in HEK293 cells. It also confirms that the
β-subunits differentially modulate the biophysical properties of
Nav1.7.
The observation that β1- and β3-subunits strongly increased
Nav1.7 INa density contrasts with several recent studies. The study
performed by Ho et al. (2012) showed no impact of any of the β-
subunits on Nav1.7 current density in HEK293 cells. The other
studies showed no impact using different cell expression systems
(Sangameswaran et al., 1997; Morgan et al., 2000; Vijayaragavan
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FIGURE 7 | Proposed scheme of the different intracellular pathways of
α-subunits depending on the presence of different β-subunits. After
synthesis in the rough endoplasmic reticulum (RER), α-subunits are rapidly
folded and undergo a first step of glycosylation in the smooth endoplasmic
reticulum (SER). It is known that N-acetlyglucosamine and oligosaccharide
chains are bound on Asp residues of the protein, a process known as
core-glycosylation. Newly synthesized glycoproteins are then translocated
into the Golgi network, where they are subject to a second step of more
complex glycosylation, involving many different enzymes. Once matured,
proteins eventually translocate to the plasma membrane. The present
findings suggest that core-glycosylated proteins can also be found anchored
at the membrane. By some yet undefined mechanism, the β1-subunit
interferes with the second glycosylation step (∗∗∗full-glycosylation on the
scheme) which leads to a modification of the glycosylation pattern of the
α-subunits. The β1-subunit enhances the core-glycosylated form of Nav1.7.
This suggests that the β1- and β3-subunits already interact with the
α-subunits before the step of full-glycosylation of the channel occurring in the
Golgi network. By enhancing the differential glycosylation pattern of Nav1.7, it
can be proposed that the β1- and β3-subunits promote stabilization of the
channel at the plasma membrane. On the contrary, it is likely that the β2- and
β4-subunits, which have no effect on the glycosylation nor the anchoring, only
briefly interact with the α-subunits before translocation of the channel to the
plasma membrane. For sake of simplicity, the shown glycosylation patterns
are arbitrary. Nav1.7 is depicted as being “freely” expressed in ER/Golgi and
membrane networks for easier interpretation of the scheme. However,
Nav1.7 is embedded in the membranes of the different organelles.
et al., 2001, 2004). These discrepant observations underline the
influence of the cellular background when studying Navs α-
subunit regulation by β-subunits. Even though this study and the
one by Ho et al. (2012) both used HEK293 cells, Ho et al., used
a clonal cell line stably expressing rat Nav1.7 cDNA, whereas the
present study used transiently transfected human Nav1.7 cDNA.
In a stable cell line, it is likely that a significant fraction of α-
subunits are already anchored at the plasma membrane; thus it is
possible that the ones interacting with the transfected β-subunits
only reflect a small fraction of membrane Navs α-subunits. Under
the conditions of transient transfection, all the membrane Navs
α-subunits are synthesised de novo and are thus more likely to
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interact with β-subunits. It is also possible that other differences,
such as the origin of the HEK293 cells or even passage numbers,
may play a significant role in the observed effects. Other stud-
ies have shown, however, that β1- and β3-subunits can increase
the current density of several other Nav isoforms (Nuss et al.,
1995; Smith and Goldin, 1998; Fahmi et al., 2001; Zimmer and
Benndorf, 2002).
A significant shortening of the time constant of current decay
was observed when Nav1.7 was co-expressed with each individual
subunit. A rapid rate of inactivation tends to reduce the refrac-
tory period of Nav1.7, meaning that β-subunits can enhance cell
excitability via this mechanism. The hastening of RFI by the β1-
subunit might also reduce the duration of the refractory periods,
allowing for faster repetitive firing of neurons.
The β1-subunit shifted V½ of inactivation toward more depo-
larized potentials, which should increase the number of channels
available for opening in response to depolarization at a given
voltage near the resting membrane potential (approximately −60
to −70mV). The β3-subunit similarly influenced this parame-
ter, and also shifted the V½ of activation toward hyperpolarized
potentials, rendering the channel more likely to open at hyperpo-
larized voltages. These results are consistent with the findings of
Ho et al., and account for the shift toward a hyperexcitable state.
The fact that the β1- and β3-subunits strongly increased
Nav1.7 current density, but onlymodestly influenced the biophys-
ical properties, suggests that the single-channel conductance is
not altered. In line with the previous, single-channel recordings
revealed that β1-subunit did not change the Nav1.5 open prob-
ability despite an important increase in current density (Nuss
et al., 1995). As a consequence, it was hypothesized that these
two subunits also increase Nav1.7 channel density at the cell sur-
face. Biotinylation of cell surface proteins was performed and a
strong decrease of the Nav1.7 signal in the input fraction when
β1-, β2-, and β4-subunits were co-transfected was observed. This
decrease was in contrast with the increase or lack of modifica-
tion of the Nav1.7 current density. The reason for this decrease
remains to be identified, but one can speculate that the expres-
sion of the β-subunits may decrease the ratio of intracellular Navs
to plasma membrane Navs by hastening forward trafficking and
stabilizing the channel at the cell surface. Furthermore, one of
the important functions of glycosylation is the proper folding and
protection of proteins with respect to proteolysis (Parodi, 2000).
The thus far not observed role of β-subunits in altering Nav1.7
glycosylation might influence the degradation by the protea-
some, accounting for the decrease in input. The β-subunits have
also been proposed to act as chaperon proteins (Valdivia et al.,
2010), further supporting a potential effect on degradation by the
proteasome.
The analysis of the Nav1.7 protein at the plasma membrane
and the subsequent treatment with the deglycosylating enzyme
led to three novel findings: (1) Under normal conditions, Nav1.7
is present in two glycosylated forms, a core-glycosylated form
with a molecular weight of ∼250 kDa and a fully-glycosylated
form with a molecular weight of ∼280 kDa; (2) The β1-subunit
can further mediate a third and intermediate migrating band,
which likely represents an alternative fully-glycosylated form
of Nav1.7; and (3) the β1-subunit increases the membrane
expression of this alternative fully-glycosylated form of Nav1.7;
whereas the β3-subunit increases the membrane expression of the
core-glycosylated form.
In studies using chimeras between the β1- and β3-subunits, it
was proposed that different parts of these subunits were involved
in the modulation of gating by direct interaction with the α-
subunits (Zimmer and Benndorf, 2002). The observation in this
study that the β1- and β3-subunits can mediate the differential
glycosylation of Nav1.7, and despite the well-documented causal
link demonstrating that differential glycosylation leads to a mod-
ification of Navs α-subunit gating (Bennett et al., 1997; Zhang
et al., 1999; Tyrrell et al., 2001), does not allow us to conclude
that the β-subunit-mediated glycosylation of the α-subunit is
responsible for the modulation of Nav1.7 gating. Further studies
to identify the potential glycosylation site of Nav1.7 are neces-
sary to determine whether the effects of the β-subunits on the
biophysical properties of Nav1.7 are also dependent on this mech-
anism. Nevertheless, the observation that the β1- and β3-subunits
influence the gating properties of Nav1.7 and alter its glycosyla-
tion pattern, while the β2- and β4-subunits do not, supports this
hypothesis.
It was recently proposed that only the upper band of biotiny-
lated Nav1.7 may reflect the functional fully-glycosylated form
of the channel, whereas the lower band represents an interme-
diate and/or immature glycosylated form of the channel which
does not participate in Na+ conductance (Laedermann et al.,
2013). The upregulation of expression of the core-glycosylated
form of Nav1.7 when the β3-subunit is co-transfected, along with
the associated 2-fold increase in the Nav1.7 current density, sug-
gests that there is no such dichotomy and that the link between
the glycosylation and functionality of the channel is more com-
plex. It is possible that these distinctly glycosylated forms of
Nav1.7 differentially participate in Na+ conductance, but their
relative contribution to the overall sodium current has yet to
be determined. For instance, quantification of the shifted upper
band when the β1-subunit was present revealed an increased sig-
nal intensity of ∼30%, which is less important than the 100%
increase of INa measured using the patch clamp approach. This
underlines that, in addition to an increased stabilization of the
channel, modification of single channel conductance by the inter-
mediate glycosylated form of Nav1.7 may also partially contribute
to the functional 2-fold increase in INa. This point, in addition
to the fact that β-subunits have the ability to shift bands from
one glycosylated state to another, demonstrates that quantifica-
tion of biotinylated proteins needs to be interpreted with caution.
It cannot be excluded that due to these shifts, some bands might
contaminate the signal of another band.
General kinetic models of biosynthesis (Schmidt and Catterall,
1987) have proposed that the β2-subunit interacts with the α-
subunit right before anchoring at the membrane. The present
findings are consistent with such a model since both β2- and β4-
subunits did not influence Nav1.7 glycosylation, and most likely
interacted after the Golgi network (Figure 7). The α-β1 com-
plex was previously shown to associate in the ER, enhancing
the trafficking to the plasma membrane (Zimmer et al., 2002).
Another study demonstrated that β1- and β3-subunits increase
the efficiency of channel trafficking from the ER to the plasma
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membrane (Fahmi et al., 2001). The β3-subunit has also been
shown to mask the ER-retention signal (Zhang et al., 2008). The
results of the present work confirm earlier demonstrated interac-
tions between the β- and α-subunits, and suggest an additional
function of both: β1- and β3-subunits interact with the α-subunit
in the ER/Golgi, where they regulate the differential glycosyla-
tion of Nav α-subunits, which in turn modulates the stabilization
of the channel at the cell membrane (Figure 7). The mecha-
nisms underlying their interaction and mediation of α-subunit
glycosylation, as well as the identification of other potential iso-
forms that would be subject to such regulation, remain to be
investigated.
PHYSIOLOGICAL RELEVANCE
These results were obtained in cellular expression system.
Whether such mechanisms also occur in native cells remain to be
investigated. This study used the Nav1.7 isoform, an important
contributor to pain processing (Lampert et al., 2010). The elec-
trophysiological results show that β1- and β3-subunits are able
to increase Nav1.7 excitability, as demonstrated by the increase
in peak current, kinetics, voltage-availability and repriming rate.
Nav1.7 is expressed in high levels in all types of sensory neu-
rons (Ho and O’leary, 2011). β-subunits are also expressed in
sensory neurons, but to a variable extent depending on cell type
(Takahashi et al., 2003; Ho et al., 2012). Furthermore, β1- and
β3-subunit expression has been reported to be increased in patho-
logical pain (Shah et al., 2000; Coward et al., 2001), where they
have been implicated in the generation of hyperexcitability. It
remains to be determined if Nav function is mediated by an
altered pattern of α-subunit glycosylation, which is an important
regulatory process of excitability in dorsal root ganglia neurons
(Tyrrell et al., 2001).
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3. Discussion 
In the two next chapters, I will discuss the results obtained in the two research papers separately and 
what they added in terms of mechanisms in the current literature about Navs regulation and 
neuropathic pain. I will discuss the questions that these studies raised and the future perspectives 
they opened. Finally, I will discuss the limitations of the work. 
3.1. Nedd4-2 project 
The role of Navs has been extensively studied in different animal models of neuropathic pain and 
led to contradictory results. However, and because the use of sodium channel blockers in the clinics 
and animal models alleviate pain symptoms, it is likely that Navs are implicated in the generation of 
neuropathic pain-associated hyperexcitability. Besides the multiple mutations that were shown to 
increase Nav1.7 function and that were linked to exaggerated pain sensitivity (Dib-Hajj, Rush et al. 
2005; Waxman and Dib-Hajj 2005; Fertleman, Baker et al. 2006; Novella, Hisama et al. 2007; 
Cheng, Dib-Hajj et al. 2008), and Nav1.7/Nav1.8 mutations associated with painful peripheral 
neuropathy (Faber, Hoeijmakers et al. 2012; Faber, Lauria et al. 2012), these channels were 
demonstrated to be important in acquired types of pain syndromes by accumulating in different 
location of the primary afferent (Gold, Weinreich et al. 2003; Hong, Morrow et al. 2004; Luo, Perry 
et al. 2008; Thakor, Lin et al. 2009; Persson, Gasser et al. 2011). The mechanisms that regulate 
Navs trafficking are multiple (Shao, Okuse et al. 2009). However, only few studies investigated 
whether such mechanisms could be responsible for Navs dysregulation in neuropathic pain. The 
protein kinase pathways were demonstrated to be implicated in Navs trafficking and consequentially 
to have a role in cellular hyperexcitability associated with neuropathic pain (Villarreal, Sachs et al. 
2009; Kakimura, Zheng et al. 2010) indicating the potential involvement of post-translational 
regulations. Here, we reported for the first time the importance of the ubiquitylation pathway in the 
primary afferent for pain processing. We highlighted the E3 ubiquitin ligase Nedd4-2 as a potent 
regulator of Nav1.7 and Nav1.8, which downregulation contributes to neuropathic pain-associated 
hyperexcitability. By using a tissue specific knockout of Nedd4-2, and by rescuying its expression 
after SNI, we were able to demonstrate both the necessity and the sufficiency of a well-balanced 
expression of this ubiquitin ligase for maintaining an appropriate cellular excitability in sensory 
neurons. However these observations also raised several questions: 
How is Nedd4-2 downregulated? 
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In the present study, we observed a downregulation of Nedd4-2 expression in terms of both mRNA 
and protein. The fact that the decrease of protein level was more important than that of mRNA 
level, leaves open a downregulation occuring at both stages.  
The up- or downregulation of hundreds of gene transcripts in DRGs after peripheral injury is a well-
known process (Costigan, Befort et al. 2002), and is largely connected to neuronal survival and 
regeneration of injured axons. It is also due to the loss of trophic factors from peripheral target 
organs and novel signalling molecules secreted around the injury such as inflammatory cytokines. 
Thus, these transcriptional changes lead to both adaptative and maladaptive responses that might 
ultimately be responsible for generating cellular hyperexcitability.  
Ubiquitin ligases of the Nedd4 family have been shown to be important for axonal guidance, axonal 
branching and development of synaptic structure and function (Myat, Henry et al. 2002; Sieburth, 
Ch'ng et al. 2005; Drinjakovic, Jung et al. 2010). Interestingly, Nedd4-2 can be secreted in 
extracellular microvesicles when interacting with Nedd4 Family-interacting protein 1 (Ndfip1) 
(Putz, Howitt et al. 2008). Both proteins have been implicated in neuronal survival (Sang, Kim et al. 
2006; Lackovic, Howitt et al. 2012). In the context of peripheral nerve injury, it is thus possible that 
Nedd4-2 would similarly be secreted from injured primary afferents promoting cell survival or 
axonal regeneration after injury. Altogether, this raises the possibility that the adaptive response of 
Nedd4-2 exosomal secretion could at the same time lead to the maladaptive decrease of its 
expression, and as a consequence increases Nav expression.  
The regulation of Nedd4-2 at a post-translational level was already largely studied in the kidney 
where phosphorylation of Nedd4-2 was shown to be of central importance. The mineralocorticoid 
hormone aldosterone induces the transcription of serum and glucocorticoid-induced kinase (SGK1) 
(Snyder, 2009), which further binds (via the WW motif), phosphorylates and prevents Nedd4-2 
activity, leading to an increase of ENaC activity. Conversely, vasopressin activates adenylate 
cyclase to increase cAMP, which in turn activates another kinase, PKA (Debonneville et al., 2001). 
Strikingly these two kinases phophorylate the same consensus sequence RxRxx(S/T) at three 
different sites (Ser 221, Thr 246 and Ser 327) and modulate Nedd4-2 ability to bind to ENaC 
making this motif a convergent point for different regulating pathway. Preliminary results from our 
laboratory (unpublished data from T. Berta) indicate that SGK1 mRNA is upregulated in DRG after 
SNI, which might diminish Nedd4-2 activity. The fate of Nedd4-2 after being phosphorylated is 
unknown. Because we observed a downregulation of Nedd4-2 protein, answering whether 
phosphorylation could lead to degradation of the protein remains to be investigated.  
It is well described that in inflammatory processes, cytokines are implicated in a complex pathway 
leading to NF-κB activation. By phosphorylation, they first activate IκB [inhibitor of nuclear factor 
κB (NF-κB)] kinase (IKK), which in turn phosphorylates and inactivates IκB inhibitory proteins. 
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The transcription factor NF-κB is no longer inhibited and can trigger its anti-apoptotic function 
(Delhase et al., 1999). More recently, a subunit of IKK, IKKβ was also reported to phosphorylate 
Ser327 of Nedd4-2 (Edinger et al., 2009) resulting in an enhanced ENaC function in the kidney. 
IKK is also enriched in unmyelinated nerves and its activation by pro-inflammatory molecules 
could possibly act as a negative regulator of Nedd4-2 in these neurons following inflammation. 
Strikingly, we also observed an important downregulation of Nedd4-2 in early time points after 
surgery in sham animals (6 hours, see Appendix 1) that, unlike SNI animals, goes back to normal 
within a couple of days. This raises the possibility that Nedd4-2 downregulation is triggered by 
inflammation inherent to surgery procedure and which remains persistent only if the nerve is 
severed.  
Finally, nerve growth factor (NGF), is a key player in nociceptor sensitization (Leung and Cahill 
2010; Dogrul, Gul et al. 2011; Gaudet, Popovich et al. 2011) by its ability to modulate  Navs, even 
though the precise mechanisms are unknown (Waxman et al., 1999). Interestingly, NGF binding to 
TrkA recpetor leads to Nedd4-2 phosphorylation, which may modulate Nav membrane expression 
(Arévalo, Waite et al. 2006). 
Are there other mechanisms that regulate Nedd4-2? 
Nedd4-2 target proteins can also be regulated by deubiquitylating (DUB) enzymes (Amerik and 
Hochstrasser 2004) allowing the removal of ubiquitin from targeted proteins. For instance a study 
(Fakitsas et al., 2007) showed that the deubiquitylating enzyme Usp2-45 can increase ENaC 
function by deubiquitylation of the channel. However, whether similar mechanisms could occur for 
Navs regulation remains to be investigated.  
What is the relevance of the PY motif in Nedd4-2 regulatory effect? Are there other motifs? 
The hydrophobic core surrounded by β-sheets of WW domains interacts with the canonical minimal 
sequence (L/P)PxY (Kasanov, Pirozzi et al. 2001) via a polyproline type II helix. We demonstrated 
the importance of the PY motif in Nedd4-2-downregulatory function by mutating Proline or 
Tyrosine of this motif. This led to the abolishment of Nedd4-2 downregulatory effect on Nav1.7-
mediated current in a cellular expression system, highlighting the importance of the PY-motif. 
Demonstrating that Nav1.9 (and also Nav1.4, even though it is not expressed in sensory neurons), 
devoid of PY motif, is not subject to Nedd4-2 downregulation would further confirm this PY-motif 
dependent pathway. 
The hydrophobic residue Tyrosine of the PY motif (Tyrosine +3) is involved in the binding to the 
WW-domain pocket, providing additional binding energy, and is thus considered as an “extended 
PY-motif” (Kanelis, Rotin et al. 2001; Henry, Kanelis et al. 2003) as demonstrated with ENaC. 
Interestingly, the consensus sequence P/LPxYxxV is observed in every containing-PY-motif Navs. 
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Strikingly, mutation of the Valine of this “extended PY-motif” (in Tyrosine +3) did not alter, or 
only minimally, the affinitiy between Nav1.7 and Nedd4-2. Nav1.7 mutation of Valine also led to a 
less pronounced downregulatory effect of Nedd4-2 as highlighted in whole-cell patch clamp 
experiments. Another study obtained similar results for Nav1.5 and Nav1.8 (Fotia, Ekberg et al. 
2004; van Bemmelen, Rougier et al. 2004). This suggests that unlike ENaC, the extended PY motif 
is not required, or only minimally, for Nedd4-2 to downregulate Navs. 
The use of an inactive Nedd4-2 mutant (Nedd4-2CS) in HEK293 cells led to an increase Nav1.7-
mediated current as compared to control condition. Because Nedd4-2 is highly expressed in 
HEK293 cell (unpublished data, see Appendix 2) we hypothesized that Nedd4-2CS upregulation of 
Nav1.7 was due to competition with endogenous Nedd4-2. We confirmed this hypothesis by 
silencing Nedd4-2, which led to similary increase of Nav1.7 current as with Nedd4-2CS. However, 
because Nedd4-1 can also downregulate Nav1.7 (data not shown), the silencing of this ubiquitin 
ligase is the next experimental control that needs to be performed. The PY motif importance for this 
competitive regulation to occur was demonstrated by showing that 72 hours after transfection, PY 
motifs mutants were not subject to endogenous downregulation whereas wild-type Nav1.7 was 
downregulated.  
As mentioned above, PY mutations in ENaC led to hypertensive diseases. The importance of this 
motif in both cardiac and neuronal Navs isoforms (Fotia, Ekberg et al. 2004; Rougier, van 
Bemmelen et al. 2005) suggests that mutations in its sequence could have important 
pathophysiological issues. In line with this, the mutation Y1977N, inside the PY-motif of Nav1.5, 
has been proposed to cause congenital long QT syndrome (Kapa, Tester et al. 2009; Rougier, 
Albesa et al. 2012). 
The regulation of Navs by Nedd4-2 might even extend beyond PY motif, involving other binding 
motifs under the dependence of other intracellular pathways. WW domains also have the ability to 
bind to alternative motifs (Sudol and Hunter 2000), such as phosphorylated Px(pS/T)P motifs. 
Accordingly, Gasser et al. (Gasser et al., 2010) showed that Nav1.6 is regulated by Nedd4-2 not 
only by the interaction with the PY motif, but also by a Pro-Gly-Ser-Pro motif in an intracellular 
loop (L1) of the channel. This motif is phosphorylated by p-p38 (activated stress-induced p38 
MAPK) converting it into a Px(pS)P, thus making it a recognizable for Nedd4-2. The authors 
reported that both sites are necessary for Nedd4-2 to downregulate Nav1.6.   
Was Nedd4-2 already identified as responsible for diseases involving cellular excitability? 
Because of the accumulating evidence of Nedd4-2 being able to regulate multiple target proteins 
and particularly ion channels (Persaud, Alberts et al. 2009), an interest for Nedd4-2 mutations or 
polymorphism has arisen. Thus far no mutations were identified, but several polymorphisms were 
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linked to hypertensive diseases (Dunn, Ishigami et al. 2002; Fouladkou, Alikhani-Koopaei et al. 
2004; Araki, Umemura et al. 2008; Luo, Wang et al. 2009). Interestingly, one of these naturally 
occurring Nedd4-2 variant was reported to have impaired downregulatory activity on ENaC in vitro 
(Fouladkou, Alikhani-Koopaei et al. 2004).  
With respect to Nav regulation, another study suggested a role for Nedd4-2 in photosensitive 
generalized epilepsy (IGE). In a study involving the screening of more than 250 families (Dibbens, 
Ekberg et al. 2007), the authors identified three rare Nedd4-2 gene variants; one missense mutation, 
one intronic mutation and one substitution mutation, all being located in the WW motif of Nedd4-2. 
However, the authors reported no loss of efficiency in Nedd4-2 downregulatory of Nav1.2 in 
Xenopus oocytes. It would be of interest to investigate whether these mutants have intact 
downregulatory effects on other Navs, as for instance Nav1.1 was reported to important in epilepsy 
(Catterall, Kalume et al. 2010). 
In the present study, rather than mutations of Nedd4-2, we reported a decrease of expression. There 
is some evidence suggesting that such an altered level of expression of Nedd4-2 could generate 
other pathological state, driven by erratic Nav expression. For instance, the human strongly 
metastatic breast cancer MDA-MB-231 cells show an increase Nedd4-2 mRNA compared to 
weakly/non-metastatic MCF-7 cells (Kuratomi et al., 2005) and it is also known that metastatic 
potential in cells lines is correlated with altered Nav expression such as Nav1.5  (Fraser et al., 2005). 
However, no relation between these observations has been proposed so far. 
What are potential other targets of Nedd4-2? 
Nedd4-2 regulates many other voltage-gated ion channels such as potassium (Kvs/KCNQs) and 
choride (ClCs) which also modulate electrical excitability in neurons (Bongiorno et al., 2011). 
Moreover Nedd4-2 regulation is not restricted to voltage-gated ion channels, but also interacts with 
amino acid, dopamine and glutamate transporters, adaptor proteins and kinases (Yang and Kumar, 
2009). Here again, identifying whether Nedd4-2 mutants could be associated with pathologies 
showing dysregluation of the above-mentioned proteins would be of interest. 
I will now discuss the limitations of the study. 
What is the relevance of the two populations? 
In this study, we segregated neuronal subpopulation based on the ratio of Nav1.8/Navtotal current as 
it was already performed in several studies (Abdulla and Smith 2002; Lopez-Santiago, Pertin et al. 
2006). Slow neurons had a ratio >0.5 whereas fast neurons ratio was <0.5. However, the authors did 
not propose any physiological functions for these two subpopulations. Based on our observations on 
Nedd4-2 knockout mice, we could only speculate that slow neurons are underlying thermal 
modality. 
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We initially made the assumption that slow and fast neurons could represent non-peptidergic and 
peptidergic neurons, which was based on the relative amount of Nav1.8 current recorded in small 
DRG neurons. Several studies reported an important co-localisation of IB4 positive neurons and 
Nav1.8 (Benn, Costigan et al. 2001; Fukuoka, Kobayashi et al. 2008) in DRG and that slower 
kinetics in these cells was due to TTX resistant currents (Stucky and Lewin 1999; Wu and Pan 
2004). However, a recent study suggested that Nav1.9, and not Nav1.8, is the most relevant co-
marker of non-peptidergic neurons (Fang, Djouhri et al. 2006). Furthermore, we characterized the 
cells based on the ratio of Nav1.8 current density to the Navtotal current, but the absolute amount of 
Nav1.8 current is only slightly smaller in fast compared to slow neurons (refer to the Nav1.8 density 
between slow and fast neurons of control conditions in Supplemental Table 2, 3, 4). Furthermore, 
non-peptidergic neurons are most likely involved in mechanical rather than thermal sensitivity 
(Abrahamsen, Zhao et al. 2008; Scherrer, Imamachi et al. 2009), which is in apparent contradiction 
with our observations.  
Altogether, these observations leave open the classification of slow and fast neurons into specific 
DRG neuronal populations with specific functions and highlight the necessity for further 
investigations. 
The distinction between intact and severed neurons: underestimation of the effect? 
In this study we used the SNI model of neuropathic pain, where severed and intact nerves are found 
to be intermingled in the same DRG, hence allowing cross-excitation between cell bodies (Devor 
and Wall 1990; Amir and Devor 1996) as well as ephaptic cross-excitation along the fibers (Lisney 
and Pover 1983). In a previous study from our group, we used fluorogold retrolabelling to identify 
injured from intact neurons in the rat (Berta, Poirot et al. 2008). This distinction highlighted 
different results in terms of mRNA, peak current and biophysical properties depending on the 
injured/non-injured identity, with the most important changes occurring in the injured neurons. 
Because we did not perform this distinction in the present study, it is possible that some of the 
observed effects are underestimated. In line with the previous assumption, the stronger 
downregulation of Nedd4-2 in the injured L4 DRG using the SNL model suggests that reduction of 
Nedd4-2 influencing on Navs mainly takes place in injured neurons. Thus, the next step would be to 
study Navs expression in L4 SNL to confirm this hypothesis. Noteworthy, in a previous study 
performed in our research group using immunofluorescence in the rat, we observed a similar 
decrease of Nedd4-2 in injured and non-injured neurons (Cachemaille, Laedermann et al. 2012). 
The previous highlights the need for further investigations to study the effect of axotomy on Nedd4-
2 regulation. 
The controversy of Na 1.7 and Na 1.8  implication in neuropathic pain. v v
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We already discussed in the introduction the controversial role of Nav1.7 and Nav1.8 in neuropathic 
pain. In humans, recent identifications of mutations in Nav1.7 and Nav1.8 in nerve fiber neuropathy 
clearly point out these two sodium channels isoform as important candidates implicated in 
neuropathic pain. However, animal studies gave inconsistent observations. Knocking out Nav1.7, 
Nav1.8, or both, using Cre recombinase and loxP sites (Agarwal, Offermanns et al. 2004), does not 
alter development of neuropathic pain symptoms (Akopian, Souslova et al. 1999; Kerr, Souslova et 
al. 2001; Nassar, Stirling et al. 2004; Nassar, Levato et al. 2005). One of the possible explanations 
is that upon gene deletion, some other genes might be modulated and compensate the deleted gene 
(Barbaric, Miller et al. 2007). The attenuation of neuropathic pain symptoms when these isoforms 
are silenced rather than knocked out (Lai, Gold et al. 2002; Yeomans, Levinson et al. 2005; Dong, 
Goregoaker et al. 2007), which is maybe less robust in terms of expression but more precise in a 
temporal manner, supports this possibility. It is also possible that Nav1.7 and Nav1.8 are 
differentially implicated in neuropathic pain depending on the species; knocking out genes is 
generally used in mice whereas knocking down genes is rather used in rats, at least in the pain 
research field. 
Sensory neuron specific Nedd4-2 knockout mouse lines. 
We have just discussed the limitation of the use of knockout mouse lines, which could account for 
the lack of effect of Nav1.7 and Nav1.8 deletion on neuropathic pain development. We used similar 
knockout mouse lines that may lack both spatial and temporal resolution. “Temporal” because the 
Cre recombinase expression starts early in development, which might allow for compensatory 
mechanisms to take place. “Spatial” because Nav1.8 (the promoter for Cre recombinase), which was 
initially thought to be exclusively expressed in small nociceptive neurons (Shields, Ahn et al. 2012), 
was recently reported to be expressed more broadly in DRG cells. One way to overcome this 
problem would be the use of inducible knockout mouse lines, such as tamoxifen induced 
recombination mice (Friedel, Wurst et al. 2011). To our knowledge, these mice have never been 
used to study Navs implication (directly, or via regulatory proteins) in neuropathic pain. An 
alternative approach would be the use of viral vector expressing Cre recombination. Thus, the viral 
vector delivery might be performed at any time point and as precisely as the injection allows.  
Limitations of the SNI model. 
It has to be acknowledged that the spared nerve injury (SNI) model used in the present study might 
not perfectly reflect the pathophysiological mechanisms of all type of neuropathic pain encountered 
in clinical practice. However and as already mentioned previously, among neuropathic pain 
conditions, mononeuropathy has the highest incidence rate (Dieleman, Kerklaan et al. 2008), 
highlighting the importance of single nerve injury. The development of animal models for nerve 
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injury–induced neuropathic pain has significantly contributed to the discovery of mechanisms that 
contribute to neuropathic pain syndromes.  
In the present study, we used the SNI model because (1) it produces robust thermal and mechanical 
hypersensitivity that lasts for an extended period of time (more than 6 months), and (2) we have 
long-standing experience with it. Under our experimental conditions, 100% of the mice that 
undergo SNI surgery develop mechanical allodynia, which corresponds well to the high percentage 
(50-70%) of patients developing neuropathic pain after traumatic nerve injury (Flores 2006; 
Ciaramitaro, Mondelli et al. 2010). Furthermore, the involvement and regulation of Navs in these 
models have been extensively studied. However, studying Nedd4-2 impact on Navs regulation in 
other neuropathic pain models such as the streptozotocin or other chemically-induced neuropathic 
pain models will give further insight on the role of Nedd4-2 in this pathology. 
Limitation of DRG culture and whole cell patch clamp. 
Recording sodium currents from neuronal primary culture is another limitation of this study. 
Neurons are undergoing an important traumatic stress after dissociation. It is possible that changes 
induced by treatment (SNI, knockout of Nedd4-2 or viral rescuing of Nedd4-2) will be biased in the 
effect mediated by the dissociation procedure itself. In native tissue, neurons are surrounded by 
connective tissue, make synapses with other neurons, communicate with satellite cells, interact with 
extracellular matrix proteins and so on. Freshly dissociated neuronal culture, by loosing 
connectivity with these other actors, will most likely undergo important molecular changes. 
Furthermore, proteolytic enzymes, such as collagenase and protease, are required to obtain cell 
preparations and might also impact on membrane protein expression. In the present study, if Nedd4-
2 reduction in SNI is due to the injury itself as we postulated, then the axotomy resulting from 
dissociation can per se trigger Nedd4-2 downregulation. However, immunofluorescence on 
dissociated DRG neurons 36 hours post-dissociation reveals that Nedd4-2 expression is still lower 
in knockout animals than in control littermates, somehow discarding this possibility. Presumably, 
this should also be the case after SNI. Another important issue is that we are recording only 
electrical activity in the cell body of the primary afferent, leaving aside the rest of the nerve, where 
most of the current is processed. Alternative electrophysiological recordings should be carried on, 
such as skin nerve preparations, in order to study the conduction of AP along the axons in the 
context of Nedd4-2 regulation. 
In this study, we made the assumption that Navs current density reflects the excitability of the cell. 
However recent evidence shows that increasing sodium conductance does not necessarily lead to 
increased excitability (Kispersky, Caplan et al. 2012) and performing current clamp to record action 
potentials properties should be carried in the future. 
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 3.2. β-subunits project 
Glycosylation and β-subunit-dependent regulation of Nav α-subunits are two well-described 
processes that significantly contribute to modulation of Nav gating. In this study, I described a new 
role for two out of the four β-subunits, namely β1 and β3-subunits, as modulators of Nav1.7 
glycosylation while β2 and β4-subunits do not. It is likely that such mechanisms are also occurring 
for other Nav isoform, but remains to be demonstrated. We also confirmed that β-subunits 
modulates Nav1.7 membrane expression and gating. Thus, we highlighted that two known 
regulatory mechanisms, glycosylation and β-subunits regulation, are converging into one single 
pathway.   
Is the β-subunits-mediated glycosylation of α-subunit responsible for the modulation of gating? 
The modification of Nav gating by α-subunit sialylation was already demonstrated (Bennett, Urcan 
et al. 1997; Zhang, Hartmann et al. 1999). The effect of β-subunits on Navs α-subunit gating is 
thought to be mediated by direct interference of the subunit with gating sensors (Zimmer and 
Benndorf 2002). In the present study, we proposed that, in addition to modulating gating of α-
subunit via direct physical interference, the β-subunit-mediated glycosylation of the α-subunit might 
be responsible for the modification of the biophysical properties. To answer this question, a starting 
point would involve the use of a cell line deficient for glycosylating enzyme or the inhibition of 
glycosylation using treatment such as tuncamycin. Determining whether β-subunit modification of 
gating is abolished when all the cellular process of glycosylation are hindered would allow 
confirming or infirming the causal link between β-subunits-mediated glycosylation of the α-subunit 
and modification of the biophysical properties by these subunits. Obviously, this approach might 
lack specificity for a given mechanisms because all the glycosylation processes, crucial for the 
proper cell function, would be impaired in the cell. Thus, the next step would be the identification 
of the amino acid(s) on the α-subunit that is (are) alternatively glycosylated upon β1 and β3-subunit 
co-expression. Mutating this site would definitively allow to demonstrate the potential causality 
between β-subunits-mediated glycosylation and modification of the biophysical properties. 
Glycosylation of β-subunits? 
Interestingly, β-subunits are themselves substrates for glycosylation (Isom, De Jongh et al. 1992).  
β-subunits and glycosylation were already proposed to collaborate for modulating α-subunit 
function. In a study, authors proposed a trans effect of β-subunit glycosylation on α-subunit gating 
(Johnson, Montpetit et al. 2004; Johnson and Bennett 2006); in short, the glycosylation of β-subunit 
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itself impacts on α-subunit gating. To show this, the authors used a cell line deficient in 
glycosylating enzyme and demonstrated that β-subunit effect on gating was no longer effective. 
However, it is possible that β-subunit ineffectiveness was due to altered α-subunit glycosylation 
rather than β-subunit defective glycosylation.  
How do β1 and β3 mediate differential glycosylation? 
In our model, we proposed that β-subunits interact, directly or indirectly, with the α-subunit early 
after synthesis and before exiting the Golgi network. Thus, demonstrating that an interaction or a 
co-localisation is already occurring in the ER/Golgi would be the next step for further investigation 
of the β-subunits effects on glycosylation. The experimental approaches could include the use of 
powerful microscopy (confocal, correlative light and electron microscopy) and use of ER/Golgi 
markers. Split-luciferase complementation assays (Shavkunov, Panova et al. 2012) would allow 
studying temporal interaction between β-subunits and α-subunits whereas pull-down experiments 
could be used to study physical interaction between the two proteins. 
To our knowledge there are no known mechanisms explaining how β-subunits could modify the 
glycosylation of α-subunit. Thus, investigating whether β-subunits modulate glycosylation by direct 
interaction with the α-subunit, or by interfering with glycosylating/deglycosylating enzymes or by 
other mechanisms remains to be done. 
Modulation of I  current; conflicting results. Na
Our first observation that β1 strongly increased Nav1.7 INa density contrasted with another study 
performed by Ho et al. revealing no influence of any of the β-subunits on Nav1.7 current density 
using the same cultured cell lines (Ho, Zhao et al. 2012) and also with another study using Xenopus 
oocytes (Sangameswaran, Fish et al. 1997; Vijayaragavan, O'Leary et al. 2001). Nevertheless, other 
studies already reported increased current density of other Navs isoforms by β-subunits (Nuss, 
Chiamvimonvat et al. 1995; Smith and Goldin 1998; Fahmi, Patel et al. 2001; Zimmer and 
Benndorf 2002). The unaltered Nav1.7 current upon expression of β2 and β4 subunits are in 
accordance with a previous study also using HEK293 cells (Ho, Zhao et al. 2012) and also in other 
recipient cells and Navs isoforms (Malhotra, Chen et al. 2001; Vijayaragavan, Powell et al. 2004; 
Aman, Grieco-Calub et al. 2009). The strong upregulatory effect of β3 subunits on Nav1.7 current 
density is also in contradiction with the study from Ho. et al. and other studies (Morgan, Stevens et 
al. 2000; Vijayaragavan, Powell et al. 2004), but here again, other groups also already reported and 
increase of Nav1.7 peak current (Fahmi, Patel et al. 2001).  
This is possibly due to different cell background, involving differential endogenous β-subunits 
expression as well as other partners (Meadows and Isom 2005). Comparing our results with the 
results obtained by Ho et al., revealed that very subtle differences (both studies were carried with 
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HEK293 cells, but Ho and colleagues used a stable cell line expressing rat Nav1.7 cDNA, whereas 
we used transient transfection of human Nav1.7 cDNA) are already sufficient to generate 
differences in β-subunit effects on Nav1.7. 
Physiological relevance. 
 Naturally occurring genetic variants in humans and genetically modified animal models have 
shown that β-subunits are implicated in numerous diseases such as pain, epilepsy, migraines or 
cardiac arrhythmias (Brackenbury and Isom 2011). However, whether α-subunit glycosylation 
would be altered in the presence of dysfunctional β-subunits has never been investigated. I already 
discussed the potential effect of β-subunits modulating Nav1.7 in the pain pathway in the discussion 
of the article. SCN2B knockout animals show altered INa current and altered pain phenotype. This is 
presumably due to their regulation of both stabilization and gating of the α-subunit. The next step is 
the investigation of the state of glycosylation of this isoform, as well as others, in these mouse lines.  
Limitations of in vitro patch clamp recording. 
I am aware of the limitations of using HEK293 cells to study the physiological function of proteins. 
The transfection of cDNAs is by itself problematic because it may saturate all the translation 
machinery, and fine mechanisms of regulations are probably very different than they are in native 
tissue. Furthermore, it is likely that many partner proteins are missing. In my research work, I 
focussed on Navs regulation in neuronal cell and using HEK293 cells, which are defined as being of 
renal origin, is also questionable. However, there is evidence that HEK293 cells are of neuronal 
origin (Shaw, Morse et al. 2002). Nevertheless, it would be more relevant to work on ex vivo 
samples, such as DRGs neurons. Using SCNB knockout mice or electroporation of β-subunits 
cDNA would allow the investigation of these subunits influence on different Navs component.  
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3.3. General Discussion 
Navs are central players in electrical processing in the nervous system and carry an important role in 
normal and pathological pain. During the past decade, numerous mutations of Nav1.7 and Nav1.8 
were identified and are incriminated in several different pain pathologies such as neuropathic pain. 
These mutations were often linked with alterations of Nav sodium conductance and a shift toward 
hyperexcitable state of the channels. However, thus far, post-translational modulation of Nav by 
regulatory proteins, which can also lead to modification of the sodium conductance, has been more 
sparsely investigated. 
The purpose of my thesis was the investigation of Navs regulation by two important players, 
Nedd4-2 and β-subunits and was done in the specific perspective of neuropathic pain disorder.  
We confirmed that Nedd4-2 downregulates Nav1.7 in mammalian cells and further extensively 
investigated the ubiquitylation of Nav1.7 and the motifs incriminated in the interaction with Nedd4-
2. The major contribution of the first article of my thesis research work was the demonstration that 
Nedd4-2 downregulation after SNI is sufficient to alter Navs expression and to generate pain 
hypersensitivity. To our knowledge, this represents the first evidence of a physiological role for 
Nedd4-2 in regulating Navs in vivo. We used a known regulatory mechanism that allowed us to 
highlight a novel physiological relevance of the ubiquitylation pathway. In addition, targeting a 
mechanism of dysregulation of Navs might open new avenues for a mechanism-based treatment of 
neuropathic pain. 
In the second part of my thesis research work, I did the opposite; we highlighted a novel mechanism 
of Navs α-subunit regulation in vitro, but whether this has any physiological implication remains to 
be investigated. Obviously, β-subunit regulation of Navs α-subunit is not novel, but the fact that 
such regulation can be driven by β-subunit dependent glycosylation has never been reported. This 
paves avenues for studying glycosylation of Navs in SCNB knockout animals, or in animals that 
underwent SNI and that show increased levels of β-subunit expression.  
As shown in the Figure 9 of the introduction, β-subunits and Nedd4-2 have opposite effects on Navs 
membrane expression. Because there is a tight balance between internalization and stabilization 
processes, I wondered whether these two mechanisms could compete one with another. To answer 
this question, I first tested whether β-subunits co-expression could impair Nedd4-2 potency to 
downregulate Nav1.7 (see Appendix 3). Nedd4-2 downregulated Nav1.7 to the same extent when β1 
or β3-subunits were co-transfected as it did with Nav1.7 alone (~70% decrease), suggesting that β-
subunits are not competing with Nedd4-2. Conversely, I also demonstrated that Nedd4-2 does not 
compete with β-subunits upregulatory effect on Nav1.7. To do so, I showed that β-subunits have the 
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same upregulatory effect on Nav1.7 than on YA mutant of Nav1.7, which is not subject to Nedd4-2 
regulation. Together, these results suggest that both pathways are independent.  
Altogether, I dissected out Navs regulatory processes, demonstrated Nedd4-2 in vivo significance 
and highlighted a new regulatory mechanism of glycosylation mediated by β-subunits in vitro.  
For an efficient treatment of neuropathic pain, there is a clear need for a better control of sensory 
neurons hyper-excitability. Much hope was coming from the development of new Nav blockers 
(Priest and Kaczorowski 2007). However, the progresses have been slow because of the great 
difficulty to design selective Navs subtype blockers that would generate fewer side effects. Only a 
few examples of such selective Navs blockers are found in the scientific literature or in the 
pharmaceutical press releases (Bhattacharya, Wickenden et al. 2009). Based on our studies, we 
propose that targeting post-translational mechanisms, which regulate Navs density at the cell 
membrane, could be used as an alternative to Nav blockers to modulate neuronal excitability. 
However, how to target ubiquitylation or glycosylation mechanisms remains a challenging task. In a 
recent study (Ernst, Avvakumov et al. 2013), a strategy for modulating enzymes of the ubiquitin 
system has been proposed; using ubiquitin variants the authors could compete with or boost 
ubiquitylation processes. Strikingly, the authors were able to enhance Nedd4 activity. This 
approach, in addition to gene therapy, could be used to rescue Nedd4-2 activity after peripheral 
nerve injury and thus reduce cellular excitability.  
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5. Appendices 
(1)  Figure of time course of Nedd4-2 expression in DRGs after sham and SNI surgery 
(2)   Figure of constitutive levels of Nedd4/Nedd4-like ubiquitin ligase in HEK293 cells 
(3)   Figure of competition between Nedd4-2 and β-subunits on Nav1.7 in HEK293 cells. 
(4)   Manuscript to be soon submitted to Molecular Pain: Voltage-gated sodium channels 
expression in mice DRG after SNI leads to re-evaluation of injured fibers projections. I 
participated to the conception and design of the experiments. I wrote the first draft of the 
manuscript and revised versions. I prepared the figures. 
(5)   Contribution to publications: 
  a. “Neuronal expression of the ubiquitin ligase Nedd4-2 in rat dorsal root ganglia: modulation 
in the spared nerve injury model of neuropathic pain” in Neuroscience (Cachemaille, 
Laedermann et al. 2012). I participated to the conception and design of the experiments. I 
performed some of the biochemical experiments. I revised the manuscript. 
  b. “Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse 
and stabilizes voltage-gated sodium channel inactivated state” in Anesthesiology (Suter, 
Kirschmann et al. 2013). I performed the patch-clamp experiment on dissociated DRG 
neurons. I revised the manuscript. 
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Appendix 1. Nedd4-2 expression in DRGs is reduced in sham 
and SNI in early time points after surgery.
Representative western blot analysis showing the decrease of 
Nedd4-2 after 6 hours in both sham and SNI conditions in L4/5 
DRGs and its associated quantification. Data are expressed as 
means ± SEM, n = 4 samples for each time point/group. ***P < 0.001 
by one-way ANOVA, post hoc Bonferroni test. Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) was used as a loading 
control.  
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Appendix 2. Constitutive  transcript  levels  of  Nedd4/Nedd4-like  E3  subfa-
mily  members  in  HEK293 cells. Levels of transcripts were normalized using 
GAPDH as a reference gene and further normalized to Nedd4-2 levels. Data are 
expressed  as  means  ±  SEM,  n  =  3  samples  per  group  and  run  in  triplicate.   
121
Nedd4-2 vs Beta1
N
av
1.
7
N
av
1.
7 
+ 
N
ed
d4
-2
N
av
1.
7 
+ 
B
et
a1
N
av
1.
7 
+ 
B
et
a1
 +
 N
ed
d4
-2
0.0
0.5
1.0
1.5
2.0
2.5
N
o
rm
a
liz
e
d
  
p
e
a
k
 c
u
rr
e
n
t 
(t
o
 N
a
v
1
.7
)
Nedd4-2 vs Beta3
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Beta1 vs Nedd4-2
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Appendix 3. β-subunits and Nedd4-2 are not competing to regulate Na
v
1.7 current 
densities in HEK293 cells. A) Bar graph quantification of Na
v
1.7 current densities 
showing that β1-subunit does not hinder Nedd4-2 downregulatory effect (-80% with 
Na
v
1.7 alone, and -65% for Na
v
1.7 co-transfected with β1-subunit). B) Bar graph quantifi-
cation of Na
v
1.7 current densites showing that β3-subunit does not hinder Nedd4-2 
downregulatory effect (-64% with Na
v
1.7 alone, and -73% for Na
v
1.7 co-transfected with 
β3-subunit). C) Bar graph quantification of Na
v
1.7 current densities showing that β
1-subunit has similar upregulatory effect on Na
v
1.7 (+160%) than on YA mutant 
(+119%). D) Bar graph quantification of Na
v
1.7 current densites showing that β3-subunit 
has the same upregulatory effect on Na
v
1.7 (+119%) than on YA mutant (+81%). These 
results suggest that these two pathways do not compete one with another. Data are 
expressed as means ± SEM. Student’s t-test, n = 8-12 for each condition.
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Abstract 
Electrical activity in nerve fibers is mainly carried by voltage-gated sodium channels (Navs), 
and their dysregulation is suspected to play a major role in hyperexcitability associated with 
neuropathic pain. We studied the modification in the transcriptional levels of Navs in dorsal 
root ganglia (DRG) in the spared nerve injury (SNI) model of neuropathic pain in mice. This 
model allows the investigation of Navs changes in injured and non-injured neurons, which are 
intermingled in the same ganglia. We observed a strong downregulation of every Navs 
isoform, even Nav1.3, which was previously shown to be strongly upregulated in rat 
neuropathic pain models, suggesting differences between these two species. We also used the 
spinal nerve ligation (SNL), where cell bodies of injured and non-injured fibers are 
anatomically separated in different DRGs, to evaluate the contribution of the axotomy itself in 
Navs downregulation. Besides the transcription analysis of Navs, we performed a careful 
characterization of axotomized neurons projection to L3, L4 and L5 DRGs after SNI by 
studying Activating Transcription Factor 3 (ATF3) expression, a known marker of nerve 
injury. This highlighted another major difference between mice and rats; most injured fibers 
actually find their cell bodies in L3 and L4 after SNI in mice whereas they were mostly found 
in L4 and L5 DRGs in the rats. The spared sural nerve, through which the overrated pain 
signal is transmitted in behavioral studies, mostly finds its origin in L4 and L5 DRGs. Thus, 
L3 is enriched with injured neurons, L4 with a mixture of injured and non-injured neurons, 
and L5 is enriched in non-injured neurons after SNI. They should be pooled only with caution 
in SNI studies in mice. We conclude that the largest Navs downregulation occurs in the DRGs 
harboring axotomized fibers and that there is a rostral shift of the DRGs harboring injured 
fibers in the C57BL/6J mice as compared to the rat.
Keywords 
Voltage-gated sodium channels (Navs), qRT-PCR, neuropathic pain, dorsal root ganglia 
(DRG), sciatic nerve, spared nerve injury (SNI), spinal nerve ligation (SNL), nerve injury, 
Activating Transcription Factor 3 (ATF3). 
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Background 
Increased electric activity is a major mechanism in the development of neuropathic pain 
following peripheral nerve injury. Spontaneous discharges can originate from both injured 
and non-injured nerve fibers or from dorsal root ganglia (DRG) (Wall and Devor 1983; Liu, 
Wall et al. 2000; Wu, Ringkamp et al. 2001; Ma, Shu et al. 2003; Amir, Kocsis et al. 2005; 
Djouhri, Koutsikou et al. 2006). Voltage-gated sodium channels (Navs) are key players in 
carrying cellular excitability (Catterall, Goldin et al. 2005) and are capital for pain processing 
(Liu and Wood 2011). Navs are heteromeric protein composed of a large pore-forming -
subunit and small -auxiliary subunits (Catterall 2000; Brackenbury and Isom 2011). From 
the nine distinct channel isoforms described (Nav1.1 to Nav1.9), Nav1.5, Nav1.8 and Nav1.9 
are resistant to tetrodotoxin (TTX). All isoforms, except Nav1.4 and Nav1.5, are expressed in 
DRGs, Nav1.7 being the most expressed TTX-sensitive isoform (Black, Dib-Hajj et al. 1996; 
Rush, Cummins et al. 2007; Berta, Poirot et al. 2008; Fukuoka, Kobayashi et al. 2008; 
Fukuoka and Noguchi 2011; Ho and O'Leary 2011). Nerve-injury-mediated hyperexcitability 
has been proposed to result from altered expression of Navs (Gold, Weinreich et al. 2003; 
Chahine, Ziane et al. 2005; Study and Kral 2005). These changes in Nav expression occur in 
both injured and non-injured neurons in rats (Decosterd, Ji et al. 2002; Fukuoka and Noguchi 
2002; Gold, Weinreich et al. 2003; Pertin, Ji et al. 2005). In different experimental models of 
neuropathic pain in rats mRNAs of most Navs were downregulated in the DRGs (Dib-Hajj, 
Black et al. 1996; Cummins and Waxman 1997; Dib-Hajj, Tyrrell et al. 1998; Sleeper, 
Cummins et al. 2000; Berta, Poirot et al. 2008) except  for an increase of Nav1.3 transcript 
(Waxman, Kocsis et al. 1994; Cummins and Waxman 1997; Berta, Poirot et al. 2008). Navs 
changes in mice models of neuropathic pain have, however, seldom been investigated. 
The various animal models of neuropathic pain involving nerve transection and/or ligation 
developed to study the pain mechanisms exhibit different relation between injured and non-
injured fibers. The first behavioral model of nerve injury used complete sciatic nerve 
transection (Wall, Devor et al. 1979). This model did probably not reflect the partial nerve 
injury observed in most neuropathic pain patients which involve also signals arising from 
intact sensory neurons (Campbell and Meyer 2006). Since then, models of partial injuries 
have been described which also allow evoked behavioral testing of the hindpaw. The L5 
spinal nerve ligation (SNL) is an experimental neuropathic pain model which displays a clear 
separation between injured and non-injured cell bodies (Kim and Chung 1992). This model 
does not allow cross-talk between injured and non-injured cell bodies in respectively L5 and 
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L4 DRGs. The spared nerve injury model (SNI) (Decosterd and Woolf 2000) involves a 
lesion of two of the three terminal branches of the sciatic nerve, the common peroneal and 
tibial nerves, sparing the sural nerve, and induces mechanical and thermal hypersensitivity in 
the territory of the sural nerve. In this model, severed and intact nerves are intermingled in the 
same DRG which may allow cross-excitation between cell bodies (Devor and Wall 1990; 
Amir and Devor 1996) as well as ephaptic cross-talk along the fibers (Lisney and Pover 
1983). Originally carried out in rats, the SNI model was further transposed and validated in 
mice (Bourquin, Süveges et al. 2006). To our knowledge, a careful characterization of injured 
and non-injured fibers projection to DRGs has not been carried in mice after SNI and the 
assumption of neuroanatomical similarities between the two species, rat and mice, is possibly 
not correct (Rigaud, Gemes et al. 2008). 
In this study, we investigated the changes in Navs transcription in mice DRGs following SNI 
and SNL surgeries. To correlate Navs expression to injury we also studied the projection of 
injured and intact fibers to L3, L4 and L5 DRGs after SNI.  
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Results 
Expression of Navs in mice L4 and L5 DRGs
We first assessed the level of expression of Navs in the DRGs of sham operated mice using 
qRT-PCR (Figure 1). Constitutively, Nav1.7 is the most expressed TTX sensitive isoform in 
L4 and L5 DRGs as it was in the rat (Berta, Poirot et al. 2008; Fukuoka, Kobayashi et al. 
2008; Ho and O'Leary 2011). Consistent with observations in rats, Nav1.8 is also highly 
expressed in mice L4 and L5 DRGs, but Nav1.9 being the most expressed isoform is specific 
to mice.  
Downregulation of Navs expression after SNI injury
Peripheral nerve injury leads to hyperexcitability, which is evidenced by ectopic discharges 
and is thought to be conducted by Navs. We thus analyzed Navs mRNA regulation after SNI in 
mice. In order to reduce the number of animals necessary for experiments, it is common to 
pool DRGs together. In parallel to what is performed in rats, we pooled L4 and L5 DRGs 
which we assumed should contain a mixture of cell bodies of injured and non-injured fibers. 
SNI induced an important downregulation of every isoforms tested (Figure 2A). Nav1.1 was 
decreased by -45%, Nav1.2 by -17%, Nav1.3 by -26%, Nav1.6 by -34%, Nav1.7 by -31%, 
Nav1.8 by -38% and Nav1.9 by -40% compared to sham.  
How a decrease in Navs mRNA in the DRG could contribute to hyperexcitability remains 
under debate, but several explanations have been proposed; besides the fact that a reduction of 
mRNA does not necessarily mean a reduction of protein level, a potential reason invoked is a 
redistribution of the Navs mRNA from the cell body to the sciatic nerve where it will be 
translated and gain its function (Thakor, Lin et al. 2009). It is also possible that an induction 
of translation to increase de novo synthesis of proteins, which will be subsequently redirected 
along axons, will lead to a reduction of transcriptional levels. 
Our results highlight an important difference between mice and rats: whereas Nav1.3 is much 
increased in rats (Waxman, Kocsis et al. 1994; Black, Cummins et al. 1999; Lindia, Köhler et 
al. 2005; Berta, Poirot et al. 2008), we observed a downregulation of this isoform in mice 
after SNI. Despite controversies in the role of sodium channels in neuropathic pain, the 
upregulation of Nav1.3 is commonly thought to be a main candidate for neuropathic pain-
associated hyperexcitability in rats (Cummins and Waxman 1997; Black, Cummins et al. 
1999). This was recently confirmed by knocking down this gene in rat after nerve injury 
which led to an attenuation of nerve injury-induced neuropathic pain symptoms (Samad, Tan 
et al. 2013). However, our results indicate that the implication of Nav1.3 might be different in 
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mice; this is corroborated by the normal development of neuropathic pain symptoms in 
Nav1.3 null mutant mice (Nassar, Baker et al. 2006). 
Axotomy is responsible for the downregulation of Navs
Because L4 and L5 DRGs contain both injured and adjacent non-injured neurons after SNI 
and to answer whether axotomy by itself is responsible for change in Navs expression, we 
then performed L5 SNL. We thus compared L4 non-injured and L5 injured DRGs to their 
homologue DRGs in sham conditions. We observed a highly significant decrease in the 
mRNA expression of almost every Navs in the injured L5 DRG. Nav1.1 was decreased by -
61%, Nav1.3 by -47%, Nav1.6 by -63%, Nav1.7 by -53%, Nav1.8 by -74%, Nav1.9 by -68%. 
Only Nav1.2 remained unchanged in injured L5 DRG (Figure 2B). In contrast, there was no 
modification in Navs expression in the non-injured L4 DRG compared to sham operated 
animals with the exception of a decrease of Nav1.1 mRNA by -33%.  
These results seem to indicate that the modification in Navs expression is due to and 
exclusively occurring in injured fibers, consistent with a previous study performed in  the rat 
SNL model (Fukuoka, Yamanaka et al. 2012). However, this result contrasts with our 
previous study carried in the rat after SNL (Berta, Poirot et al. 2008) where we observed a 
small, but significant increase of Nav1.6, Nav1.7, Nav1.8 and Nav1.9 in L4 non-injured DRG. 
Regulation of Navs in distinct DRGs after SNI leads to re-assess the innervation. 
To refine our analysis of DRGs housing injured and non-injured fibers after SNI, we collected 
L4 and L5 separately after surgery instead of combining them. We also collected L3 DRG, 
because, as can be observed in our dissection procedure (see Figure 3) and following the 
description of differential anatomical relationships in mice strains by Rigaud et al. (Rigaud, 
Gemes et al. 2008), this DRG is likely to provide fibers to the sciatic nerve. Nav1.1 mRNA 
was significantly decreased by -52% in L4 and the same tendency was observed for L3 (-
43%, p = 0.082) but not in L5 (-9%). Nav1.2, Nav1.3 and Nav1.6 mRNA expression remained 
unchanged in all three ganglia despite an observable trend to decrease in L3 (-40%, -43% and 
-32% for Nav1.2, Nav1.3 and Nav1.6, respectively) and L4 (-21%, -36% and -42% for Nav1.2, 
Nav1.3 and Nav1.6, respectively) whereas no such trend was seen in L5 DRG (-2%, +29% and 
-11%, for Nav1.2, Nav1.3 and Nav1.6, respectively) (Figure 2C). The high variability, due to 
the weak endogenous expression of these isoforms (Figure 1) and the necessity to pool the 
DRGs from 8 animals (see Methods), might be responsible for the lack of statistical 
significance in the decrease of Nav1.1, Nav1.2, Nav1.3 and Nav1.6. Nav1.7 mRNA was 
significantly decreased in L3 (-35%), but remained statistically unchanged in L4 (-16%) and 
L5 (-16%). Nav1.8 mRNA was strongly downregulated in L3 (-47%) and L4 DRGs (-49%) 
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and was also downregulated in L5 DRG, but to a minor extent (-19%). Nav1.9 mRNA was 
downregulated in all three ganglia to a similar level (-27% for L3, -37% for L4 and -29% for 
L5).   
Our observations in the SNL model, made us hypothesize that the injury is responsible for the 
decrease of Navs expression. Our results in the SNI model, when analyzing separately each 
DRG from L3 to L5, consistently shows a more important downregulation of Navs expression 
in L3 and L4 as compared to L5 (even if not always statistically significant). This raises the 
possibility that L3 and L4 (rather than L4 and L5) harbor most of the injured fibers following 
SNI surgery. 
Identification of L3, L4 and L5 DRGs in C57BL/6J mice 
Segmentation of the lumbar vertebral column varies significantly between different mice 
strains (Green 1941). Rigaud et al. recently demonstrated that DBA/2J strain possess five 
lumbar bony segments, whereas C57BL/6J strain possess six segments (Rigaud, Gemes et al. 
2008). Because of this variability between strains, we describe the precise dissecting 
procedure to harvest L3, L4 and L5 DRGs in C57BL/6J mice. 
Figure 3 shows a representative photography of the sciatic nerve, L2 to L6 spinal nerves with 
their DRGs, and spinal cord of a C57BL/6J mouse after dissection. The sites of SNI, 
SNIv(cp,t), a SNI variant sparing common peroneal (cp) and tibial (t) nerves (Bourquin, 
Süveges et al. 2006), and SNL injuries are illustrated on the picture and on the drawn 
extensions of the sciatic nerve trifurcation into sural, common peroneal and tibial nerves. 
Following the sciatic nerve into the rostral direction conducts to the first bifurcation heading 
to L5 spinal nerve and to the branches leading to L4/L3/L2 DRGs. Based on the dissection, it 
is likely that L3 DRG also receives afferents from the femoral/saphenous nerve, which can 
help to identify the correct DRGs. Unlike in the rat, the sciatic nerve in the mice does not find 
any of its fibers originating from the L6 DRG, which seems to confirm a rostral shift in the 
mice to find homologous DRGs as compared to the rat (Rigaud, Gemes et al. 2008). 
Injured fibers in the SNI model in the mice project to L3 and L4 
In rats, 98% of sciatic nerve fibers originate from L4-L5 DRGs, whereas the saphenous nerve 
(part of the femoral nerve) fibers have their cell somas located in the L3 DRG (Swett, Torigoe 
et al. 1991). This explains that L4 and L5 are the main DRGs of interest in the SNI model in 
rats. However, Rigaud et al demonstrated that rats L4-L5 DRGs rather find their functional 
and anatomical homologous in the mice L3-L4 DRGs (Rigaud, Gemes et al. 2008). The latter, 
in addition to our observations that L3 DRG shows a stronger downregulation of Navs 
transcript as compared to L5, suggest that the ganglia likely to be subject to injury-related 
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phenotypic changes might need to be reconsidered in mice. We consequently investigated the 
amount of injured fibers received by each ganglion after SNI. Using immunofluorescence 
(IF), we studied the expression of ATF3, a member of ATF/CREB family and marker of 
axotomized neurons (Tsujino, Kondo et al. 2000; Tsuzuki, Kondo et al. 2001). In sham 
operated animals, ATF3-Immunoreactivity (IR) is only weakly observable and reaches a 
maximum of 8% for L3 (Supplemental Figure 1 and Figure 4B). Because naïve animals 
showed no IR for ATF3 at all (Supplemental Figure 1), it is likely that surgical exposure by 
itself already induces the activation of ATF3 expression as it has already been proposed 
(Shortland, Baytug et al. 2006). Seven days after SNI surgery, the percentage of ATF3 
positive cells in L3 (37%) and L4 DRGs (34%) was significantly increased as compared to 
sham condition (Figure 4A, B) whereas in L5 the low percentage of ATF3 positive cells 
observed in sham was maintained (3%). This result contrasts with the strong increase of ATF3 
expression observed in L5 in rats after SNI (Takahashi, Kikuchi et al. 2003) and clearly 
confirms that most of the common peroneal and tibial injured fibers have their cell bodies 
located in L3/L4 rather than in L5 DRGs in mice. We also studied the mRNA expression of 
ATF3 level in L3 to L5 DRGs using qRT-PCR. This approach supported the dramatic 
increased of ATF3 in L3 and L4 and the unchanged expression in L5 (Figure 4C).   
So what is the relevance of L5 DRG in the mice SNI model? We used the same approach as 
above, but with the variant of the SNI transecting only the sural nerve (SNIv(cp,t)), in order to 
investigate whether fibers from this nerve would project to L5 DRGs. Sham surgery revealed 
that the percentage of ATF3-IR cells was 8%, 7% and 4% for L3 to L5 respectively (Figure 
5B), which was not different from sham condition of the traditional SNI. After SNIv(cp,t), there 
was a significant increase of ATF3-IR cells in L4 (17%) and L5 (15%) as compared to sham 
condition (Figure 5A, 5B). Conversely, the number of injured cells was not increased in L3 
(7%). This suggests that sural nerve find its origin in L4 and L5 DRGs. 
Even though we did not perform typical anatomical study using for instance retrolabelling, 
our results seem to confirm that tibial and common-peronal nerves, that represent the injured 
fibers in the SNI, predominantly find their origins in L3 and L4 DRGs. Nevertheless, the 
observation that transection of the sural nerves induces an increase of ATF3 postive neurons 
in L4 and L5, highlights the importance of L5 ganglion in SNI as well. This demonstrates that 
when using the SNI model in mice, DRGs should be pooled with caution because L3, L4 and 
L5 DRGs provide very different information. L3 DRGs will be enriched in injured neurons, 
L4 will present a mixture of injured and non-injured neurons and finally L5 will mostly be 
enriched in spared sural neurons (Figure 6). 
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Conclusion 
We here showed that the expression of most of Navs mRNAs is downregulated in the 
axotomized lumbar DRGs after SNI and SNL in mice. For SNI, this is similar to rats except 
for Nav1.3 which is increased in rats. This phenotypic change is mostly due to axotomized 
neurons in SNI and SNL. Finally, we re-evaluated the projection of injured neurons after SNI. 
The injured common peroneal and tibial nerves are projecting to L3 and L4 DRGs and the 
non-injured sural nerve to L4 and L5 DRGs in C57BL/6J mice. This is of great importance 
when investigating nerve-injury mediated modification in DRGs after SNI in mice. L3 DRG 
should be harvested for the changes in the injured nerve, L4 for a mixture of injured and non-
injured and finally L5 for the non-injured sural nerve. 
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Methods 
Surgery:  
All procedures were approved by the Committee on Animal Experimentation for the Canton 
of Vaud, Switzerland, in accordance with Swiss Federal Law on Animal Welfare and 
guidelines of the International Association for Study of Pain (Zimmermann 1983).  
Spared nerve injury model (SNI) of neuropathic pain was previously described in rats 
(Decosterd and Woolf 2000; Pertin, Gosselin et al. 2012) and in mice (Bourquin, Süveges et 
al. 2006). Briefly, adult C57BL/6J mice (Charles River, L’Arbresle, France) were 
anesthetized with 1.5% isoflurane and after exposure of the sciatic nerve, the common 
peroneal and tibial nerves were ligated together with a 6.0 silk suture (Ethicon, Johnson and 
Johnson AG, Zug, Switzerland) and transected. In the SNI variant (SNIv(cp,t)) (Bourquin, 
Süveges et al. 2006)  the ligation and transection were performed on the sural nerve, leaving 
the common peroneal and tibial nerves intact. The incision was closed in distinct layers 
(muscle and skin). Sham surgery was performed similarly except for the nerve transection.   
Spinal nerve ligation surgery (SNL) was adapted from the procedure described by Kim and 
Chung (Kim and Chung 1992) transposed to mice. Briefly, after skin and muscle incision the 
L5 transverse process of vertebra was exposed and carefully removed. The L4 and L5 spinal 
nerves were exposed and the L5 spinal nerve was tightly ligated and transected distal to the 
ligature. The incision was closed in distinct layers (muscle and skin).  
Dissection:  
Briefly, mice were terminally anesthetized with sodium pentobarbital (Esconarkon; Streuli 
Pharma AG, Uznach, Switzerland) and biceps femoris muscle of left thigh was incised. The 
artery genus descendes was used as a reference for muscle incision, which further lead to the 
exposure of the sciatic nerve and trifurcation to the peripheral branches: common peroneal, 
tibial and sural nerves. The sciatic nerve was followed in the rostral direction, removing 
muscular tissue, until reaching the vertebral column. Vertebral lamina, pedicles and spinous 
processes were trimmed away to expose spinal cord and DRGs. For the nomenclature of 
DRGs, refer to Figure 4. 
Quantitative real-time Reverse Transcription PCR (qRT-PCR): 
Ipsilateral DRGs were rapidly dissected and collected in RNA-later solution (Qiagen, Basel, 
Switzerland). For SNI, 2 series of mice were used, one with a pool of L4 and L5 together as 
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was usually done (4 DRGs pooled from 2 mice per sample) and one series where L3, L4 and 
L5 were dissected separately (8 DRGs pooled from 8 mice per sample). For SNL we always 
separate L4 and L5 DRGs (2 DRGs pooled from 2 mice per sample) as they represent 
respectively non-injured and injured neurons. For all conditions tested we used n = 3-4 
samples. mRNA was extracted and purified with RNeasy Plus Mini kit (Qiagen) and 
quantified using RNA 6000 Nano Assay (Agilent Technologies AG, Basel, Switzerland). A 
total of 600 ng of RNA was reverse transcribed for each sample using Omniscript reverse 
transcriptase (Qiagen). Primer’s sequences and working concentrations for Navs -subunits, 
ATF3 and glyceraldehyde-3-phosphate deshydrogenase (GAPDH) can be found in Table 1. 
We used GAPDH as reference gene to normalize Navs mRNA expression since it is not 
altered in SNI and SNL conditions (Renganathan, Dib-Hajj et al. 2002). Gene-specific mRNA 
analyses were performed using the iQ SYBR-green Supermix (BioRad, Reinach, Switzerland) 
and the iQ5 real-time PCR detection system (BioRad). Only reactions with appropriate 
amplification and melting curves determining the amplicon specificity were analyzed. All 
samples were run in triplicate. 
Immunofluorescence:  
One week after sham, SNI or SNIv(cp,t) surgery, animals were lethally anesthetized with 
sodium pentobarbital (Esconarkon) and transcardially perfused with saline solution, directly 
followed by paraformaldehyde 4% diluted in phosphate buffered saline (PBS). L3 to L5 
DRGs were dissected and post-fixed at 4°C for 90 min and then transferred in sucrose 
solution (20% sucrose in PBS) overnight. The following day, tissues were mounted in 
cryoembedding fluid (Tissue-Tek; Sakura Finetek, Zoeterwoude, Holland), frozen, 
cryosectioned in 12µm-thick sections and thaw-mounted onto slides. 
We used the rabbit anti-ATF3 antibody (1:300, Santa Cruz Biotechnology, Heidelberg, 
Germany) as nuclear marker of injured neurons and the goat anti-HuD antibody (Elav like 
proteins, 1:50, Santa Cruz Biotechnology) as marker of total neuron number. Secondary 
antibodies were as follow: Cy3-conjugated anti-rabbit (1:400, Jackson ImmunoResearch, 
Suffolk, UK) for ATF3 and AlexaFluor 488-conjugated anti-goat (Molecular Probes, Basel, 
Switzerland) for HuD. Standard protocols for fluorescent immunohistochemistry were used. 
Sections of DRGs were blocked for 30 min at room temperature (RT) with normal horse 
serum (NHS) 10% and PBS 1X-Triton X-100 0.3%. Primary antibodies were diluted in NHS 
5% and PBS 1X-Triton X-100 0.1% and incubated on sections overnight at 4°C. Slides were 
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washed in PBS 1X and then incubated for 90 min at RT with the corresponding secondary 
antibody diluted in NHS 1% and PBS 1X-Triton X-100 0.1%. Slides were washed in PBS 1X 
and mounted in Mowiol medium (Calbiochem, Merck Millipore, Darmstadt, Germany). 
Fluorescence was detected using an epifluorescent microscope (AxioVision, Carl Zeiss, 
Feldbach, Switzerland). Images were taken at 20× magnification, with the same parameters 
used between experimental conditions. The complete DRG images were reconstructed by 
juxtaposing the different images using Photoshop CS4 software (11.0, Sun Microsystems, 
Redwood City, CA). Mean cell counts from each DRG are the average of 4 to 7 sections. The 
first section was randomly selected and the next ones were chosen every 72 um from the 
series of consecutive cut sections. Four animals were analyzed per condition. Percentage of 
injured neurons was expressed as the number of ATF3-IR neurons over the total cell number 
(HuD-IR neurons). Note that the percentage of ATF3 positive cells is probably a slight under-
estimation of the actual proportion of injured cells because it represents the ratio of ATF3 
positive cells over HuD positive cells, which were counted independently to the presence or 
absence of the nucleus (one cell might have been counted twice in different stack). 
Statistical analysis:  
For immunofluorescence experiments, number of positive cells in sham and SNI were tested 
for statistical difference using bilateral unpaired Student’s t test. For qPCR, normalized 
transcripts from 3 to 4 samples were compared in sham versus treated conditions using 
bilateral, unpaired Student’s t test. 
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Figure Legends 
Figure 1: 
Constitutive mRNA expression of Navs isoforms in sham mice DRGs.  
Constitutive levels of mRNA were determined by qPCR and normalized using GAPDH as a 
reference gene. qPCR efficiencies were obtained by the standard curve method (Pertin, Ji et 
al. 2005) and integrated for calculation of the relative expression. Data are expressed as mean 
± SEM, n = 4 samples (2 animals per sample). 
Figure 2: 
SNI and SNL modulate Navs mRNA expression in mice DRGs.  
Transcription profile: (A) one week after SNI in pooled L4/L5 DRGs. Nav1.1 (p < 0.0001), 
Nav1.2 (p = 0.0171), Nav1.3 (p = 0.003), Nav1.6 (p = 0.001), Nav1.7 (p < 0.0001), Nav1.8 (p < 
0.0001) and Nav1.9 (p < 0.0001) are all downregulated after SNI. (B) One week after SNL in 
L4 and L5 DRGs. In injured L5 DRG (black bars), Nav1.1 (p = 0.005), Nav1.3 (p = 0.017), 
Nav1.6 (p = 0.006), Nav1.7 (p = 0.011), Nav1.8 (p = 0.001) and Nav1.9 (p = 0.004) were 
significantly decreased and only Nav1.2 was unchanged (p = 0.362). In non-injured L4 DRG 
(white bars), only Nav1.1 was decreased (p = 0.045) but Nav1.2 (p = 0.982), Nav1.3 (p = 
0.172), Nav1.6 (p = 0.247), Nav1.7 (p = 0.593), Nav1.8 (p = 0.731) and Nav1.9 (p = 0.378) 
remained unchanged. (C) One week after SNI in separated L3, L4 and L5 DRGs. Nav1.1 was 
only significantly downregulated in L4 (L3, p = 0.082; L4, p = 0.023; L5, p = 0.253). Nav1.2 
(L3, p = 0.145; L4, p = 0.333; L5, p = 0.944), Nav1.3 (L3, p = 0.139, L4, p = 0.189, L5, p = 
0.344), Nav1.6 (L3, p = 0.171, L4, p = 0.051, L5, p = 0.168) remained statistically unchanged 
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in every DRG tested. Nav1.7 was only significantly downregulated in L3 (L3, p = 0.005, L4, p
= 0.138, L5, p = 0.104). Nav1.8 (L3, p = 0.001, L4, p < 0.001, L5, p = 0.021) and Nav1.9 (L3, 
p= 0.031; L4, p = 0.006; L5, p = 0.046) were downregulated in all three DRGs.  
For A, B and C, mRNA levels are expressed as ratio of level in SNI/Sham or SNL/sham. Data 
are expressed as mean ± SEM, n = 3-4 samples, Student’s t test to compare sham to SNI or 
SNL.   
Figure 3:  
Representative postero-lateral view of mouse DRGs dissection. 
On the photography, L3, L4 and L5 spinal nerves (black arrows) linked to L3, L4 and L5 
DRGs respectively, are the main contributors of the sciatic nerve. L6 does not contribute to 
the sciatic nerve. Sites of SNI, SNIv(cp,t) and SNL lesions are shown. SNI: Spared Nerve 
Injury; SNIv (cp,t): Spared Nerve Injury variant , sparing common peroneal (cp) and tibial (t) 
nerves; SNL: Spinal Nerve Ligation  
Figure 4: 
ATF3 expression increases in mice L3, and L4 but not L5 DRG neurons after SNI. (A) 
Representative immunofluorescence showing that ATF3 (marker of injured neurons, red) is 
up-regulated in L3 and L4 DRG neurons (HuD positive cells, green) after SNI. Scale bar = 50 
m. (B) Quantification of ATF3-Immunoreactivity (IR) in L3, L4 and L5 DRG neurons one 
week after SNI or sham surgery. ATF3-IR is increased in L3 (p < 0.0001) and L4 (p < 
0.0001) after SNI but remained the same in L5 (p = 0.986). Data are expressed as mean ± 
SEM, n = 4 animals in each group. Student’s t test. (C) mRNA levels of ATF3 one week after 
SNI compared to sham surgery in L3, L4 and L5 DRGs. ATF3 mRNA is increased in L3 (p = 
0.0003) and L4 (p = 0.0003 ) but not in L5 (p = 0.987) after SNI.  Levels of transcripts were 
first normalized to GAPDH as a reference gene and then to sham for each DRG. Data are 
expressed as mean ± SEM, n = 3-4 animals in each group. Student’s t test. SNI: Spared Nerve 
Injury 
Figure 5: 
ATF3 expression increases in mice L4 and L5 but not L3 DRG neurons after SNIv(cp,t). 
Representative immunofluorescence showing that ATF3 (marker of injured neurons, red) is 
mostly upregulated in L4 and L5 DRG neurons (HuD positive cells, green). Scale bar = 50 
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m. (B) Quantification of ATF3-IR in L3, L4 and L5 DRG neurons one week after SNIv(cp,t)
or sham surgery. ATF3 is increased in L4 (p < 0.002) and L5 (p < 0.002) after SNIv(cp,t)  but 
not in L5 (p = 0.291). Data are expressed as mean ± SEM, n = 4 animals in each group. 
Student’s t test. SNIv(cp,t): Spared Nerve Injury variant , sparing common peroneal (cp) and 
tibial (t) nerves  
Figure 6: 
Schematic view of sciatic nerve branches with projections of injured fibers into DRGs. 
On the scheme, we show that tibial and common peroneal nerves predominantly originate in 
L3 and L4 DRGs (red fibers) while the sural mainly originate from L4 and L5 (blue fibers). 
SNI: Spared Nerve Injury; SNIv(cp,t): Spared Nerve Injury variant , sparing common peroneal 
(cp) and tibial (t) nerves. 
Supplemental Figure 1: 
Sham surgery increases ATF3 expression in L3, L4 and L5 mice DRG neurons. 
Representative immunofluorescence showing that ATF3 is also expressed in every DRG 
tested after sham surgery (see Figure 5B for quantification). Conversely, naïve animals show 
no ATF3-IR in any of the DRG tested (only L4 is shown). Scale bar = 50 m.  
Table 1: 
Primer List. 
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Navs relative expression in L4/L5 DRGs
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Table 1
List of primers sequences
gene name Primer sequence 5'-3' Primer concentration
(Fw) TCCATGACAACTTTGGCATTG
(Rev) CAGTCTTCTGGGTGGCAGTGA
(Fw) AGCTGAGATTCGCCATCCAGAA
(Rev) CTCGCCGCCTCCTTTTCCT
(Fw) AACAAGCTTGATTCACATACAATAAG
(Rev) AGGAGGGCGGACAAGCTG
(Fw) GGGAACGCCCATCAAAGAAG
(Rev) ACGCTATCGTAGGAAGGTGG
(Fw) AGGCATGAGGGTGGTTGTGAACG
(Rev) CAGAAGATGAGGCACACCAGTAGC
(Fw) AGTAACCCTCCAGAATGGTCCAA
(Rev) GTCTAACCAGTTCCACGGGTCT
(Fw) TCCTTTATTCATAATCCCAGCCTCAC
(Rev) GATCGGTTCCGTCTCTCTTTGC
(Fw) ACCGACAATCAGAGCGAGGAG
(Rev) ACAGACTAGAAATGGACAGAATCACC
(Fw) TGAGGCAACACTACTTCACCAATG
(Rev) AGCCAGAAACCAAGGTACTAATGATG
Nav1.8
Nav1.9
200 nM
200 nM
100 nM
300 nM
200 nM
200 nM
200 nM
300 nM
Nav1.2
Nav1.3
Nav1.6
Nav1.7
200 nMGAPDH
ATF3
Nav1.1
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IN RAT DORSAL ROOT GANGLIA: MODULATION IN THE SPARED
NERVE INJURY MODEL OF NEUROPATHIC PAINM. CACHEMAILLE, a,b* C. J. LAEDERMANN, a,b,c
M. PERTIN, a,b H. ABRIEL, c R.-D. GOSSELIN a,b
AND I. DECOSTERD a,b
aPain Center, Department of Anesthesiology, University
Hospital Center (CHUV) and University of Lausanne (UNIL),
Lausanne, Switzerland
bDepartment of Fundamental Neurosciences (DNF), University
of Lausanne, Lausanne, Switzerland
cDepartment of Clinical Research, University of Bern, Bern,
SwitzerlandAbstract—Neuronal hyperexcitability following peripheral
nerve lesions may stem from altered activity of voltage-
gated sodium channels (VGSCs), which gives rise to
allodynia or hyperalgesia. In vitro, the ubiquitin ligase
Nedd4-2 is a negative regulator of VGSC a-subunits (Nav),
in particular Nav1.7, a key actor in nociceptor excitability.
We therefore studied Nedd4-2 in rat nociceptors, its
co-expression with Nav1.7 and Nav1.8, and its regulation in
pathology. Adult rats were submitted to the spared nerve
injury (SNI) model of neuropathic pain or injected with com-
plete Freund’s adjuvant (CFA), a model of inﬂammatory
pain. L4 dorsal root ganglia (DRG) were analyzed in sham-
operated animals, seven days after SNI and 48 h after CFA
with immunoﬂuorescence and Western blot. We observed
Nedd4-2 expression in almost 50% of DRG neurons, mostly
small and medium-sized. A preponderant localization is
found in the non-peptidergic sub-population. Additionally,
55.7 ± 2.7% and 55.0 ± 3.6% of Nedd4-2-positive cells are
co-labeled with Nav1.7 and Nav1.8 respectively. SNI
signiﬁcantly decreases the proportion of Nedd4-2-positive
neurons from 45.9 ± 1.9% to 33.5 ± 0.7% (p< 0.01) and
the total Nedd4-2 protein to 44%± 0.13% of its basal level
(p< 0.01, n= 4 animals in each group, mean ± SEM). In
contrast, no change in Nedd4-2 was found after peripheral
inﬂammation induced by CFA. These results indicate that
Nedd4-2 is present in nociceptive neurons, is downregu-
lated after peripheral nerve injury, and might therefore0306-4522/12 $36.00  2012 IBRO. Published by Elsevier Ltd. All rights reserve
http://dx.doi.org/10.1016/j.neuroscience.2012.09.044
*Correspondence to: M. Cachemaille, Pain Center, Department of
Anesthesiology, University Hospital Center (CHUV) and University
of Lausanne (UNIL), Bugnon 46, 1011 Lausanne, Switzerland.
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Abbreviations: ATF-3, Activating Transcription Factor 3; CFA,
complete Freund’s adjuvant; DRG, dorsal root ganglion; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; HEK293, Human
Embryonic Kidney cells; IB4, isolectin B4; IR, immunoreactivity; NGS,
normal goat serum; RT, room temperature; SNI, spared nerve injury;
VGSCs, voltage-gated sodium channels.
370contribute to the dysregulation of Navs involved in the
hyperexcitability associated with peripheral nerve injuries.
 2012 IBRO. Published by Elsevier Ltd. All rights reserved.
Key words: Nedd4-2, neuropathic pain, voltage-gated sodium
channels, Nav1.7, Nav1.8, dorsal root ganglion.
INTRODUCTION
Neuropathic pain aﬀects a high proportion of the world
population (Bouhassira et al., 2008) and originates from
a maladaptive plasticity caused by a lesion in the
somatosensory system (Woolf and Salter, 2000;
Costigan et al., 2009). Clinically, it is associated
with sensory dysfunctions referred as spontaneous pain,
allodynia and hyperalgesia (Woolf and Decosterd,
1999). Convergent studies have shown that after a
peripheral nerve lesion, ectopic activity, potentially
accounting for pain symptoms, arises in injured and
non-injured Ab (normally non-nociceptive), Ad and
C-ﬁbers (nociceptive) and in dorsal root ganglion (DRG)
(Ma et al., 2003; Wu et al., 2001; Devor, 2009).
Membrane hyperexcitability is thought to cause such
abnormal generation of action potentials in DRG
neurons (Amir et al., 2005) with the dysregulation of
voltage-gated sodium channels (VGSCs) being the
cornerstone of this regulation (Rush et al., 2007; Sheets
et al., 2008).
Increased membrane ion permeability during action
potential relies on the pore forming a-subunit (Nav) of
VGSCs, and its inhibition explains conduction blockade
by local anesthetics (Catterall, 2000). Remarkably, the
stability and internalization of ion channels are under the
control of post-translational modiﬁcations, especially
their ubiquitylation by E3 ubiquitin ligases driving their
routing to degradation (Abriel and Staub, 2005). In
particular the Nedd4 family of E3 proteins are potent
regulators of channels, including Nav (Abriel et al., 1999;
Harvey and Kumar, 1999; van Bemmelen et al., 2004;
Kabra et al., 2008). Most of the ten Nav isoforms are
expressed in DRG neurons and contribute to
electrogenesis, with a speciﬁc expression for Nav1.7,
Nav1.8 and Nav1.9 in the peripheral nervous system
(Black et al., 2002; Rush et al., 2007; Ho and O’Leary,
2011). Interestingly, mutations leading to loss or gain of
Nav1.7 function result in congenital insensitivity to pain
or lead to severe familial pain disorders (Raouf et al.,
2010). Mice with selective knock out of Nav1.7, Nav1.8d.
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sensitivity or diminished response to inﬂammatory pain
(Nassar et al., 2004). These data suggest a key role of
peripheral Navs in basal nociception, and also a
possible impact of the regulation of nociceptor-speciﬁc
Nav in pathological pain. Various reports have indicated
that inﬂammatory and neuropathic pain are associated
with changes in Nav1.7, Nav1.8 and Nav1.9 expression
at both the mRNA and the protein levels in DRG
neurons (Cummins and Waxman, 1997; Berta et al.,
2008; Strickland et al., 2008; Thakor et al., 2009) but
the mechanism leading to the selective alteration of
some Nav currents in neuropathic pain is still unclear
(Berta et al., 2008). One theory posits the existence of
reﬁned mechanisms at the post-translational level
leading to change in Nav function or traﬃcking. In this
context Nedd4-2, a well-described Nedd4 member, can
interact with all Navs expressed in DRG neurons (except
Nav1.9) via their C-terminal PY motive. Indeed, Xenopus
oocytes exogenously coexpressing Nedd4-2 with
Nav1.2, 1.7 and 1.8 present a reduction of their
respective currents (Fotia et al., 2004). However,
despite the apparent importance of Nav regulation by
Nedd4-2, the expression of Nedd4-2 in the nociceptive
pathway has not been studied so far.
The aim of the present study is ﬁrst to investigate
in vivo the expression of Nedd4-2 in rat DRG and
characterize its localization in the diﬀerent subpo-
pulations of primary sensory neurons using speciﬁc
markers. In addition, we have assessed Nedd4-2
modulation in rodent models of neuropathic and
inﬂammatory pain. Our results indicate that Nedd4-2
immunoreactivity (IR) is present in small diameter
nociceptive neurons together with Nav1.7 and Nav1.8
and that this expression is down-regulated after nerve
injury.EXPERIMENTAL PROCEDURES
Surgery
All procedures were approved by the Committee on Animal
Experimentation for the Canton of Vaud, Switzerland, in
accordance with Swiss Federal Law on Animal Welfare and
guidelines of the International Association for Study of Pain
(IASP) (Zimmermann, 1983). We used the spared nerve
injury (SNI) model of neuropathic pain as previously described
(Decosterd and Woolf, 2000). Brieﬂy, adult Sprague–Dawley
rats were deeply anesthetized using 1.5% isoﬂurane and,
after exposure of the sciatic nerve, the common peroneal and
tibial nerves were ligated with 5.0 silk sutures and transected
while the sural nerve was left intact. Muscle and skin were
closed in two distinct layers with 5.0 silk thread and wound
clips. Sham surgery was performed similarly, although without
nerve damage, as the control condition. Eight animals were
used for SNI (n= 4 for immunolabeling and n= 4 for
Western blot) and a similar group of eight rats was used for
sham surgery.
For experiments with complete Freund’s adjuvant (CFA), rats
were injected with 50 ll of CFA (Sigma, St. Louis MO, USA,
n= 4) or NaCl 0.9% (n= 4), in the dorsal part of the left
hindpaw, under isoﬂurane anesthesia (1.5% isoﬂurane).
Animals were kept for 48 h and tissues dissected at this time-
point for further analysis (Nagakura et al., 2003).Immunohistochemistry
One week after the SNI surgery or 48 h after CFA injection,
animals were lethally anesthetized with sodium pentobarbital
and transcardially perfused with saline, followed by
paraformaldehyde 4% in PBS. L4 DRGs (Hammond et al.,
2004) were dissected and post-ﬁxed at 4 C for 90 min and
then transferred in 20% sucrose in PBS overnight. The
following day, tissues were mounted in cryoembedding ﬂuid
(Tissue-Tek; Sakura Finetek, Zoeterwoude, Holland). Then
samples were frozen, cryosectioned in 12-lm thick sections
and thaw-mounted onto slides.
Nedd4-2 was revealed using a speciﬁc rabbit anti-Nedd4-2
antibody (Nedd4-2, 1:100, generously provided by Olivier
Staub, Department of Pharmacology and Toxicology, University
of Lausanne, Switzerland). For the colocalization experiments,
antibodies were as follows: mouse anti-peripherin (Peripherin;
1:500, Chemicon International, Billerica, MA, USA), mouse
anti-neuroﬁlament 200 (NF200, 1:400, Sigma, St. Louis, MO,
USA), rat anti-Substance P (1:400, BD Bioscience, Basel,
Switzerland), mouse anti-Nav1.7 (1:100, Neuromab, Davis, CA,
USA), mouse anti-Nav1.8 (1:100, Neuromab, Davis, CA, USA),
rabbit anti-Activating Transcription Factor 3 (ATF-3, 1:200,
Santa Cruz Biotechnology, Heidelberg, Germany). Secondary
antibodies were as follows: Cy3-conjugated anti-rabbit (1:400,
Jackson ImmunoResearch, Suﬀol, UK) for Nedd4-2,
Cy3-conjugated anti-mouse (1:300, Jackson ImmunoResearch)
for Nav1.7, FITC-conjugated anti-rabbit (1:200, Jackson
ImmunoResearch, Suﬀol) for ATF-3, FITC-conjugated anti-rat
(1:200, Jackson ImmunoResearch, Suﬀol) for Substance P,
Alexa 488 anti-rabbit (1:500, Molecular Probes, Basel,
Switzerland) for Nedd4-2 and Alexa 488 anti-mouse (1:1000,
Molecular Probes) for peripherin, NF200, Nav1.8. Non-
peptidergic neurons were stained using biotinylated griﬀonia
simplicifolia Isolectin B4 (IB4) (1:100, Vector Laboratories,
Burlingame, CA) followed by AMCA-conjugated streptavidin
(1:50; Jackson ImmunoResearch). Standard protocols for
ﬂuorescent immunohistochemistry were used. Sections of
DRGs were blocked for 30 min at room temperature (RT) with
10% normal goat serum (NGS) and 0.3% PBS 1X-Triton
X-100. Primary antibodies were diluted in 5% NGS and 0.1%
PBS 1X-Triton X-100, and incubated on sections overnight at
4 C. For ATF-3/Nedd4-2 dual labeling, the sequence of the
protocol started with the primary and secondary incubations for
ATF-3 followed by primary and secondary probing for Nedd4-2
(Pertin et al., 2005; Fukuoka et al., 2012). Control experiments
were performed to rule out the possibility of a nuclear presence
of Nedd4-2. Slides were washed in PBS and then incubated at
RT with the corresponding secondary antibody or AMCA-
conjugated streptavidin diluted in NGS 1% and PBS 1X-Triton
X-100 0.1% for 90 min. Slides were washed in PBS and
mounted in Mowiol medium (Calbiochem, Gibbstown, NJ).Pictures and counting
Fluorescence was detected using an epiﬂuorescent microscope
(AxioPlan and AxiVision, Carl Zeiss, Feldbach, Switzerland).
Images were taken at 20 magniﬁcation, with the same
parameters used between experimental conditions, saved as
TIFF ﬁles and then juxtaposed as one picture using Photoshop
CS4 software (11.0, Sun Microsystems, Redwood City, CA) in
order to reconstruct a complete DRG. The same parameters
for image capture were used between experimental conditions
and ganglia from four animals were analyzed per condition.
Mean cell counts from each animal were the average of four
sections selected 60 lm apart. The ﬁrst slide was randomly
selected and the three next ones were chosen every ﬁve slides
from the series of consecutive cut sections. In all conditions,
only neurons in which the nucleus was visible were counted.
The observer was blinded to experimental groups. Counts of150
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total number of labeled and unlabeled neuronal proﬁles. Neuronal
cross-sectional areas were measured in lm2 and the mean gray
value of each cell was recorded based on mean pixel intensity
using ImageJ software (1.42, National Institute of Mental
Health, Bethesda, MD, USA). Groups for cell area were as
follows: 0–600 lm2 for small neurons, 600–1200 lm2 for
medium-sized neurons and >1200 lm2 for large neurons
(Harper and Lawson, 1985; Noguchi et al., 1993).Threshold of detection for IR-positive cells
Positively labeled cells were identiﬁed on acquired digital images
by the experimenter. The accuracy of detection was veriﬁed for
each condition by determining the signal/background threshold
as follows (King et al., 2009). Ten pictures were randomly
chosen in images libraries of four independent markers
(Nedd4-2, Nav1.7, peripherin and NF-200). Background
intensities were measured and averaged. The ﬁnal threshold of
mean gray values was calculated by adding two standard
deviations, giving a value of 18. Twenty out of 718 Nedd4-2-
positive cells (sham) and 42 out of 616 positive cells (SNI)
were below the detection threshold. For Nav1.7 counting, all
positive cells were above the detection threshold.ACell transfection
Human Embryonic Kidney cells (HEK293) were cultured in
DMEM (Gibco, Life Technologies, Zug, Switzerland)
supplemented with 10% fetal bovine serum, 0.2% glutamine
and gentamicin (20 mg/mL) at 37 C in a 5% CO2 incubator.
For control of antibodies, cells were transfected, using calcium
phosphate, with 0.8 lg of truncated human Nedd4-2 cDNA
(without the amino-terminal C2 domain) cloned into pcDNA3.1
(generously provided by Olivier Staub, Department of
Pharmacology and Toxicology, Lausanne, Switzerland) or 1 lg
of Nav1.7 cDNA cloned into pCIN5h and provided by Dr. Simon
Tate (Convergence Pharmaceuticals, Cambridge, UK). Protein
extraction was performed 48 h after transfection.B
GAPDH
Nedd4-2
150
130
100
75
kDa
34
1 2 3
Nedd4-2
Fig. 1. Protein expression of Nedd4-2 in rat DRG. (A) Nedd4-2-
immunoreactivity (IR) in rat L4 DRG (scale bar = 100 lm). (B)
Western blot analysis of Nedd4-2. Lane 1: rat L4 DRG; lane 2:
HEK293 cells; lane 3: Nedd4-2 transfected HEK293 cells; GAPDH
was used as a loading control.Western blotting
Animals were sacriﬁced 7 days after Sham or SNI surgery, or
48 h after CFA injection. L4 and L5 DRGs were quickly
dissected and kept at 80 C until use. HEK293 transfected
cells were detached using dissociation buﬀer (Invitrogen, Life
Technologies), centrifuged at 2000g for 2 min at RT and
supernatants were removed. Homogenization of DRGs or HEK
cells was done in 100 mM Tris–HCl (pH 6.8), SDS 2%, glycerol
20%, NaCl and complete protease inhibitor cocktail tablets
(Roche, Basel, Switzerland). Samples were centrifuged at
14,000 rpm for 20 min at 4 C and proteins in the supernatants
were quantiﬁed using Bradford assays. Protein samples
(15–20 lg) were separated by SDS–PAGE and transferred
onto PVDF membranes (BioRad, Hercules, CA). Blots were
blocked with non fat dry milk 5% for 30 min at RT and then
incubated overnight at 4 C with the appropriate antibody:
rabbit anti-Nedd4-2 (1:100) (Flores et al., 2005), mouse anti-
Nav1.7 (1:400, Neuromab) or mouse anti-Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH, 1:500,000, Abcam,
Cambridge, UK). These blots were further incubated with
horseradish peroxydase-conjugated secondary antibody anti-
mouse or anti-rabbit (1:2000, Dako, Heverlee, Belgium),
developed in Super Signal Solution (Pierce, Rockford, IL, USA)
and revealed with LAS-4000-Mini Fujiﬁlm (Bucher Biotec,
Basel, Switzerland). Pixel intensities were quantiﬁed with
ImageJ. Results were expressed as the ratio of the signal of
interest over sham after normalization by GAPDH loading control.Statistics
Data are represented as mean ± SEM. Comparisons between
groups were performed using Student’s t test or a one-way
ANOVA followed by Dunnett’s Multiple Comparison Test for
Fig. 3F. Statistical analyses were done with JMP statistical
software (5.01, SAS institute, Cary, NC). Diﬀerences were
considered signiﬁcant at p-values below 0.05.RESULTS
Nedd4-2 is present in nociceptive neurons
Nedd4-2 IR is widely distributed in rat DRG neurons
(Fig. 1A). Western blot analysis (Fig. 1B) reveals one
major band in DRG at approximately 120 kDa corres-
ponding to the endogenous form of Nedd4-2 (lane 1). In
HEK293 cells, the endogenous form of Nedd4-2
corresponds to a slightly lower band (115 kDa), in line
with species diﬀerences (van Bemmelen et al., 2004;
Rougier et al., 2005). In DRG, we inconstantly observed
one additional band between 100 and 120 kDa, which is
known to be a splice variant (Itani et al., 2003; Hryciw
et al., 2004) (see Figs. 3A and 5B). As a positive
control, the analysis of HEK293 cells transfected with a
truncated form of human Nedd4-2 cDNA showed a
robust protein level at 100 kDa, in line with the size of
the construct (Kamynina et al., 2001).
We thoroughly explored the molecular identity of
Nedd4-2-immunopositive DRG neurons using dual
immunoﬂuorescence (Fig. 2). The six sets of counting
performed throughout our study gave overall
percentages of Nedd4-2-expressing neurons ranging151
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Fig. 2. Nedd4-2 is mainly present in nociceptive DRG neurons and colocalizes with the sodium channels Nav1.7 and Nav1.8. (A) Representative
double immunoﬂuorescence for Nedd4-2 (ﬁrst column) with the markers peripherin, NF-200, IB4, Substance P, or with Nav1.7 and Nav1.8 (second
column) and merged images (third column, arrows) in rat DRG neurons (sham group). (B) Quantitative analysis of Nedd4-2-IR with the diﬀerent
markers. Among all Nedd4.-2-positive neurons, 54.8 ± 3.8% co-stained for peripherin, 7.8 ± 2.7% for NF-200, 51.9 ± 2.2% for IB4, 9.0 ± 1.2%
for Substance P, 57.7 ± 2.7% for Nav1.7 and 55.0 ± 3.6% for Nav1.8. (C) Among the following markers, many co-stained with Nedd4-2: peripherin
(65.6 ± 3.2%), NF-200 (13.1 ± 3.7%), IB4 (77.3 ± 4.6%), Substance P (33.1 ± 2.8%), Nav1.7 (64.0 ± 2.9%) and Nav1.8 (59.4 ± 4.9%). Data are
presented as mean ± SEM. n= 4. Scale bar = 50 lm.
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(n= 4). Peripherin, an intermediate ﬁlament selective
for small sensory neurons presumably nociceptive, is
found in about half of neurons with Nedd4-2-IR (Fig. 2B)and conversely Nedd4-2-IR is present in a large majority
of peripherin-positive neurons (Fig. 2C). Nedd4.2 is
weakly expressed in the NF200-postive large myeli-
nated ﬁber cell population. Within the subpopulations of152
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sented in the non-peptidergic neurons (IB4 positive)while less than 10% of Nedd4-2 immunoreactive cells
are positive for the neuropeptide Substance P.153
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Fig. 4. Nedd4-2-IR and Nav1.7 expression one week after SNI. (A) Immunoﬂuorescence showing the colocalization (right panel, arrows) between
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expressed in DRG neurons and is predominantly
localized in small diameter sensory neurons, which
include many nociceptive neurons.Nedd4-2-IR is decreased after SNI
In order to test the hypothesis that Nedd4-2 plays a role in
the hyperexcitability associated with neuropathic pain in
rats, we explored the regulation of its expression
following peripheral nerve injury. Using Western blot
analysis of L4 DRG (Fig. 3A and B), we observed a
decrease of about 56% in Nedd4-2 protein content
after SNI. Similar results were observed using
immunoﬂuorescence on DRG (Fig. 3E and F):
quantiﬁcation indicated a decrease in the number of
Nedd4-2-IR cell proﬁles after SNI. In addition, we
evaluated whether Nedd4-2 signal could be shifted to
another DRG neurons subpopulation after nerve injury
(Fig. 3C). The distribution of Nedd4-2-positive neurons
in DRG cells of diﬀerent sizes conﬁrms an expression
mainly in small neurons (<600 lm2), but no signiﬁcant
diﬀerence was detected between sham and SNI groups.
The reduction of Nedd4-2-IR observed after SNI is not
associated with a decrease of mean pixel intensity
calculated for individual neurons (Fig. 3D), but rather
with a reduced number of Nedd4-2-expressing neurons
(Fig. 3F).We therefore investigated whether the downregulation
of Nedd4-2-IR occurs in injured DRG neurons (injured
aﬀerents of the tibial and peroneal nerves) after SNI,
which are known to be positive for the transcription
factor ATF-3 (Tsujino et al., 2000; Miyoshi et al., 2011).
As anticipated, the proportion of immunoreactive
neurons for ATF-3 in SNI rats is higher than in the sham
group (34.8 ± 2.8% as compared to 4.8 ± 0.2%), yet a
detailed analysis shows that downregulation of Nedd4-2
occurs in both injured (ATF positive) and the remaining
non-injured (ATF negative) neurons present in the DRG
(Fig. 3F). This suggests that neuronal deterioration and
in turn the previously reported neuronal death following
nerve section (Tandrup et al., 2000; McKay Hart et al.,
2002) is unlikely to account for the reduction of Nedd4-2
IR, in line with the reported absence of neuronal death
in neuropathic pain without axonal injury (Schaeﬀer
et al., 2010).Nedd4-2-IR colocalizes with sodium channels Nav1.7
and Nav1.8
The regulation of ion channels by Nedd4-2, in particular
the voltage-gated sodium channels Nav1.7 and Nav1.8,
implies their coexpression in the same DRG neurons. In
line with this hypothesis, strong colocalizations between
Nedd4-2 and Nav1.7 (Figs. 2 and 4A) or Nav1.8 (Fig. 2)
were found. More than 60% of Nav1.7-positive neurons155
M. Cachemaille et al. / Neuroscience 227 (2012) 370–380 377co-expressed Nedd4-2, a value that dropped
concomitantly with Nedd4-2 downregulation after SNI
(64.0 ± 2.9% to 40.1 ± 3.0% in sham and SNI groups
respectively, p< 0.01, n= 4 in each group).
A signiﬁcant increase in the number of Nav1.7
immunoreactive neuronal proﬁles is observed after SNI
as compared to sham (Fig. 4B), without any signiﬁcant
change in the distribution of Nav1.7-IR cross-sectional
area (Fig. 4C). The enrichment in Nav1.7-IR is mostly
observed in small neurons (0–600 lm2) and a
simultaneous increase in mean pixel intensity is
observed in individual cells of this category after SNI
(Fig. 4D). Remarkably, Western blot quantiﬁcation
shows a decrease in Nav1.7 content in DRG after SNI
(Fig. 4F–G).
Many Nav1.8-IR cells express Nedd4-2 (Fig. 2A–C) in
a proportion that is not altered by SNI (59.4 ± 4.9% and
59.6 ± 5.3% in sham and SNI groups respectively,
n= 4). Conversely, 55.0 ± 3.6% of Nedd4-2-IR proﬁles
showed Nav1.8-IR, but this proportion was signiﬁcantly
decreased to 38.6 ± 4.4% after SNI (p< 0.05, n= 4).
This parallels the known downregulation of Nav1.8 after
peripheral nerve injury, which is here conﬁrmed by the
decrease of cells expressing Nav1.8 in DRG:
46.9 ± 5.2% of total DRG neuronal proﬁles showed
Nav1.8-IR from control rats compared with 21.1 ± 1.7%
of DRG neuronal proﬁles from SNI animals (p< 0.01,
n= 4).
Nedd4-2 IR is not altered by peripheral inﬂammation
We further tested the hypothesis that Nedd4-2 might be
regulated after peripheral inﬂammation (Fig. 5). As
shown in (Fig. 5A and B) 48 h following intraplantar
injection of CFA, neither the density of Nedd4-2-positive
neurons nor the global Nedd4-2 content was modiﬁed.
DISCUSSION
In the present study, we characterized the expression of
Nedd4-2 in primary sensory neurons and showed its
downregulation after a peripheral nerve lesion. Using
immunoﬂuorescence and Western blot, we ﬁrst
established the presence of Nedd4-2-IR in DRG
neurons and its main localization in small-diameter
neurons. Furthermore, after SNI, we found a signiﬁcant
decrease in Nedd4-2 content in DRG neurons. Finally
we demonstrated that the expressions of Nav1.7 and
Nav1.8 strongly co-localize with Nedd4-2-IR in the basal
condition and after peripheral nerve injury.
The demonstration of a colocalization between
Nedd4-2 and Nav1.7 or Nav1.8 immunoreactivities was
the ﬁrst crucial step before postulating an involvement of
Nedd4-2 in the regulation of Nav after peripheral nerve
injury. In rat DRG, we found that a large proportion of
neurons were immunoreactive for Nedd4-2, a proportion
that further increased when we considered the sole
population of small neurons that express peripherin. This
result, together with the low percentage of Nedd4-2-
positive cells in myelinated NF200 immunoreactive
neurons (presumably non-nociceptive except the Ad sub-
population), suggests that Nedd4-2 may have a role toplay in the physiology of nociceptive neurons. In
addition, the further enrichment of Nedd4-2 in
IB4-positive nociceptive neurons (77.3 ± 4.6%) indi-
cates a putative speciﬁc role of Nedd4-2 in the
excitability of non-peptidergic nociceptors, a cell popu-
lation described as having longer duration action
potentials and expressing a high density of Nav1.8
(Stucky and Lewin, 1999). The marked downregulation
of Nedd4-2-IR in DRG neurons following peripheral
nerve injury suggests changes in ion channel traﬃcking
and the possible role of this in neuropathic pain is a
promising subject for future study. After nerve injury, the
reduced proportions of Nedd4-2-positive neurons were
not signiﬁcantly diﬀerent between injured (ATF-3
positive) and non-injured (ATF-3 negative) DRG
neuronal populations. This might imply that Nedd4-2
downregulation contributes to Nav turnover in both
injured (axotomized) and non-injured adjacent neurons.
Sodium channels exist both at the plasma membrane
and in intracellular pools (Schmidt et al., 1985; Ritchie
et al., 1990). Multiple and complex mechanisms
contribute to the forward traﬃcking of sodium channels
– and other voltage-gated ion channels – from the
intracellular pool to their subsequent functional insertion
in the plasma membrane. In this process, insertion is
counter-balanced by various post-translational
modiﬁcations including ubiquitylation and consequent
internalization of the channel (Jenkins and Bennett,
2001; Okuse et al., 2002; Garrido et al., 2003; Mohler
et al., 2004; Lopez-Santiago et al., 2006), a pheno-
menon in which Nedd4-2 has been implicated in trans-
fected cells (Fotia et al., 2004). In SNI, the Nedd4-2
decrease may inﬂuence this balance, possibly leading to
an accumulation of Nav at the cell membrane while the
total quantity of sodium channels in neurons may
remain stable. This mechanism might explain
discrepancies that have been reported between the
apparent rate of Nav synthesis and the observed
functional current, as in the case of TTX sensitive Nav
isoforms (Berta et al., 2008). In accordance with
previous studies on Nav1.7 transcriptional expression
(Raymond et al., 2004; Berta et al., 2008), we found a
signiﬁcant reduction in total Nav1.7 protein after SNI.
Nevertheless, the number of Nav1.7-IR neurons was
increased after SNI. This discrepancy might originate
from a redistribution of Nav1.7 protein to a diﬀerent
neuronal compartment more easily accessible to the
antibody, such as plasma membrane. It is also possible
that following peripheral nerve injury Nav1.7 is
upregulated but redistributed from the soma of sensory
neurons toward ﬁbers resulting in apparent
simultaneous signal reduction in the cell bodies and
increase in the total DRG protein content.
Further investigations should be conducted in order to
distinguish the membrane and intracellular pools of
Nav1.7 using electrophysiological and biochemical appro-
aches. Nav1.7 has so far never been investigated in DRG
using patch clamp techniques due to the diﬃculty to
selectively isolate its currents. Interestingly, however,
Nav1.7 speciﬁc blockers have recently been developed
and will allow Nav1.7 exploration (Schmalhofer et al.,156
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strategies might also be employed to quantify the
internalization and membrane targeting of Nav in
neuropathic pain and the importance of the speciﬁc
interaction with Nedd4-2 in this process.
The strong downregulation of Nav1.8, in line with
many other studies but in apparent contradiction of our
hypothesis, would suggest that a transcriptional
downregulatory mechanism predominates regardless of
the inhibition by Nedd4-2 of channel internalization.
In addition, it was already proposed that the
downregulation of Nav1.8 mRNA and protein in DRGs is
due to a redistribution of this channel along the axons of
injured (Thakor et al., 2009) or uninjured nerves (Gold
et al., 2003). Nedd4-2 downregulation in the DRG might
also impact Nav1.8 expression at the membrane along
the axon and further studies are needed to answer this
question.
Nedd4-2 is not the only potential post-translational
regulator of Nav. An interaction between p11 (from the
S100 protein family) and Nav1.8 has been reported to
facilitate Nav1.8 sorting toward the cell membrane
(Okuse et al., 2002). Besides, ankyrin interacts with and
upregulates Nav1.5 in cardiac cells (Mohler et al., 2004)
as well as Nav1.2 and Nav1.6 at nodes of Ranvier
(Jenkins and Bennett, 2001; Garrido et al., 2003). In
addition, Navb-subunits fulﬁll important regulatory
functions. In particular, the b2-subunit was shown to
modulate mRNA and protein expression of various Nav
(Lopez-Santiago et al., 2006) and is increased after
nerve injury (Pertin et al., 2005). Finally, protein kinases
such as PKA or PKC also modulate VGSC, with PKA
increasing Nav1.8 and decreasing Nav1.7 currents
while PKC decreases Nav1.8 and Nav1.7 currents
(Vijayaragavan et al., 2004). Nedd4-2 interacts
speciﬁcally via one of its WW domains (protein–protein
interaction modules) with a PY motif situated in the
COOH termini of Nav or ENaC (Harvey et al., 1999;
Rougier et al., 2005). Previous studies have established
the connection between Nedd4-2 and the Nav in vitro
(Fotia et al., 2004; van Bemmelen et al., 2004;
Rougier et al., 2005). In cardiac cells, Nav1.5 can be
downregulated by Nedd4-2 (Abriel et al., 2000; van
Bemmelen et al., 2004) implying a probable modulation
of cardiac excitability. With the exception of Nav1.4 and
Nav1.9, all Nav contain the speciﬁc PY motif suggesting
an interaction with Nedd4-2. These include Nav1.6,
whose mRNA is the third most abundant among sodium
channels in the DRG (Berta et al., 2008); this channel
has recently been reported to be modulated by Nedd4-2
(Gasser et al., 2010). Additionally, Nav1.2, mainly
present in the central nervous system, has been shown
to be downregulated when associated with Nedd4-2
(Fotia et al., 2004; Rougier et al., 2005). In addition to
Nav, Voltage-gated K+ channels play major roles in
modulating electrical excitability in neurons. For
instance, KCNQ2/3/5contain a PY motif and is
subjected to Nedd4-2 dependent downregulation in a
Xenopus oocyte expression system (Ekberg et al.,
2007; Pongs, 2008; Bongiorno and Poronnik, 2011).
This regulation and modulation of K+ channels mightalso be a key point in the excitability generated after a
peripheral nerve injury.
Finally, besides its expression level, Nedd4-2
is regulated by a direct phosphorylation as well
(Debonneville et al., 2001; Snyder, 2009). In particular,
serum- and glucocorticoid kinase 1 (Debonneville et al.,
2001) increases ENaC cell-surface expression through
a negative regulation of Nedd4-2 (Alvarez et al., 1999).
These ﬁndings imply a posttranslational regulation of
Nedd4-2 playing therefore a role in Nav modulation.
Upstream regulatory mechanisms of Nedd4-2 might
therefore represent other perspectives to explore in the
context of peripheral nerve injuries.CONCLUSION
In summary, we have demonstrated in vivo the presence
of the ubiquitin ligase Nedd4-2 in the rat DRG. Moreover
meticulous analyses of the immunoreactive cell
populations showed its presence mainly in small
nociceptive neurons, especially the non-peptidergic
neurons. We also colocalized Nedd4-2 with Nav1.7 and
Nav1.8. In a model of peripheral nerve injury, the
decrease of Nedd4-2-positive neurons suggests a
putative role in altered Nav turnover, especially Nav1.7,
which could contribute to hyperexcitability. Future
studies will shed light on the exact molecular impact of
Nedd4-2 on Nav in nociceptors and pathological pain.
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ABSTRACT
Background: Voltage-gated sodium channels dysregulation 
is important for hyperexcitability leading to pain persistence. 
Sodium channel blockers currently used to treat neuropathic 
pain are poorly tolerated. Getting new molecules to clinical 
use is laborious. We here propose a drug already marketed as 
anticonvulsant, rufinamide.
Methods: We compared the behavioral effect of rufinamide 
to amitriptyline using the Spared Nerve Injury neuropathic 
pain model in mice. We compared the effect of rufinamide on 
sodium currents using in vitro patch clamp in cells express-
ing the voltage-gated sodium channel Nav1.7 isoform and 
on dissociated dorsal root ganglion neurons to amitriptyline 
and mexiletine.
Results: In naive mice, amitriptyline (20 mg/kg) increased 
withdrawal threshold to mechanical stimulation from 1.3 
(0.6–1.9) (median [95% CI]) to 2.3 g (2.2–2.5) and latency 
of withdrawal to heat stimulation from 13.1 (10.4–15.5) to 
30.0 s (21.8–31.9), whereas rufinamide had no effect. Rufin-
amide and amitriptyline alleviated injury-induced mechani-
cal allodynia for 4 h (maximal effect: 0.10 ± 0.03 g (mean 
± SD) to 1.99 ± 0.26 g for rufinamide and 0.25 ± 0.22 g 
to 1.92 ± 0.85 g for amitriptyline). All drugs reduced peak 
current and stabilized the inactivated state of voltage-gated 
sodium channel Nav1.7, with similar effects in dorsal root 
ganglion neurons.
Conclusions: At doses alleviating neuropathic pain, ami-
triptyline showed alteration of behavioral response possibly 
related to either alteration of basal pain sensitivity or seda-
tive effect or both. Side-effects and drug tolerance/compli-
ance are major problems with drugs such as amitriptyline. 
Rufinamide seems to have a better tolerability profile and 
could be a new alternative to explore for the treatment of 
neuropathic pain.
P AIN is essential for survival as it serves as an alert to engage protective behavior. Neuropathic pain, caused by 
a lesion or disease of the somatosensory nervous system, affects 
7% of the population1 and possesses no protective purpose.
Sodium channels are major targets for the development 
of new drug to treat neuropathic pain.2 Nerve injury changes 
the expression of sodium channels3 which affects peripheral 
nerve hyperexcitability and ectopic discharges along the 
nerve, in the dorsal root ganglion or at the injury site.4,5 They 
are composed of a α-pore forming subunit associated to one 
or two β-modulating subunits. Nine genes encode for the 
α-subunits, Nav1.1–1.9.6
Current therapy for neuropathic pain involves adjuvant 
medications—not primarily developed for this purpose—
such as anticonvulsants, antidepressants, or local anesthetics.7 
Tricyclic antidepressants are considered as first-line treatment 
in different international guidelines.8 Their mode of action 
does not seem to be linked to their antidepressant actions 
as acknowledged by their faster onset.9 Amitriptyline was 
shown to interact with sodium channels as exemplified by its 
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What We Already Know about This Topic 
•	 Neuropathic pain remains a poorly treated chronic pain 
condition
•	 Rufinamide is an antiepileptic drug that is thought to produce 
its effect against seizures through reducing sodium channel 
activity
What This Article Tells Us That Is New 
•	 Rufinamide may produce, in part, an effect against neuro­
pathic pain by interfering with the sodium channel subtype 
Nav 1.7 implicated in pain transmission
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cardiac toxicity and this target could also play a role in pain 
modulation.10 Mexiletine, a sodium channel blocker and an 
oral analog of local anesthetics has been used in the treatment 
of neuropathic pain11 but its tolerance on long-term therapy 
raises considerable questions as shown by a median discon-
tinuation of treatment of 43 days in a recent study.12 Rufin-
amide is an antiepileptic drug licensed for Lennox-Gastaut 
syndrome, a refractory type of epilepsy.13 It is considered to 
inhibit sodium channels, stabilizing its inactive form, and 
reducing the firing of sodium-dependent action potentials.
Since the discovery that loss-of-function mutations in 
SCN9A, the gene encoding for Nav1.7 isoform, are associ-
ated with congenital insensitivity to pain,14 it has become 
a potential target for treatment. Moreover, gain-of-function 
mutations SCN9A are associated with familial pain syn-
dromes (erythromelalgia and paroxysmal extreme pain dis-
order)15 and in subset of patients with idiopathic small nerve 
fiber neuropathy or generalized pain syndromes.16,17 Nav1.7 
is expressed in sensory, sympathetic, and myenteric fibers.18–20 
It exhibits slower recovery from fast inactivation21,22 com-
pared with other tetrodotoxin-sensitive channels Nav1.4 and 
1.6 and slower inactivation at potentials close to the mem-
brane resting potential, thus contributing to the large ramp 
current during slow depolarization.23 Nav1.7 is thought to 
play an important role in “boosting” the depolarization of 
small diameter nociceptive neurons.
In the present study, we investigated the analgesic effect 
of rufinamide on the spared nerve injury (SNI) model of 
neuropathic pain and amitriptyline was used as a positive 
control. Our null hypothesis was that treated and control 
groups show the same behavior. We also explored the effect 
of rufinamide on heterogeneously expressed Nav1.7 chan-
nels and used mexiletine and amitriptyline as control. We 
finally tested the effect of rufinamide on dorsal root ganglia 
neurons. For electrophysiological studies, our null hypothesis 
was that the drugs do not change the measured parameters, 
which were V1/2 of activation and steady-state inactivation, 
frequency-dependent inhibition and t1/2 of recovery from 
inactivation.
Materials and Methods
Drugs
Rufinamide (R8404), amitriptyline (A8404), and mexiletine 
(M2727) were purchased from Sigma (Buchs, Switzerland). 
For behavioral experiment, rufinamide was dissolved in 
dimethylsulfoxide (DMSO) and then mixed with 1 × 
phosphate buffered saline to the desired concentration. 
Control was 30% DMSO in 1 × phosphate buffered saline. 
Doses (5, 10, 25, 50 mg/kg) were chosen corresponding to the 
therapeutic ones used in epilepsy models in mice (rufinamide 
was effective in the maximal electroshock test (effective dose 
23.9 mg/kg orally) and in the pentylenetetrazol induced 
seizure test (54 mg/kg, intraperitoneally).24 Amitriptyline 
was dissolved directly in sterile 0.9% saline and doses were 
chosen according to previous studies in neuropathic pain 
models. Drugs were administered intraperitoneally.
Animal Experiments
All experiments were approved by the Committee on Animal 
Experimentation of the Canton de Vaud, Lausanne, Switzer-
land, in accordance with Swiss Federal law on animal care 
and the guidelines of the International Association for the 
Study of Pain.25 5-week-old C57BL/6 male mice (Charles 
River, l’Abresle, France) weighting 20–25 g at the start of 
experiment were housed in the same room, 5 per cage, at 
constant temperature of 21°C and a 12/12 dark/light cycle. 
No other animals were housed in that room. Mice had ad 
libitum access to water and food.
Surgery
SNI surgery26,27 on mice28 was performed under 1.5–2.5% 
isoflurane (Abott AG, Baar, ZG, Switzerland) anesthesia. 
Briefly, the left hindlimb was immobilized in a lateral posi-
tion and slightly elevated. Incision was made at mid-thigh 
level using the femur as a landmark and a section was made 
through the biceps femoris in the direction of point of ori-
gin of the vascular structure. The three peripheral branches 
(sural, common peroneal, and tibial nerves) of the sciatic 
nerve were exposed without stretching nerve structures. 
Both tibial and common peroneal nerves were ligated using 
a 6.0 silk suture and transected together. The sural nerve was 
carefully preserved by avoiding any nerve stretch or nerve 
contact.
Behavior
For all the behavioral experiments, the observer was blinded 
to the treatment applied.
Mechanical Sensitivity. Animals were habituated to the 
testing environment daily for at least 2 days before base-
line testing. The room temperature and humidity remained 
stable for all experiments. For testing mechanical sensitivity, 
animals were put under inverted plastic boxes on an elevated 
mesh floor and allowed 10 min for habituation before the 
threshold testing. Mechanical allodynia was tested using 
a series of von Frey hairs with logarithmically increment-
ing stiffness (0.02, 0.04, 0.08, 0.16, 0.32, 0.64, 1.28, and 
2.56 g). The filaments were applied perpendicularly to the 
plantar surface 1–2 s. The 50% withdrawal threshold was 
determined using Dixon’s up–down method.29
Heat Sensitivity. The effect of rufinamide and amitriptyline 
on basal heat sensitivity was assessed with the Hot Plate assay. 
Briefly, the animals were placed on the hot-plate surface set 
at 52°C. The latency of response (in seconds) was deter-
mined as the time until a hindlimb lick or jump occurred. 
The cutoff was set at 30 s to avoid tissue damage.
Activity was quantified with the Activ-meter (Bioseb, 
Vitrolles, France). The total activity (summation of immo-
bile, slow and fast activity given by the software) of naive 
animals in their home cage was measured during the 4 h 
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following injection of rufinamide (50 mg/kg) and amitrip-
tyline (10 mg/kg). It was compared with the activity after 
saline injection. All experiments for activity were performed 
between 5 and 9 PM.
A five-point sedation score from 0 to 4 points was used 
for rufinamide (50 mg/kg) and amitriptyline (10 mg/kg), 0 = 
normal behavior, normal locomotion, 1 = awake, slow loco-
motion, 2 = no locomotion, eyes half closed, still responding 
to righting reflex, 3 = asleep, eyes closed, still responding to 
righting reflex, 4 = no righting reflex, adapted from Boast 
et al.30
Experimental Design
For drug effect on naïve animals, eight animals per group 
were used to assess mechanical withdrawal threshold and heat 
withdrawal latency. For the Activ-meter, six animals were 
used in a cross-over design for rufinamide and amitriptyline.
Normal mechanical threshold was assessed before sur-
gery without difference between groups. SNI surgery was 
performed and 1 week later allodynia-like behavior was 
tested before intraperitoneal injection of rufinamide. Two 
series of experiments were done, the first one compared 
rufinamide 25 mg/kg and 50 mg/kg with DMSO 30% (n 
= 10 per group, 9 for DMSO) and the second one com-
pared rufinamide 5 mg/kg and 10 mg/kg with DMSO 30% 
(n = 8 per group) at 20-40-60-120-240 min and 24 h. After 
a washout period of 1 week the animals of the first series 
were tested with amitriptyline 10 or 20 mg/kg or saline at 
60-120-240 min and 24 h after intraperitoneal injection (n = 
9 per group for amitriptyline 20 mg/kg and 10 per group for 
amitriptyline 10 mg/kg and saline).
Plasma levels of the drug were assessed at 120 min after 
injection of 50 mg/kg rufinamide. Mice (n = 3) were anes-
thetized with isoflurane and 1 ml of blood was collected 
intracardially. Drug levels were analyzed by the pharmaceu-
tical monitoring laboratory of Lavigny, Switzerland.#
Electrophysiology
Rufinamide was dissolved in DMSO at 10 mM as stock 
solution and diluted daily at desired concentration in 
the extracellular medium. As control, the same DMSO 
concentration was used (1% for 100 1% for 100 mM, to 5% 
for 500 mM). Higher concentration could not be achieved 
without increasing DMSO content. Amitriptyline and 
mexiletine were dissolved in extracellular medium directly.
Human embryonic kidney 293 cells stably express-
ing Nav1.7 were kindly provided by Simon Tate (Ph.D., 
Chief Scientific Officer, Convergence Pharmaceuticals, 
Cambridge, United Kingdom) and were cultured in Dul-
becco’s modified Eagle’s medium-F12 + L-Glutamine (Invi-
trogen, Merelbeke, Belgium) supplemented with 5% fetal 
bovine serum and geneticin 0.4 mg/ml. Measurements were 
made at room temperature using pClamp software, version 
10.2, and a VE-2 amplifier (Alembic Instruments, Mon-
treal, Quebec, Canada). The sampling rate was 30 kHz. 
Data were smoothed and analyzed using Clampfit soft-
ware version 10.2.0.12 (Axon Instruments, Union City, 
CA) and KaleidaGraph (Synergy Software, Reading, PA). 
Whole-cell patch clamp recordings were conducted using 
an internal solution containing (in millimole per liter 
(mM)) CsCl 60, Cesium aspartate 70, EGTA 11, MgCl2 
1, CaCl2 1, HEPES 10, and Na2-adenosine triphosphate 
5, pH adjusted to 7.2 with CsOH; and an external solu-
tion containing NaCl 50, n-methyl-D-glutamine-Cl 80, 
CaCl2 2, MgCl2 1.2, CsCl 5, HEPES 10, and glucose 5, pH 
adjusted to 7.4 with CsOH. Holding potential was −100 
mV. The values were not corrected for liquid junction poten-
tial. Pipette resistance was ranging from 2 to 4 MOhm. Only 
data from cells having stable access resistance over the dura-
tion of the experiment were used; cells for which signs of 
poor voltage-clamp control, such as delayed inflections of the 
current or discontinuities in the peak sodium current (INa) 
versus Vm curve, were not analyzed. Around 15% of sealed 
cells were lost. Data were filtered after acquisition using 
Boxcar 9 points. Peak currents were measured with a single 
10 ms pulse protocol to −10mV from the holding potential. 
Percentage inhibition was calculated as (peakvehicle − peakdrug)/
peakvehicle × 100 for each cell and then mean inhibition for 
each drug and concentration was calculated. Other proto-
cols are shown as inserts in the figures. The linear ascending 
segment of the current-voltage relationship was used to esti-
mate the reversal potential for each trace before obtaining 
the voltage-dependent activation curve. Voltage dependence 
of activation and steady-state inactivation curves were indi-
vidually fitted with Boltzmann relationships, y(Vm) = 1/(1 + 
exp[(Vm − V1/2)/K]) in which y is the normalized current or 
conductance, Vm is the membrane potential, V1/2 is the volt-
age at which half of the channels are activated or inactivated, 
and K is the slope factor. The value of t1/2 of recovery from 
inactivation was calculated by interpolation from a linear 
relation between the two points juxtaposing half recovery (y1 
< 0.5 < y2), using the relation x = (0.5−[y1x2−y2x1]/[x2−x1]) × 
(x2−x1)/(y2−y1). For use-dependent block, the percentage of 
decrease of current was calculated between the 1st and 50th 
pulse.
For ex-vivo recordings, dorsal root ganglion neurons 
were collected from adult C57BL/6 mice (4–8 weeks old). 
Briefly, L4 and L5 dorsal root ganglion neurons were har-
vested and digested in Liberase blendzyme thermolysin 
medium (Roche, Indianapolis, IN) 0.5 U/dorsal root gan-
glion with 12 μM EDTA in 5 ml Complete Saline Solution 
(in mM, NaCl 137, KCl 5.3, MgCl2-6H2O 1, Sorbitol 25, 
HEPES 10, CaCl2 3, and pH adjusted to 7.2 with NaOH) 
for 20 min at 37°C. Neurons were further digested with 
Liberase blendzyme TL with EDTA in Complete Saline 
Solution with papaïn (30 U/ml) for 10 min. Finally neurons 
were suspended in dorsal root ganglion medium mix (89% 
#http://www.ilavigny.ch/html/hopital/laboratoire.php. Accessed 
June 21, 2012.
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DMEM/F-12, 10% bovine serum albumin, 1% penicil-
lin/streptomycin) supplemented with 1.5 mg/ml of trypsin 
inhibitor and 1.5 mg/ml of purified bovine serum albumin. 
Mechanical dissociation was performed using a pipetman 
and neurons were plated on poly-D-lysine-coated coverslips 
and incubated 12 h before recording to allow recovery and 
adhesion of neurons. Neurons were only recorded for 12 
more hours to prevent long-term culture phenotypic changes 
and neurite outgrowth that degrades space clamp. Small 
neurons (diameter < 30 µm) were recorded using an EPC-
10 amplifier (HEKA Electronics, Lambrecht, Germany) and 
Patchmaster/Fitmaster software for data acquisition/analy-
sis. The sampling interval was 20 μs and a 5 kHz filter was 
used in all experiments. Experiments were carried out in the 
whole-cell patch clamp configuration. Extracellular solution 
contained (in mM) NaCl 30, tetraethylammonium–Cl 110, 
KCl 3, CaCl2 1, MgCl2 1, HEPES 10, Glucose 10, CdCl 
0.1; pH was adjusted to 7.3 using Tris base, osmolarity was 
adjusted to 320 mOsm/l with sucrose. The pipette solution 
contained cerebrospinal fluid 140, NaCl 10, MgCl2 2, CaCl2 
0.1, EGTA 1.1, HEPES 10, pH was adjusted to 7.2 with 
CsOH and osmolarity was adjusted to 310 mOsm/l. Pipettes 
were pulled from Borosilicate glass (World Precision Instru-
ments, Sarasota, FL) and had a resistance < 3 MOhm, when 
filled with the pipette solution. Capacity transients were 
canceled and series resistance was compensated to around 
90%. Leakage current was digitally subtracted online using 
hyperpolarizing control pulses, applied after the test pulse, of 
one-fourth test pulse amplitude (P/4 procedure). For current 
density measurements, membrane currents were normalized 
to the membrane capacitance which was calculated from the 
integral of the transient current in response to a brief hyper-
polarizing pulse of 10 mV from the holding potential.
Once in whole-cell configuration, cells were held at −60 
mV for 5 min to dialyze the cell with CsF solution (fluoride 
shifts Nav1.8 steady-state activation and inactivation to 
hyperpolarized potentials) to reach Nav1.8 stable biophysical 
properties and to inactivate Nav1.9 current and was further 
clamped at −80 mV for 2 more minutes. Whole-cell Na 
currents were elicited by a series of 100 ms test pulses ranging 
from −80 to +40 mV in increments of 5 mV at a frequency 
of 0.33 Hz. Test pulses were preceded by a prepulse of 3 s 
at −120 mV. Normalized conductance (G/Gmax) was fitted 
as described for in vitro recordings and V1/2 and slope factor 
were extracted from the equation. Steady-state inactivation 
curves were measured from a holding potential of −120 mV 
using 500 ms prepulses to the indicated potentials followed 
by a test pulse to 0 mV. Again, V1/2 and slope factors were 
obtained as mentioned for in vitro recordings.
Recovery from inactivation curves was obtained with a 
standard two-pulse protocol consisting of a depolarizing 
pulse from a holding potential of −120 to 0 mV for 50 ms 
to inactivate the channels, followed by a variable duration 
step (from 0.05 to 3276.8 ms) back to −120 mV to promote 
recovery. The availability of the channels was assessed with a 
second test pulse at 0 mV and the ratio of the second pulse 
versus the first was plotted against the recovery interval. The 
t1/2 of recovery was calculated as mentioned previously.
Statistics
Behavioral Statistics. For the time course and drug effect 
on mechanical allodynia after nerve injury three experi-
ments were done separately: (1) rufinamide 25 mg/kg, 
rufinamide 50 mg/kg, and DMSO 30%; (2) rufinamide 
5 mg/kg, rufinamide 10 mg/kg, and DMSO 30%; and (3) 
amitriptyline 10 mg/kg, amitriptyline 20 mg/kg, and saline. 
The log values of withdrawal thresholds were assessed for 
each experiment using an Anova two-ways with Bonferroni 
correction for repeated measures from preinjection to 24 h 
after injection. For the development of allodynia, baseline 
and preinjection were compared by using the Wilcoxon 
matched-pairs signed rank test (Bonferroni’s correction for 
multiple testing) because baseline values are skewed. For 
clarity purposes on figure 1, a mean value of both DMSO 
groups is used and values are presented as mean ± SD also 
for baseline. For the drug effect on naïve animals, data were 
analyzed with Kruskal-Wallis test and Dunn’s correction 
for multiple testing. The numerical data are presented as 
median with 95% CI.
Electrophysiological Statistics. Data are presented as mean 
± SD and were analyzed using paired student t tests for drug 
effect.
All hypotheses were challenged using two-tailed testing 
and P value less than 0.05 was used as the level of signifi-
cance. Statistical analysis was performed using Prism 5 for 
windows, version 5.03, GraphPad Software, San Diego, CA.
Results
1. Behavior
1.1 Rufinamide Reduces Mechanical Allodynia after 
SNI. All animals developed allodynia 1 week after surgery 
(P < 0.05, preinjection vs. baseline for all groups). Rufin-
amide significantly and dose-dependently alleviated SNI-
induced allodynia (fig. 1A), with maximal effect from 
0.10 ± 0.03 (mean ± SD) to 1.99 ± 0.26 g. The effect was seen 
already 20 min following injection, peaked at 60 min, lasted 
for at least 4 h, but had faded 24 h after drug administration. 
At the highest dose of rufinamide, allodynia-like behavior 
was completely reversed. The vehicle DMSO showed a ten-
dency for anti-allodynic effect but the values did not reach 
statistical significance in multiple testing.
1.2 Amitriptyline Reduces Mechanical Allodynia after 
SNI. All animals showed allodynia before injection of ami-
triptyline (P < 0.05 preinjection vs. baseline for all groups). 
Amitriptyline alleviated the allodynic behavior from 60 
to 240 min after injection and the effect had disappeared 
at 24 h (fig. 1B) with maximal effect from 0.25 ± 0.22 
to 1.92 ± 0.85 g. There was no difference between 10 and 
20 mg/kg.
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1.3 Amitriptyline But Not Rufinamide Affects Basal Sen-
sitivity. Rufinamide (50 mg/kg) did not modify basal 
mechanical sensitivity of naive animals or heat withdrawal 
latency. We therefore did not test lower doses (fig. 2, A and 
B). On the other hand, amitriptyline at 20 mg/kg increased 
withdrawal threshold for innocuous mechanical stimulation 
with von Frey hairs from 1.3 (0.6–1.9) (median and 95% 
CI) to 2.3 g (2.2–2.5) and increased withdrawal latency on 
heat stimulation compared with saline from 13.1 (10.4–
15.5) (median, 95% CI) to 30.0 s (21.8–31.9). We therefore 
tested amitriptyline at 10 mg/kg and also observed antino-
ciceptive effect on heat stimulation (withdrawal threshold 
from 10.5 [7.2–11.7] to 25.3 [16.4–27.7]), but no statisti-
cally significant difference on non-noxious mechanical stim-
ulation (fig. 2, A and B).
Animals injected with rufinamide 50 mg/kg did not lower 
their total activity measured over 4 h after injection with 
the Activ-meter as compared with saline-injected controls. 
Fig.1. RUF and (AMI) alleviate mechanical allodynia after 
SNI. A, RUF dose-dependently alleviates neuropathic be-
havior following SNI from 20 to 240 min after injection with 
a peak at 60 min and a loss of effect at 24 h. B, AMI allevi-
ates neuropathic behavior following SNI from 60 to 240 min 
after injection and lost its effect at 24 h, (*P < 0.05, **P < 0.01, 
***P < 0.001 vs. PreInj). AMI = amitriptyline; BL = baseline; 
DMSO = dimethylsulfoxide; Preinj = pre-injection (1 week af-
ter SNI for RUF, 2 weeks for AMI); RUF = Rufinamide; SNI = 
spared nerve injury. Values are presented as mean ± SD.
Fig. 2. RUF and AMI differentially affect basal sensitivity and 
activity of naïve animals. A, RUF at 50 mg/kg does not affect 
withdrawal threshold to mechanical stimulation with von Frey 
filaments as compared to AMI which significantly increased 
the threshold at the dose of 20 mg/kg (not statistically signifi-
cant for 10mg/kg), n = 8. B, RUF at 50 mg/kg does not affect 
withdrawal latency to heat stimulation as compared to AMI 
which significantly increased the latency at the dose of 10 and 
20 mg/kg, n = 8. C, The total activity (in hours) of the animals 
was measured using the Activ-meter system over a 4 h period 
following drug injection and compared with activity following 
saline. AMI (10 mg/kg) but not RUF (50 mg/kg) significantly 
reduces the activity compared with control, n = 6. Data are 
expressed as median (horizontal line) and box and whiskers 
with first and third quartiles (box), and minimum and maximum 
(whiskers), ns=non-significant, *P < 0.05, **P < 0.01 versus 
CTRL. AMI = amitriptyline; CTRL = control; RUF = Rufinamide. 
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Amitriptyline decreased total activity statistically signifi-
cantly compared with saline-injected controls (fig. 2C).
Amitriptyline increased the score of sedation from 0 
(saline group) to 2(0–3) (median, [range], n = 8). Rufin-
amide did not change the score (0).
1.4 Rufinamide Plasma Level Corresponds to Therapeutic 
Level for Epileptic Patients. At peak effect for mechani-
cal allodynia, the range of plasma level for rufinamide was 
68–86 mM.
2. Effect of Rufinamide on Nav1.7 Channel Compared with 
Amitriptyline and Mexiletine
2.1 Rufinamide Reduces Nav1.7 Peak Current. Rufinamide 
reduced INa induced by a single pulse depolarization using 
human embryonic kidney 293 cells stably expressing Nav1.7 
(fig. 3). The most substantial reduction obtained with rufin-
amide was 28.3%, at a concentration of 500 µM. The drug 
could not be dissolved at higher concentration. A concentra-
tion of 100 µM was used for the rest of the testing to avoid 
the high DMSO concentration used for 500 µM. With high 
concentration of amitriptyline and mexiletine a complete 
inhibition of INa could be obtained and EC50 was used for 
the following experiments (fig. 3).
2.2 Rufinamide Shifts Steady-State Inactivation of 
Nav1.7. The voltage dependence of activation was examined 
using a series of 10 ms depolarizing test pulses from −80 to 
+85 mV from a holding potential of −100 mV. Rufinamide 
had no effect on voltage dependency of activation for Nav1.7 
sodium channel, nor did amitriptyline and mexiletine. No 
statistically significant changes were seen in V1/2 of activation. 
Slopes were slightly altered by rufinamide and mexiletine 
(fig. 4). For the steady-state inactivation experiments, cells 
were given a 500 ms conditioning pulse at voltages between 
−130 and −10 mV from a holding potential of −100 
mV followed by a 20 ms test pulse. Normalized sodium 
currents (INa/Imax) measured during test pulses were plotted 
against conditioning voltage. Rufinamide shifted the steady-
state inactivation relationship to more hyperpolarized 
value with a V1/2 of inactivation shifting from −81.8 ± 4.4 
to −87.6 ± 4.9 mV. The control drugs had a similar effect 
with shift of V1/2 of inactivation, from −78.9 ± 2.8 to 
−88.4 ± 1.1 mV for amitriptyline and from −79.8 ± 3.0 to 
−91.4 ± 2.6 mV for mexiletine. The slopes of steady-state 
inactivation curves were not influenced by any of the tested 
drugs (fig. 4).
2.3 Rufinamide Prolongs the Recovery from Fast Inactiva-
tion of Nav1.7. Effects on the recovery from fast inactivation 
was examined with a standard double-pulse protocol consist-
ing of a depolarizing pulse to −10 mV to inactivate the chan-
nels followed by a variable duration (0.25–2000 ms) step to 
the holding potential of −100 mV to promote recovery. The 
availability of the channels at the end of the recovery interval 
was assessed with a standard test pulse. The ratios of response 
of second/first pulse were plotted versus the recovery inter-
val. The t1/2 of recovery was interpolated. It was statistically 
significantly prolonged for the three tested drugs (fig. 5).
2.4 Rufinamide Shows Use-dependent Inhibition of 
Nav1.7. Frequency-dependent or use-dependent blocking 
refers to the accumulation of channels in inactivated state 
when subjected to a train of depolarizing pulses at high fre-
quency. We applied a series of 50 pulses at varying frequen-
cies (2, 5, 10, 25, 50 Hz) and plotted the normalized current 
against the pulse number. Rufinamide at 100 µM increased 
the use-dependent block at all frequencies tested, except 2 
Hz. Amitriptyline and mexiletine also increased the use-
dependent block, even at 2 Hz (fig. 6).
Fig. 3. Drugs inhibit voltage-gated sodium channel Nav 1.7 peak current. A, Percentage reduction of peak current after single 
pulse stimulation. B, Example of traces with the drug concentrations used afterwards in the biophysical properties testing, 
respectively, 100, 10, and 100 μM for RUF, AMI, and MEX. Transients were blanked. AMI = amitriptyline; MEX = mexiletine; RUF 
= Rufinamide.
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3. Rufinamide Influences INa in Dorsal Root  
Ganglion Neurons
We then wanted to validate the effect of rufinamide using 
dissociated mouse dorsal root ganglion neurons which con-
tain also other Nav channels and the β-subunits. We first 
observed that rufinamide at 100 µM consistently induced 
a statistically significant 10.1% mean reduction in peak 
sodium current densities from 956 ± 396 to 850 ± 339 pA/
pF (P < 0.05) despite a great variability in absolute values of 
current density (fig. 7A). We then assessed voltage depen-
dence of activation and inactivation of the sodium current 
on the dorsal root ganglion with step protocols. The global 
effect of rufinamide on dorsal root ganglion was similar to 
the one observed using human embryonic kidney 293 cells 
expressing only Nav1.7. The voltage dependence of activa-
tion was unchanged and the inactivation curve was shifted 
with statistical significance toward more hyperpolarized 
potentials, from a V1/2 of inactivation of −64.4 ± 16.8 mV to 
−69.4 ± 17.1 mV (P < 0.0001) (fig. 7B). Finally we observed 
that rufinamide also delayed t1/2 of recovery from inactiva-
tion from 2.58 ± 2.12 to 6.24 ± 5.04 ms (P < 0.05) (fig. 7C).
Discussion
We here demonstrate that rufinamide alleviates mechani-
cal allodynia-like behavior in the SNI model of neuropathic 
pain in mice. Its effect is comparable to amitriptyline, but 
with no interference on basal sensitivity and activity tests. 
Fig. 4. Drugs induce a shift of inactivation properties of voltage-gated sodium channel Nav1.7. RUF, AMI, and MEX (at, respec-
tively, 100, 10, and 100 μM) induce a hyperpolarizing shift in SSI without changing ACT properties of the voltage-gated sodium 
channel Nav1.7. V1/2 of activation/inactivation, slopes, P values and n values are summarized in the tables. Insert: stimulation 
protocols. Values are mean ± SD. ACT = activation; AMI = amitriptyline; CTRL = control; MEX = mexiletine; RUF = Rufinamide; 
SSI = steady-state inactivation.
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We also show that rufinamide modulates Nav1.7. It stabilizes 
the channel in its inactivated state similarly to amitriptyline 
and mexiletine, and delays its recovery from inactivation. By 
the observation of rufinamide effect on total sodium cur-
rents recorded in dorsal root ganglion neurons, we finally 
validated a potential peripheral mechanism of action of 
rufinamide for the treatment of neuropathic pain.
Effect of Rufinamide on Mechanical Allodynia after  
SNI in Mice
To our knowledge, this is the first trial testing rufinamide in 
a model of neuropathic pain.
Amitriptyline is a first-line treatment for clinical neuro-
pathic pain.8 Amitriptyline alleviates neuropathic pain-like 
behavior in the chronic constriction injury31,32 and spinal 
nerve ligation models33 but failed to affect mechanical allo-
dynia in these models34,35 or on paw pressure hypersensitivity 
in a rat diabetes-related pain model.36 In rats, amitriptyline 
decreased mechanical allodynia 3–5 days after SNI37 but not 
after 2–4 weeks.38 When administered perisurgically for 1 
week, amitriptyline failed to prevent the development of 
mechanical allodynia in rodents.39
Despite diverging results explained by the different sen-
sory modalities tested, timing, dose, and administration 
route or species/genetic background,40,41 the SNI model 
remains a robust neuropathic pain model in rodents. In rats, 
mechanical allodynia following SNI does not respond to 
moderate doses of morphine, gabapentin, carbamazepine, 
MK-80138, lidocaine, lamotrigine,42 or rofecoxib.43 Other 
groups showed a transient effect of high dose of morphine 
(6 mg/kg, effect < 3 h), mexiletine (37 mg/kg, < 1 h) or gaba-
pentin (100 mg/kg, < 5 h)44 and tocainide.42 Side-effects and 
sedation are rarely mentioned but with high doses, many of 
the tested drugs in SNI could impair basal sensitivity.38
Rufinamide alleviates dose-dependently mechanical 
allodynia in this model, without inducing any changes in 
sedation or affecting basal sensitivity. Amitriptyline reduced 
allodynia, but also modified basal pain sensitivity and 
sedation score, which could participate in its anti-allodynic 
effect. Amitriptyline has been shown previously to change 
locomotor activity in rodents attributable to sedation, ataxia, 
changes in nociception, depression, or anxiety.45–49 In one 
study, amitriptyline did not change locomotor activity in the 
chronic constriction injury model despite reducing allodynia. 
Fig. 5. Drugs induce a prolongation of recovery from inactivation of voltage-gated sodium channel Nav1.7. RUF, AMI, and MEX, 
at, respectively, 100, 10, and 100 μM, prolonged in a statistically significant way the half time (t1/2) of recovery from inactivation 
of Nav1.7 channel. Values of interest are summarized in the table. Insert: stimulation protocol. Values are mean ± SD. AMI = 
amitriptyline; CTRL = control; MEX = mexiletine; RUF = Rufinamide.
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We are in agreement with others who showed an increase in 
thermal latency after acute amitriptyline treatment.45,50
Rufinamide Has the Potential of a New Treatment for 
Neuropathic Pain
As first-line therapy for the treatment of neuropathic 
pain, clinical guidelines propose tricyclic antidepressants 
(amitriptyline), serotonin and norepinephrine reuptake 
inhibitors (duloxetine and venlafaxine) or anticonvulsants 
targeting α2-δ subunit of calcium channels (gabapentin and 
pregabalin).8,51 The most effective antidepressants in the 
treatment of neuropathic pain have sodium channel block-
ing properties,52 which may contribute to their analgesic 
activity.10,53 Sodium channel blockers as first-line evidence-
based treatment recommendation have not yet been 
suggested except for two specific conditions: carbamazepine 
Fig. 6. Drugs induce a use-dependent block of voltage-gated sodium channel Nav1.7. RUF, AMI, and MEX, at, respectively, 100, 
10, and 100 μM, all induced a statistically significant use-dependent block with stimulation frequencies from 2 to 50 Hz (except 
RUF at 2 Hz). All frequencies are shown in tables but for clarity purposes only 10 and 25 Hz are shown graphically. Values are 
mean ± SD. AMI = amitriptyline; CTRL = control; MEX = mexiletine; RUF = Rufinamide.
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in trigeminal neuralgia51 and topical lidocaine in posther-
petic neuralgia with irritable nociceptor.11 The systemic 
delivery of a sodium channel blocker is limited by poor 
tolerability (and restricted availability in many coun-
tries) of mexiletine or high risk of drug interaction with 
carbamazepine.54
In clinical practice, the efficacy of amitriptyline on 
neuropathic pain is variable.55,56 Amitriptyline is well known 
for its side-effects, predominantly sedation, hypotension, 
and anti-cholinergic effects, considerably reducing patient’s 
compliance.57 In particular, sedation has been known for a 
long time even at “light” dosage (50 mg).58,59 For rufinamide, 
in a study on Lennox-Gastaut syndrome, the incidence 
of adverse events for somnolence or vomiting was more 
common in the rufinamide-treated group,13 but causing 
only 2 or 3 patients out of 74 to withdraw from the study, 
respectively.
Drug interaction is also a major issue for pain therapy. 
Rufinamide presents favorable pharmacokinetic parameters; 
it is well absorbed orally and is not a substrate of cytochrome 
p450 system, thereby reducing its potential interactions. It 
is however a mild inducer of CYP3A4.60 Rufinamide may 
be a mood-stabilizing molecule with anxiolytic properties61 
that could be an added value considering the large propor-
tion of psychiatric mood-disorders encountered in chronic 
pain patients.62 The toxicity studies in rodents show a greater 
safety ratio than other anticonvulsants.24 Na channels are still 
a major target in the development of new analgesic drugs,22,63 
but rufinamide already being on the market, might offer a 
new treatment opportunity in the pain field, whereas other 
drugs trying their way through clinical trials have failed.64,65 
Rufinamide offers a valuable alternative to the current first-
line treatments for the management of neuropathic pain.
Site of Action of Rufinamide
The site of action of rufinamide is unknown. Its effects on 
biophysical properties of sodium currents are similar to 
amitriptyline and mexiletine. Amitriptyline and mexiletine 
apparently interact with residues on the DIVS6 segment.66,67 
DIS6 (domain I segment 6), DIIIS6 (domain III segment 
6), and DIVS6 (domain IV segment 6) segments may jointly 
form parts of the amitriptyline/local anesthetic receptor.68
Following the recent report of the crystal structure of the 
voltage-gated sodium channel, we hope new mechanistic 
knowledge will be gained in drug-channel interactions.69
We demonstrated the action of rufinamide on the 
peripherally expressed Nav1.7 isoform of sodium channel 
but we do not intend to show any specific Nav1.7 blocking 
properties. Indeed the drug is used in the treatment 
of epilepsy and therefore should also act on centrally 
expressed sodium channels. Rufinamide showed no relevant 
interaction with monoaminergic binding sites in radioligand 
binding studies and no interactions with benzodiazepine 
or γ-aminobutyric acid receptors, 5-HT1 and 5HT2 
receptors, α- or β-adrenoceptors, or human recombinant 
metabotropic glutamate receptor subtypes 1b, 2, or 4 
(mGluR1b, mGluR2, mGluR4). However, an inhibitory 
effect of rufinamide at the mGluR5 subtype was observed 
at 100 µM60. mGluR5 is upregulated in the dorsal root 
ganglia and spinal cord after spinal nerve ligation (but not 
after partial sciatic nerve ligation)70 and peripheral mGluR5 
Fig. 7. Effects of rufinamide on freshly dissociated dorsal root 
ganglion neurons. A, RUF at 100 μM induced a 10% reduc-
tion in sodium peak current density (P = 0.0084, n = 7, hori-
zontal bars represent mean values). B, It significantly shifted 
the SSI curve to a hyperpolarizing direction (V1/2 of inactiva-
tion from −64.4 ± 16.8 to −69.4 ± 17.1 mV, P < 0.0001, n = 6) 
without changing activation properties (V1/2 of activation from 
−40.6 ± 8.4 to −43.4 ± 5.1 mV, P = 0.17, n = 7). C, RUF also pro-
longed recovery from inactivation with half-time (t1/2) for CTRL 
and RUF of, respectively, 2.58 ± 2.12 and 6.24 ± 5.04 ms, P = 
0.0028, n = 6. Values are mean ± SD. CTRL = control; RUF = 
Rufinamide; SSI = steady-state inactivation.
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agonists can produce thermal hyperalgesia.71 In neuropathic 
pain, mGluR5 antagonists mostly show an effect on 
thermal sensitivity but not on mechanical allodynia.70,72 
The magnitude of effect mGluR5 antagonist on mechanical 
allodynia is below 40% of recovery toward baseline values 
for systemic administration on spinal nerve ligation model 
or chronic constriction injury in rats73 and 66% reduction 
for intrathecal delivery with a shallow dose–response curve 
following spinal nerve ligation.74 Antagonizing mGluR5 
could prevent the development of mechanical allodynia 
after sciatic nerve constriction injury but not reverse it.75,76 
Altogether, the effects of mGluR5 antagonists are indeed not 
as potent as the complete reversal of established mechanical 
allodynia through rufinamide. Therefore, we suggest 
mGluR5 is not the major target for rufinamide.
Therapeutic plasmatic concentration for epilepsy (20–200 
µM)13 and plasmatic concentration in our study at the time 
of anti-allodynic effect (range 68–86 μM) are in the range of 
concentration used for in vitro testing (100 μM). Rufinamide 
at the concentration we used does not completely block the 
current but globally the channel is less excitable. After nerve 
injury, hyperexcitability and ectopic discharges at the neu-
roma or in the dorsal root ganglion4 might be affected by the 
modulation of Na channel properties by rufinamide whereas 
there is no effect on nociception on a naïve nerve. We there-
fore suggest the anti-allodynic effect of rufinamide is related to 
its Na channel blocking properties.
Limitations of the Study
Differential Effect of Rufinamide, Amitriptyline, and Mexi-
letine on Nav1.7 Sodium Channel. We used the ED50 (half 
maximal effective concentration) of amitriptyline and mexi-
letine, 10 µM and 100 µM, respectively. The plasma concen-
trations of these two drugs are typically around 0.3 µM77 and 
2.3–9.3 µM57. Rufinamide was used at 100 µM, attribut-
able to its low solubility in patch clamp solution. Our study 
is not intended to compare the effect size of the drugs on 
the different biophysical properties. The low solubility of 
rufinamide impeded a comparison of the three drugs at their 
ED50 values. The effect on peak current on Nav1.7 as well 
as on dorsal root ganglion neurons is low but nonetheless 
statistically significant and reproducible.
Effect of DMSO as Control
DMSO was used to dissolve rufinamide despite the potential 
neurotoxicity with prolonged administration at high dose.78 
It was also used as a treatment option in osteoarthritis79 but 
only with relative efficacy on pain scores. We did not see any 
effect of DMSO on naïve animal sensitivity behavior regard-
ing toxicity and compared the anti-allodynic of rufinamide 
with DMSO.
Conclusion and Future Directions
We here show that rufinamide dose-dependently allevi-
ates neuropathic pain behavior in the SNI model in mice. 
We show in vitro electrophysiological data that rufinamide 
induces a hyperpolarizing shift in the steady-state inactiva-
tion curve, a use-dependent block and a delay in recovery 
from inactivation from Nav1.7-mediated current and ex-
vivo data that the same stabilizing effect on inactivation is 
also present in dorsal root ganglion neurons. Sodium chan-
nels blockers still belong to the potential targets to treat 
neuropathic pain but often do not come on the market for 
toxicity or side-effects issues. Rufinamide is currently on the 
market and could therefore be used in clinical studies in the 
pain field rapidly. With the low rate of success from current 
chronic pain therapy, a new drug would be highly valued.
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